SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP)

ABSTRACT

The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.15/524,595, filed on May 4, 2017, which is a U.S. National PhaseApplication under 35 U.S.C. § 371 of International Application No.PCT/US2015/059078, filed on Nov. 4, 2015, which claims priority to U.S.Provisional Patent Application No. 62/075,643, filed Nov. 5, 2014, theentire disclosures of which are hereby incorporated by reference intheir entireties for any and all purposes.

GOVERNMENT LICENSE RIGHTS

This invention was made with government support under DA033978 andHG005031 awarded by the National Institutes of Health. The governmenthas certain rights in the invention.

FIELD

The present technology relates to compounds useful as mitochondrialpermeability transition pore (mtPTP) inhibitors. In some embodiments,the present technology provides treatments of various diseases involvingmtPTP, such as the treatment of multiple sclerosis, amyotropic lateralsclerosis, Alzheimer's disease, Huntington's disease, Parkinson'sdisease, insulin-induced hypoglycemia, cerebral ischemia, brain damagefrom epilepsy or experimental trauma, Bethlem myopathy, pancreatitis,hepatitis, diabetic retinopathy, muscular dystrophy, heart infarction,and stroke. The present technology is also generally applicable towardthe treatment of disorders governed at least in part by anover-accumulation of reactive oxygen species and/or [Ca²⁺]dysregulation.

BACKGROUND

Mitochondrial permeability transition pore (mtPTP) channel plays asignificant role in a variety of human diseases states where commonpathology is based upon mitochondrial dysfunction. Mitochondrialpermeability transition pore (mtPTP) is a high-conductance channel ofthe inner mitochondrial membrane (IMM) mediating Ca²⁺ release andaffected by voltage, pH and, cyclosporin A (CsA), and activated by anaccumulation of mitochondrial Ca²⁺ and oxidative stress.

Although robust assays for the activity of the mtPTP have beenestablished, the identification of small molecule inhibitors has beenunexpectedly slow.

There remains a need for compounds which are effective inhibitors of themtPTP. Compounds that prevent mtPTP opening are useful in treating andpreventing cellular damage, [Ca²] dysregulation, and/or the reactiveoxygen species associated with oxidative stress-related disorders.

SUMMARY

Herein are disclosed small molecule inhibitors of mtPTP activation.These compounds are “fit-for-purpose” and are useful for therapeuticallychallenging human diseases, such as, multiple sclerosis, amyotropiclateral sclerosis, Alzheimer's disease, muscular dystrophies,pancreatitis, type II diabetes, heart infarction, and stroke.

The mitochondrial permeability transition pore (mtPTP) is avoltage-dependent, high-conductance channel of the inner mitochondrialmembrane activated by mitochondrial accumulation of Ca²⁺. Normalactivity of the mtPTP is defined by transient opening of the channelwhile persistent opening caused by sustained overloads in bothmitochondrial and cellular Ca²⁺ ultimately resulting in cell death andnumerous conditions of disease. Effectively generating successfultherapies for mtPTP-based pathologies has been fairly limited. Earlypharmacological agents targeting the mtPTP have been restricted toagents which affect the regulatory component, cyclophilin D.

The inventors diligent studies have found results consistent with theformation of Ca²⁺-dependent conformational changes of dimers of F-ATPsynthase as the basis for mtPTP opening. These dimers are highlyentropically favored through formation of disulfide bonds. Further, theinventors found that F-ATP synthase switches from a Mg²⁺-dependentsystem sythesizing ATP into a Ca²⁺-dependent pore (the mtPTP) whichdecreases the inner mitochondrial membrane (IMM) transmembranepotential. Decrease in IMM potential has been observed to stimulate theopening of the mtPTP. Accordingly, without being bound by theory, theinventors contemplate inhibitors of the Ca²⁺-dependent F-ATP synthase“mtPTP” dimer induce an inhibition of pore opening. Thus, the compoundsdisclosed herein also treat cellular damage precipitated by [Ca²⁺]dysregulation and/or the reactive oxygen species associated withoxidative stress-related disorders.

In an aspect, the present technology provides compounds of Formula I:

or a pharmaceutically acceptable salt thereof, where:Y¹ and W¹ are each independently are O, N, NH, NR⁶, S, CH, or CR⁷, or Y¹and W¹ are each independently CR⁸ or NR⁸ where R⁸ joins Y¹ and W¹ toform an aryl, heteroaryl, or heterocylyl ring; Z¹, Z², and Z³ are eachindependently CH, C—R⁹, or N; m is 1 or 2; G¹ is C═O, C═S, SO, or SO₂;R¹, R², R⁴, R⁵, R⁶, R⁷, and R⁹ are independently at each occurrencehydrogen, halogen, hydroxyl, alkyl, cycloalkyl, alkenyl, alkoxy,alkynyl, amino, aminosulfinyl, aminosulfonyl, sulfinyl, sulfonyl,sulfonyloxy, aminosulfonyloxy, aminosulfinyloxy, aminosulfonylamino,acylamino, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino,aminocarbonyl, acyloxy, aryl, heteroaryl, cyano, nitro, carboxyl,carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, acyl, orformyl; or two adjacent R¹, R², R⁴, R⁵, R⁶, R⁷, and R⁹ together form anaryl, heteroaryl, or heterocyclyl ring; and R³ is hydrogen, alkyl,cycloalkyl, alkenyl, or alkynyl.

In an aspect, the present technology provides compounds of Formula IV:

or a pharmaceutically acceptable salt thereof, where:Y² is O, NH, NR²⁵, or S;W² is N, CH, or CR²⁶; where when Y² is NR²⁵ and W² is CR²⁶ then R²⁵ andR²⁶ may optionally join Y² and W² to form an aryl, heteroaryl, orheterocylyl ring; Z⁴, Z⁵, and Z⁶ are each independently CH, C—R²⁷, or N;andR²², R²³, R²⁴, R²⁵, R²⁶, and R²⁷ are independently at each occurrencehydrogen, halogen, hydroxyl, alkyl, cycloalkyl, alkenyl, alkoxy,alkynyl, amino, aminosulfinyl, aminosulfonyl, sulfinyl, sulfonyl,sulfonyloxy, aminosulfonyloxy, aminosulfinyloxy, aminosulfonylamino,acylamino, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino,aminocarbonyl, acyloxy, aryl, heteroaryl, cyano, nitro, carboxyl,carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, acyl, orformyl; or two R²², R²³, R²⁴, R²⁵, R²⁶, and R²⁷ together form an aryl,heteroaryl, or heterocyclyl ring.

In an aspect, the compound of the present technology is a compound ofFormula V:

or a pharmaceutically acceptable salt thereof, where G³ is C═O, C═S, orSO₂; and A¹ and B¹ are each independently alkyl, cycloalkyl, aryl, orheteroaryl.

In a related aspect, pharmaceutical compositions are provided thatinclude one or more compounds of Formula I, II, IIa, III, IV, and/or Vdescribed herein and a pharmaceutically acceptable excipient. Thepharmaceutical composition may include one or more mitochondrialtargeting molecules, including but not limited to any one or more of themitochondrial targeting molecules described in Wipf et. al. “TargetingMitochondria” Acc. Chem. Res. 2008, 41, 87-97 and references citedtherein, each of which is incorporated by reference in their entiretiesfor any and all purposes.

In an aspect, a method is provided for treating a disease mediated atleast in part by [Ca²⁺] dysregulation and/or an accumulation of by areactive oxygen species, where the method involves administering to apatient an effective amount of one or more compounds of Formula I, II,IIa, III, IV, and/or V, or a pharmaceutical composition comprising apharmaceutically acceptable excipient and an effective amount of one ormore compounds of Formula I, II, IIa, III, IV, and/or V describedherein.

Diseases mediated at least in part by [Ca²⁺] dysregulation and/or theaccumulation of by a reactive oxygen species include those selected fromthe group consisting of Huntington's disease and other polyglutaminedisorders, ischemic reperfusion injury, multiple sclerosis, amyotropiclateral sclerosis, Alzheimer's disease, Huntington's disease,Parkinson's disease, insulin-induced hypoglycaemia, cerebral ischemia,brain damage from epilepsy or experimental trauma, Bethlem myopathy,pancreatitis, hepatitis, diabetic retinopathy, muscular dystrophy,traumatic brain injury, type II diabetes, heart infarction, stroke,general central nervous system (CNS) infections such as viral, bacterialor parasites, for example, poliomyelitis, Lyme disease (Borreliaburgdorferi infection) and malaria, cancers with cerebral localization,Tourette's syndrome, hepatic encephalopathy, systemic lupus, analgesiaand opiate withdrawal symptoms, feeding behaviour, schizophrenia,chronic anxiety, depressive disorders, disorders of the developing oraged brain, diseases of addiction, diabetes, and complications thereof.

In an aspect, an article of manufacture is provided for use ininhibiting mtPTP and treating a disease mediated at least in part by[Ca²⁺] dysregulation and/or a reactive oxygen species, where the articleincludes a composition that includes a compound of Formula I, II, IIa,III, IV, and/or V as provided herein. The article of manufacture mayfurther include a label with instructions for using the composition totreat the disease.

These and other embodiments are described in further detail herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 presents coiling events in control (CRL_MO) zebrafish embryos andexon 9 col6a1 morphant (Ex9_MO) zebrafish embryos, where exon 9 col6a1morphant (Ex9_MO) zebrafish embryos were further tested with theindicated concentrations of a compound of the present technology.

FIG. 2 provides the results of response evoked by touching control(CRL_MO) zebrafish embryos and exon 9 col6a1 morphant (Ex9_MO) zebrafishembryos with a pipette tip, where the exon 9 col6a1 morphant (Ex9_MO)zebrafish embryos were further tested with the indicated concentrationsof a compound of the present technology.

FIG. 3 discloses birefringence classes of control (CRL_MO) zebrafishembryos, exon 9 col6a1 morphant (Ex9_MO) zebrafish embryos, and exon 9col6a1 morphant zebrafish embryos treated with the indicatedconcentrations of a compound of the present technology showing normalbirefringence, mild myopathic phenotype, and strong myopathic phenotype,as indicated. All are shown at 48 hpf, where in the treated embryostreatment with the compound of the present technology occurred at 21hpf.

DETAILED DESCRIPTION

Throughout this application, the text refers to various embodiments ofthe present compounds, compositions, and methods. The variousembodiments described are meant to provide a variety of illustrativeexamples and should not be construed as descriptions of alternativespecies. Specific embodiments are not intended as an exhaustivedescription or as a limitation to the broader aspects discussed herein.One aspect described in conjunction with a particular embodiment is notnecessarily limited to that embodiment and can be practiced with anyother embodiment(s).

1. Definitions

As used herein, the following definitions shall apply unless otherwiseindicated. Further, if any term or symbol used herein is not defined asset forth below, it shall have its ordinary meaning in the art.

As used herein and in the appended claims, singular articles such as “a”and “an” and “the” and similar referents in the context of describingthe elements (especially in the context of the following claims) are tobe construed to cover both the singular and the plural, unless otherwiseindicated herein or clearly contradicted by context. Recitation ofranges of values herein are merely intended to serve as a shorthandmethod of referring individually to each separate value falling withinthe range, unless otherwise indicated herein, and each separate value isincorporated into the specification as if it were individually recitedherein. All methods described herein can be performed in any suitableorder unless otherwise indicated herein or otherwise clearlycontradicted by context. The use of any and all examples, or exemplarylanguage (e.g., “such as”) provided herein, is intended merely to betterilluminate the embodiments and does not pose a limitation on the scopeof the claims unless otherwise stated. No language in the specificationshould be construed as indicating any non-claimed element as essential.

As used herein, “about” will be understood by persons of ordinary skillin the art and will vary to some extent depending upon the context inwhich it is used. If there are uses of the term which are not clear topersons of ordinary skill in the art, given the context in which it isused, “about” will mean up to plus or minus 10% of the particular term.

Generally, reference to a certain element, such as hydrogen or H, ismeant to include all isotopes of that element. For example, if an Rgroup is defined to include hydrogen or H, it also includes deuteriumand tritium. Compounds comprising radioisotopes such as tritium, C¹⁴,P³² and S³⁵ are thus within the scope of the present technology.Procedures for inserting such labels into the compounds of the presenttechnology will be readily apparent to those skilled in the art based onthe disclosure herein.

In general, “substituted” refers to an alkyl, cycloalkyl, alkenyl,alkynyl, heterocyclyl, aryl, heteroaryl, or ether group, as definedbelow (e.g., an alkyl group) in which one or more bonds to a hydrogenatom contained therein are replaced by a bond to non-hydrogen ornon-carbon atoms. Substituted groups also include groups in which one ormore bonds to a carbon(s) or hydrogen(s) atom are replaced by one ormore bonds, including double or triple bonds, to a heteroatom. Thus, asubstituted group will be substituted with one or more substituents,unless otherwise specified. In some embodiments, a substituted group issubstituted with 1, 2, 3, 4, 5, or 6 substituents. Examples ofsubstituent groups include: halogens (i.e., F, Cl, Br, and I);hydroxyls; alkyl, aryl, hetercyclyl, heteroaryl, alkoxy, alkenoxy,alkynoxy, aryloxy, aralkyloxy, heterocyclyloxy, and heterocyclylalkoxygroups; carbonyls (oxo); carboxyls; esters; urethanes; oximes;hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides;sulfoxides; sulfones; sulfonyls; sulfonamides; amines; N-oxides;hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines;guanidines; enamines; imides; isocyanates; isothiocyanates; cyanates;thiocyanates; imines; nitro groups; nitriles (i.e., CN); and the like.

As used herein, C_(m)-C_(n), such as C₁-C₁₂, C₁-C₈, or C₁-C₆ when usedbefore a group refers to that group containing m to n carbon atoms.

“Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groupshaving from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms.Alkyl groups may be unsubstituted or unsubstituted as well as linear orbranched. This term includes, by way of example, linear and branchedhydrocarbyl groups such as methyl (CH₃—), ethyl (CH₃CH₂—), n-propyl(CH₃CH₂CH₂—), isopropyl ((CH₃)₂CH—), n-butyl (CH₃CH₂CH₂CH₂—), isobutyl((CH₃)₂CHCH₂—), sec-butyl ((CH₃)(CH₃CH₂)CH—), t-butyl ((CH₃)₃C—),n-pentyl (CH₃CH₂CH₂CH₂CH₂—), and neopentyl ((CH₃)₃CCH₂—). Preferredsubstituted alkyl groups include halogenated alkyl groups andparticularly halogenated methyl groups such as trifluoromethyl,difluromethyl, fluoromethyl and the like.

“Alkenyl” refers to straight or branched hydrocarbyl groups having from2 to 6 carbon atoms and preferably 2 to 4 carbon atoms and having atleast 1 and preferably from 1 to 2 sites of unsaturation. Alkenyl groupsmay be unsubstituted or substituted. Such groups are exemplified, forexample, by vinyl, allyl, and but-3-en-1-yl. Included within this termare the cis and trans isomers or mixtures of these isomers.

“Alkynyl” refers to straight or branched monovalent hydrocarbyl groupshaving from 2 to 6 carbon atoms and preferably 2 to 3 carbon atoms andhaving at least 1 and preferably from 1 to 2 sites of acetylenic (—C≡C—)unsaturation. Examples of such alkynyl groups include acetylenyl(—C≡CH), and propargyl (—CH₂C≡CH). Alkynyl groups may be unsubstitutedor substituted.

“Alkoxy” refers to the group —O-alkyl wherein alkyl is defined herein.Alkoxy groups may be unsubstituted or substituted. Alkoxy includes, byway of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy,t-butoxy, sec-butoxy, and n-pentoxy. Preferred substituted alkoxy groups(—O-(substituted alkyl)) include halogenated alkyl groups andparticularly halogenated methyl groups such as trifluoromethyl,difluromethyl, fluoromethyl, and the like.

“Acyl” refers to the groups H—C(O)—, alkyl-C(O)—, alkenyl-C(O)—,alkynyl-C(O)—, cycloalkyl-C(O)—, aryl-C(O)—, heteroaryl-C(O)—, andheterocyclyl-C(O)—.

“Acylamino” refers to the groups —NR¹³⁰C(O)alkyl, —NR¹³⁰C(O)cycloalkyl,—NR¹³⁰C(O)alkenyl, —NR¹³⁰C(O)alkynyl, —NR¹³⁰C(O)aryl,—NR¹³⁰C(O)heteroaryl, and —NR³⁰C(O)heterocyclyl, wherein R¹³⁰ isindependently at each occurrence hydrogen or alkyl.

“Acyloxy” refers to the groups alkyl-C(O)O—, substituted alkyl-C(O)O—,alkenyl-C(O)O—, substituted alkenyl-C(O)O—, alkynyl-C(O)O—, substitutedalkynyl-C(O)O—, aryl-C(O)O—, substituted aryl-C(O)O—, cycloalkyl-C(O)O—,substituted cycloalkyl-C(O)O—, heteroaryl-C(O)O—, substitutedheteroaryl-C(O)O—, heterocyclic-C(O)O—, and substitutedheterocyclic-C(O)O—.

“Amino” refers to —NR¹³¹R¹³² where R¹³¹ and R¹³² are each independentlyhydrogen, alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl,heterocyclyl, or sulfonyl. When R¹³¹ is hydrogen and R¹³² is alkyl, thesubstituted amino group is sometimes referred to herein as alkylamino.When R¹³¹ and R¹³² are alkyl, the substituted amino group is sometimesreferred to herein as dialkylamino. When referring to a monosubstitutedamino, it is meant that either R¹³¹ or R¹³² is hydrogen but not both.When referring to a disubstituted amino, it is meant that neither R¹³¹nor R¹³² are hydrogen.

“Aminocarbonyl” refers to the group —C(O)NR¹³³R¹³⁴ where R¹³³ and R¹³⁴are each independently hydrogen, alkyl, alkenyl, alkoxy, alkynyl, aryl,cycloalkyl, heteroaryl, or heterocyclyl, where R¹³³ and R¹³⁴ areoptionally joined together with the nitrogen bound thereto to form aheterocyclic group.

“Aminothiocarbonyl” refers to the group —C(S)NR¹³⁵R¹³⁶ where R¹³⁵ andR¹³⁶ are independently selected from the group consisting of hydrogen,alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl, andheterocyclyl, where R¹³⁵ and R¹³⁶ are optionally joined together withthe nitrogen bound thereto to form a heterocyclic or substitutedheterocyclic group.

“Aminocarbonylamino” refers to the group —NR¹³⁷C(O)NR¹³⁸R¹³⁹ where R¹³⁷is hydrogen or alkyl and R¹³⁸ and R¹³⁹ are independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkoxy, alkynyl, aryl,cycloalkyl, heteroaryl, and heterocyclyl, where R¹³⁸ and R¹³⁹ areoptionally joined together with the nitrogen bound thereto to form aheterocyclic group.

“Aminothiocarbonylamino” refers to the group —NR¹⁴⁰C(S)NR¹⁴¹R¹⁴² whereR¹⁴⁰ is hydrogen or alkyl and R¹⁴¹ and R¹⁴² are independently selectedfrom the group consisting of hydrogen, alkyl, alkenyl, alkoxy, alkynyl,aryl, cycloalkyl, heteroaryl, and heterocyclyl, where R¹⁴¹ and R¹⁴² areoptionally joined together with the nitrogen bound thereto to form aheterocyclic group.

“Aminocarbonyloxy” refers to the group —O—C(O)NR¹⁴³R¹⁴⁴ where R¹⁴³ andR¹⁴⁴ are independently selected from the group consisting of hydrogen,alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl, andheterocyclyl, where R¹⁴³ and R¹⁴⁴ are optionally joined together withthe nitrogen bound thereto to form a heterocyclic group.

“Aminosulfonyl” refers to the group —SO₂NR¹⁴⁵R¹⁴⁶ where R¹⁴⁵ and R¹⁴⁶are independently selected from the group consisting of hydrogen, alkyl,alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl, andheterocyclyl, where R¹⁴⁵ and R¹⁴⁶ are optionally joined together withthe nitrogen bound thereto to form a heterocyclic group.

“Aminosulfonyloxy” refers to the group —O—SO₂NR¹⁴⁷R¹⁴⁸ where R¹⁴⁷ andR¹⁴⁸ are each independently selected from the group consisting ofhydrogen, alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl,and heterocyclyl, where R¹⁴⁷ and R¹⁴⁸ are optionally joined togetherwith the nitrogen bound thereto to form a heterocyclic group.

“Aminosulfonylamino” refers to the group —NR¹⁴⁹—SO₂NR¹⁵⁰R¹⁵¹ where R¹⁴⁹is hydrogen or alkyl and R¹⁵⁰ and R¹⁵¹ are independently selected fromthe group consisting of hydrogen, alkyl, alkenyl, alkoxy, alkynyl, aryl,cycloalkyl, heteroaryl, and heterocyclyl, where R¹⁵⁰ and R¹⁵¹ areoptionally joined together with the nitrogen bound thereto to form aheterocyclic group.

“Amidino” refers to the group —C(═NR¹⁵²)NR¹⁵³R¹⁵⁴ where R¹⁵², R¹⁵³, andR¹⁵⁴ are independently selected from the group consisting of hydrogen,alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl, andheterocyclyl, where R¹⁵³ and R¹⁵⁴ are optionally joined together withthe nitrogen bound thereto to form a heterocyclic group.

“Aryl” or “Ar” refers to a monovalent aromatic carbocyclic group of from6 to 14 carbon atoms having a single ring (e.g., phenyl (Ph)) ormultiple condensed rings (e.g., naphthyl or anthryl) which condensedrings may or may not be aromatic (e.g., 2-benzoxazolinone,2H-1,4-benzoxazin-3(4H)-one-7-yl, and the like) provided that the pointof attachment is at an aromatic carbon atom. Aryl groups may beunsubstituted or substituted. Preferred aryl groups include phenyl andnaphthyl. Substituted aryl includes aryl groups which are substitutedwith 1 to 5, preferably 1 to 3, or more preferably 1 to 2 substituents.

“Aryloxy” refers to the group —O-aryl, where aryl is as defined herein,that includes, by way of example, phenoxy and naphthoxy.

“Arylthio” refers to the group —S-aryl, where aryl is as defined herein.

“Carbonyl” refers to the divalent group —C(O)— which is equivalent to—C(═O)—.

“Carboxy” or “carboxyl” refers to —COOH or salts thereof.

“Carboxyl ester” or “carboxy ester” refers to the groups —C(O)O-alkyl,—C(O)O-alkenyl, —C(O)O-alkynyl, —C(O)O-aryl, —C(O)O-cycloalkyl,—C(O)O-heteroaryl, and —C(O)O-heterocyclyl.

“(Carboxyl ester)amino” refers to the groups —NR¹⁵⁵—C(O)O-alkyl,—NR¹⁵⁵—C(O)O-alkenyl, —NR¹⁵⁵—C(O)O-alkynyl, —NR¹⁵⁵—C(O)O-aryl,—NR¹⁵⁵—C(O)O-cycloalkyl, —NR¹⁵⁵—C(O)O-heteroaryl, and—NR¹⁵⁵—C(O)O-heterocyclyl, wherein R¹⁵⁵ is independently at eachoccurrence alkyl or hydrogen.

“(Carboxyl ester)oxy” refers to the groups —O—C(O)O-alkyl,—O—C(O)O-alkenyl, —O—C(O)O-alkynyl, —O—C(O)O-aryl, —O—C(O)O-cycloalkyl,—O—C(O)O-heteroaryl, and —O—C(O)O-heterocyclyl.

“Cyano” refers to the group —C≡N.

“Cycloalkyl” refers to a saturated or unsaturated but nonaromatic cyclicalkyl groups of from 3 to 10 ringcarbon atoms having single or multiplecyclic rings including fused, bridged, and spiro ring systems.Cycloalkyl groups may be unsubstituted or substituted. “C_(x)cycloalkyl” refers to a cycloalkyl group having x number of ring carbonatoms. Examples of suitable cycloalkyl groups include, for instance,adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl.

“Cycloalkyloxy” refers to —O-cycloalkyl.

“Cycloalkylthio” refers to —S-cycloalkyl.

“Guanidino” refers to —NR¹⁵⁶C(═NR¹⁵⁷)N(R¹⁵⁸)₂ where R¹⁵⁶ and R¹⁵⁷ areeach independently hydrogen, alkyl, aryl, heteroaryl, and heterocyclyl,and R¹⁵⁸ is independently at each occurrence hydrogen, alkyl, aryl,heteroaryl, and heterocyclyl and two R¹⁵⁸ groups are optionally joinedtogether with the nitrogen bound thereto to form a heterocyclyl group.

“Halo” or “halogen” refers to fluoro, chloro, bromo and iodo andpreferably is fluoro or chloro.

“Hydroxy” or “hydroxyl” refers to the group —OH.

“Heteroaryl” refers to an aromatic group of from 1 to 10 carbon atomsand 1 to 4 heteroatoms selected from the group consisting of oxygen,nitrogen and sulfur within the ring. Such heteroaryl groups can have asingle ring (e.g., pyridinyl or furyl) or multiple condensed rings(e.g., indolizinyl or benzothienyl) wherein the condensed rings may ormay not be aromatic and/or contain a heteroatom provided that the pointof attachment is through an atom of the aromatic heteroaryl group.Heteroaryl groups may be unsubstituted or substituted. The nitrogenand/or the sulfur ring atom(s) of the heteroaryl group may optionally beoxidized to provide for the N-oxide (N→O), sulfinyl, or sulfonylmoieties. Preferred heteroaryls include 5 or 6 membered heteroaryls suchas pyridinyl, pyrrolyl, indolyl, thiophenyl, and furanyl.

“Heteroaryloxy” refers to —O-heteroaryl.

“Heteroarylthio” refers to the group —S-heteroaryl.

“Heterocycle” or “heterocyclic” or “heterocycloalkyl” or “heterocyclyl”refers to a saturated or partially saturated, but not aromatic, grouphaving from 1 to 10 ring carbon atoms and from 1 to 4 ring heteroatomsselected from the group consisting of nitrogen, sulfur, or oxygen.Heterocyclyl groups may be unsubstituted or substituted. “C_(x)heterocyclyl” refers to a heterocycloalkyl group having x number of ringatoms including the ring heteroatoms. Heterocycle encompasses singlering or multiple condensed rings, including fused bridged and spiro ringsystems. In fused ring systems, one or more the rings can be cycloalkyl,aryl or heteroaryl provided that the point of attachment is through thenon-aromatic ring. The nitrogen and/or sulfur atom(s) of theheterocyclic group may optionally be oxidized to provide for theN-oxide, sulfinyl, sulfonyl moieties.

“Heterocyclyloxy” refers to the group —O-heterocycyl.

“Heterocyclylthio” refers to the group —S-heterocycyl.

Examples of heterocyclyl and heteroaryl include, but are not limited to,azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine,pyridazine, indolizine, isoindole, indole, dihydroindole, indazole,purine, quinolizine, isoquinoline, quinoline, phthalazine,naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine,carbazole, carboline, phenanthridine, acridine, phenanthroline,isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine,imidazolidine, imidazoline, piperidine, piperazine, indoline,phthalimide, 1,2,3,4-tetrahydroisoquinoline,4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene,benzo[b]thiophene, morpholinyl, thiomorpholinyl (also referred to asthiamorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl, pyrrolidine,and tetrahydrofuranyl.

“Nitro” refers to the group —NO₂.

“Oxo” refers to (═O) or (O⁻).

“Spiro ring systems” refers to bicyclic ring systems that have a singlering carbon atom common to both rings.

“Sulfinyl” refers to the divalent group —SO—.

“Sulfonyl” refers to the divalent group —S(O)₂— where a “substitutedsulfonyl” is —SO₂-alkyl, —SO₂—OH, —SO₂-alkenyl, —SO₂-cycloalkyl,—SO₂-aryl, —SO₂-heteroaryl, and —SO₂-heterocyclyl. Sulfonyl groups maybe unsubstituted or substituted. Substituted sulfonyl includes groupssuch as methyl-SO₂—, phenyl-SO₂—, and 4-methylphenyl-SO₂—. Preferredsubstituted alkyl groups on the substituted alkyl-SO₂— includehalogenated alkyl groups and particularly halogenated methyl groups suchas trifluoromethyl, difluromethyl, fluoromethyl and the like.

“Sulfonyloxy” refers to —OSO₂-alkyl, —OSO₂—OH, —OSO₂-alkenyl,—OSO₂-cycloalkyl, —OSO₂-aryl, —OSO₂-heteroaryl, and —OSO₂-heterocyclyl.

“Thioacyl” refers to H—C(S)—, alkyl-C(S)—, alkenyl-C(S)—, alkynyl-C(S)—,cycloalkyl-C(S)—, aryl-C(S)—, heteroaryl-C(S)—, and heterocyclyl-C(S)—.

“Mercapto” or “thiol” refers to the group —SH.

“Formyl” refers to the group —C(O)H.

“Thiocarbonyl” refers to the divalent group —C(S)— which is equivalentto —C(═S)—.

“Thione” refers to the atom (═S).

“Alkylthio” refers to the group —S-alkyl.

Stereoisomers of compounds (also known as optical isomers) include allchiral, diastereomeric, and racemic forms of a structure, unless thespecific stereochemistry is expressly indicated. Thus, compounds used inthe present technology include enriched or resolved optical isomers atany or all asymmetric atoms as are apparent from the depictions. Bothracemic and diastereomeric mixtures, as well as the individual opticalisomers can be isolated or synthesized so as to be substantially free oftheir enantiomeric or diastereomeric partners, and these stereoisomersare all within the scope of the present technology.

The compounds of the present technology may exist as solvates,especially hydrates. Hydrates may form during manufacture of thecompounds or compositions comprising the compounds, or hydrates may formover time due to the hygroscopic nature of the compounds. Compounds ofthe present technology may exist as organic solvates as well, includingDMF, ether, and alcohol solvates among others. The identification andpreparation of any particular solvate is within the skill of theordinary artisan of synthetic organic or medicinal chemistry.

“Tautomers” refer to alternate forms of a compound that differ in theposition of a proton, such as enol-keto and imine-enamine tautomers, orthe tautomeric forms of heteroaryl groups containing a ring atomattached to both a ring —NH— moiety and a ring ═N— moiety such aspyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.

“Treating” or “treatment” of a disease in a patient refers to 1)preventing the disease from occurring in a patient that is predisposedor does not yet display symptoms of the disease; 2) inhibiting thedisease or arresting its development; or 3) ameliorating or causingregression of the disease.

Unless indicated otherwise, the nomenclature of substituents that arenot explicitly defined herein are arrived at by naming the terminalportion of the functionality followed by the adjacent functionalitytoward the point of attachment. For example, the substituent“alkoxycarbonylalkyl” refers to the group (alkoxy)-C(O)-(alkyl)-.

It is understood that in all substituted groups defined above, polymersarrived at by defining substituents with further substituents tothemselves (e.g., substituted aryl having a substituted aryl group as asubstituent which is itself substituted with a substituted aryl group,etc.) are not intended for inclusion herein. In such cases, the maximumnumber of such substituents is three. That is to say that each of theabove definitions is constrained by a limitation that, for example,substituted aryl groups are limited to -substituted aryl-(substitutedaryl)-substituted aryl.

It is understood that the above definitions are not intended to includeimpermissible substitution patterns (e.g., methyl substituted with 5fluoro groups). Such impermissible substitution patterns are well knownto the skilled artisan.

Pharmaceutically acceptable salts of compounds described herein arewithin the scope of the present technology and include acid or baseaddition salts which retain the desired pharmacological activity and isnot biologically undesirable (e.g., the salt is not unduly toxic,allergenic, or irritating, and is bioavailable). When the compound ofthe present technology has a basic group, such as, for example, an aminogroup, pharmaceutically acceptable salts can be formed with inorganicacids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuricacid, and phosphoric acid), organic acids (e.g. alginate, formic acid,acetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid,tartaric acid, lactic acid, maleic acid, citric acid, succinic acid,malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid, and p-toluenesulfonic acid) or acidic amino acids (suchas aspartic acid and glutamic acid). When the compound of the presenttechnology has an acidic group, such as for example, a carboxylic acidgroup, it can form salts with metals, such as alkali and earth alkalimetals (e.g. Na⁺, Li⁺, K⁺, Ca²⁺, Mg²⁺, Zn²⁺), ammonia or organic amines(e.g. dicyclohexylamine, trimethylamine, triethylamine, pyridine,picoline, ethanolamine, diethanolamine, triethanolamine) or basic aminoacids (e.g. arginine, lysine and ornithine). Such salts can be preparedin situ during isolation and purification of the compounds or byseparately reacting the purified compound in its free base or free acidform with a suitable acid or base, respectively, and isolating the saltthus formed.

2. Compounds of the Present Technology

The present technology is directed to compounds, compositions, andmethods of using said compounds as inhibiting the mtPTP. The compoundsof the present technology are useful in treating a variety of disorders,such as those mediated at least in part by [Ca²⁺] dysregulation and/orthe accumulation of by a reactive oxygen species.

In an aspect, the present technology provides compounds of Formula I:

or a pharmaceutically acceptable salt thereof, where:Y¹ and W¹ are each independently are O, N, NH, NR⁶, S, CH, or CR⁷, or Y¹and W¹ are each independently CR⁸ or NR⁸ where R⁸ joins Y¹ and W¹ toform an aryl, heteroaryl, or heterocylyl ring; Z¹, Z², and Z³ are eachindependently CH, C—R⁹, or N; m is 1 or 2; G¹ is C═O, C═S, SO, or SO₂;R¹, R², R⁴, R⁵, R⁶, R⁷, and R⁹ are independently at each occurrencehydrogen, halogen, hydroxyl, alkyl, cycloalkyl, alkenyl, alkoxy,alkynyl, amino, aminosulfinyl, aminosulfonyl, sulfinyl, sulfonyl,sulfonyloxy, aminosulfonyloxy, aminosulfinyloxy, aminosulfonylamino,acylamino, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino,aminocarbonyl, acyloxy, aryl, heterocyclyl, heteroaryl, cyano, nitro,carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy,acyl, or formyl; or two adjacent R¹, R², R⁴, R⁵, R⁶, R⁷, and R⁹ togetherform an aryl, heteroaryl, or heterocyclyl ring; and R³ is hydrogen,alkyl, cycloalkyl, alkenyl, or alkynyl.

The compound of Formula I may be a compound of Formula II or III:

or a pharmaceutically acceptable salt thereof, where:Y¹ is O, NIH, NR⁶, or S;W^(Y) is N, CH, or CR⁷;Z¹, Z², Z³, R⁴ and R⁵ are as defined above;G² is C═O, C═S, SO, or SO₂;R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independentlyat each occurrence hydrogen, halogen, hydroxyl, alkyl, cycloalkyl,alkenyl, alkoxy, alkynyl, amino, aminosulfinyl, aminosulfonyl, sulfinyl,sulfonyl, sulfonyloxy, aminosulfonyloxy, aminosulfinyloxy,aminosulfonylamino, acylamino, aminocarbonyloxy, aminocarbonylamino,aminothiocarbonylamino, aminocarbonyl, acyloxy, aryl, heterocyclyl,heteroaryl, cyano, nitro, carboxyl, carboxyl ester, (carboxylester)amino, (carboxyl ester)oxy, acyl, or formyl; or two adjacent R¹⁰,R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ together form an aryl,heteroaryl, or heterocyclyl ring; andR²⁰ is hydrogen, alkyl, cycloalkyl, alkenyl, or alkynyl.

In any embodiment herein, R¹, R², R⁴, R⁵, R⁶, R⁷, R⁹, R¹⁰, R¹¹, R¹²,R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, and/or R¹⁹ may independently at eachoccurrence be hydrogen, C₁-C₈ alkyl, C₃-C₈ cycloalkyl, C₁-C₈ alkenyl,C₂-C₈ alkynyl, aryl, cyano, carboxyl, carboxyl ester, acyl, formyl,C₃-C₇ heteroaryl, or C₃-C₇ heterocyclyl, or two adjacent R¹, R², R⁴, R⁵,R⁶, R⁷, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, and/or R¹⁹together form an aryl, heteroaryl, or heterocyclyl ring.

The compound of Formula II may be a compound of formula IIa:

where R²¹ is H, F, Cl, or alkoxy. In any embodiment herein, R²¹ may beH, F, Cl, or methoxy. In any embodiment herein, Z¹ may be CH. In anyembodiment herein, it may be that Y¹ is O and W¹ is N or Y¹ is NH and W¹is N.

In an aspect, the present technology provides compounds of Formula IV:

or a pharmaceutically acceptable salt thereof, where:Y² is O, NH, NR²⁵, or S;W² is N, CH, or CR²⁶; where when Y² is NR²⁵ and W² is CR²⁶ then R²⁵ andR²⁶ may optionally join Y² and W² to form an aryl, heteroaryl, orheterocylyl ring;Z⁴, Z⁵, and Z⁶ are each independently CH, C—R²⁷, or N; andR²², R²³, R²⁴, R²⁵, R²⁶, and R²⁷ are independently at each occurrencehydrogen, halogen, hydroxyl, alkyl, cycloalkyl, alkenyl, alkoxy,alkynyl, amino, aminosulfinyl, aminosulfonyl, sulfinyl, sulfonyl,sulfonyloxy, aminosulfonyloxy, aminosulfinyloxy, aminosulfonylamino,acylamino, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino,aminocarbonyl, acyloxy, aryl, heteroaryl, cyano, nitro, carboxyl,carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, acyl, orformyl; or two R²², R²³, R²⁴, R²⁵, R²⁶, and R²⁷ together form an aryl,heteroaryl, or heterocyclyl ring.

In an aspect, the compound of the present technology is a compound ofFormula V:

or a pharmaceutically acceptable salt thereof, where G³ is C═O, C═S, orSO₂; and A¹ and B¹ are each independently alkyl, cycloalkyl, aryl, orheteroaryl.

For example, a compound according for Formula V includes compounds ofFormulas VI and VII:

or a pharmaceutically acceptable salt thereof, where:Z⁷, Z⁸, Z⁹, Z¹⁰, Z¹¹, and Z¹² are each independently CH, C—R³⁸, or N;andR³⁰, R³², R³³, R³⁴, R³⁶, and R³⁷ are independently at each occurrencehydrogen, halogen, hydroxyl, alkyl, cycloalkyl, alkenyl, alkoxy,alkynyl, amino, aminosulfinyl, aminosulfonyl, sulfinyl, sulfonyl,sulfonyloxy, aminosulfonyloxy, aminosulfinyloxy, aminosulfonylamino,acylamino, aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino,aminocarbonyl, acyloxy, aryl, heteroaryl, cyano, nitro, carboxyl,carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, acyl, orformyl; or two adjacent R³², R³³, R³⁶, and R³⁷ together form an aryl,heteroaryl, or heterocyclyl ring; andR³¹ and R³⁵ are each independently hydrogen, alkyl, cycloalkyl, alkenyl,alkynyl, aryl, or heteroaryl.

The compound of Formula I, II, IIa, III, IV, and/or V may be any one ofthe compounds shown below and in Tables 1 & 2 herein, as well aspharmaceutically acceptable salts thereof.

In some embodiments, the present technology is a pharmaceuticalcomposition comprising one or more compounds disclosed herein and apharmaceutically acceptable excipient. The pharmaceutical compositionsof any embodiment herein may be formulated for oral, parenteral, nasal,or topical administration. In any embodiment herein, the pharmaceuticalcomposition may include an effective amount of a compound of anyembodiment of the present technology. The compound of the presenttechnology may be present in an amount effective for the treatment ofmultiple sclerosis, amyotropic lateral sclerosis, ischemic reperfusioninjury, Alzheimer's disease, Huntington's disease, Parkinson's disease,insulin-induced hypoglycemia, cerebral ischemia, brain damage fromepilepsy or experimental trauma, Bethlem myopathy, pancreatitis,hepatitis (type A, and/or B, and/or C), type II diabetes, diabeticretinopathy, muscular dystrophy, traumatic brain injury, heartinfarction, and/or stroke.

“Treating” within the context of the instant technology, meansalleviation, in whole or in part, of symptoms associated with a disorderor disease, or slowing, inhibition or halting of further progression orworsening of those symptoms, or prevention or prophylaxis of the diseaseor disorder in a subject at risk for developing the disease or disorder.

As used herein, an “effective amount” of a compound of the presenttechnology refers to an amount of the compound that alleviates, in wholeor in part, symptoms associated with a disorder or disease, or slows orhalts of further progression or worsening of those symptoms, or preventsor provides prophylaxis for the disease or disorder in a subject at riskfor developing the disease or disorder. Those skilled in the art arereadily able to determine an effective amount. For example, one way ofassessing an effective amount for a particular disease state is bysimply administering a compound of the present technology to a patientin increasing amounts until progression of the disease state isdecreased or stopped.

The instant compositions can be formulated for various routes ofadministration, for example, by oral, parenteral, topical, injection,rectal, nasal, or via implanted reservoir. Parenteral or systemicadministration includes, but is not limited to, subcutaneous,intravenous, intraperitoneally, intramuscular, intrathecal,intracranial, and intracerebroventricular injections. The followingdosage forms are given by way of example and should not be construed aslimiting the instant technology.

For oral, buccal, and sublingual administration, powders, suspensions,granules, tablets, pills, capsules, gelcaps, and caplets are acceptableas solid dosage forms. These can be prepared, for example, by mixing oneor more compounds disclosed herein, or pharmaceutically acceptable saltsor stereoisomers thereof, with at least one additive such as a starch orother additive. Suitable additives are sucrose, lactose, cellulosesugar, mannitol, maltitol, dextran, starch, agar, alginates, chitins,chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens,casein, albumin, synthetic or semi-synthetic polymers or glycerides.Optionally, oral dosage forms can contain other ingredients to aid inadministration, such as an inactive diluent, or lubricants such asmagnesium stearate, or preservatives such as paraben or sorbic acid, oranti-oxidants such as ascorbic acid, tocopherol or cysteine, adisintegrating agent, binders, thickeners, buffers, sweeteners,flavoring agents or perfuming agents. Tablets and pills may be furthertreated with suitable coating materials known in the art.

Liquid dosage forms for oral administration may be in the form ofpharmaceutically acceptable emulsions, syrups, elixirs, suspensions, andsolutions, which may contain an inactive diluent, such as water.Pharmaceutical formulations and medicaments may be prepared as liquidsuspensions or solutions using a sterile liquid, such as, but notlimited to, an oil, water, an alcohol, and combinations of these.Pharmaceutically suitable surfactants, suspending agents, emulsifyingagents, may be added for oral or parenteral administration.

As noted above, suspensions may include oils. Such oils include, but arenot limited to, peanut oil, sesame oil, cottonseed oil, corn oil andolive oil. Suspension preparation may also contain esters of fatty acidssuch as ethyl oleate, isopropyl myristate, fatty acid glycerides andacetylated fatty acid glycerides. Suspension formulations may includealcohols, such as, but not limited to, ethanol, isopropyl alcohol,hexadecyl alcohol, glycerol and propylene glycol. Ethers, such as butnot limited to, poly(ethyleneglycol), petroleum hydrocarbons such asmineral oil and petrolatum; and water may also be used in suspensionformulations.

Injectable dosage forms generally include aqueous suspensions or oilsuspensions, which may be prepared using a suitable dispersant orwetting agent and a suspending agent. Injectable forms may be insolution phase or in the form of a suspension, which is prepared with asolvent or diluent. Acceptable solvents or vehicles include sterilizedwater, Ringer's solution, or an isotonic aqueous saline solution.Alternatively, sterile oils may be employed as solvents or suspendingagents. Typically, the oil or fatty acid is non-volatile, includingnatural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.

For injection, the pharmaceutical formulation and/or medicament may be apowder suitable for reconstitution with an appropriate solution asdescribed above. Examples of these include, but are not limited to,freeze dried, rotary dried or spray dried powders, amorphous powders,granules, precipitates, or particulates. For injection, the formulationsmay optionally contain stabilizers, pH modifiers, surfactants,bioavailability modifiers and combinations of these.

Dosage units for rectal administration may be prepared in the form ofsuppositories which may contain the composition of matter in a mixturewith a neutral fat base, or they may be prepared in the form ofgelatin-rectal capsules which contain the active substance in a mixturewith a vegetable oil or paraffin oil.

Compounds of the present technology may be administered to the lungs byinhalation through the nose or mouth. Suitable pharmaceuticalformulations for inhalation include solutions, sprays, dry powders, oraerosols containing any appropriate solvents and optionally othercompounds such as, but not limited to, stabilizers, antimicrobialagents, antioxidants, pH modifiers, surfactants, bioavailabilitymodifiers and combinations of these. Formulations for inhalationadministration contain as excipients, for example, lactose,polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate. Aqueousand nonaqueous aerosols are typically used for delivery of inventivecompounds by inhalation.

Ordinarily, an aqueous aerosol is made by formulating an aqueoussolution or suspension of the compound together with conventionalpharmaceutically acceptable carriers and stabilizers. The carriers andstabilizers vary with the requirements of the particular compound, buttypically include nonionic surfactants (Tweens, Pluronics, orpolyethylene glycol), innocuous proteins such as serum albumin, sorbitanesters, oleic acid, lecithin, amino acids such as glycine, buffers,salts, sugars or sugar alcohols. Aerosols generally are prepared fromisotonic solutions. A nonaqueous suspension (e.g., in a fluorocarbonpropellant) can also be used to deliver compounds of the presenttechnology.

Aerosols containing compounds for use according to the presenttechnology are conveniently delivered using an inhaler, atomizer,pressurized pack or a nebulizer and a suitable propellant, e.g., withoutlimitation, pressurized dichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, nitrogen, air, or carbon dioxide. In the caseof a pressurized aerosol, the dosage unit may be controlled by providinga valve to deliver a metered amount. Capsules and cartridges of, forexample, gelatin for use in an inhaler or insufflator may be formulatedcontaining a powder mix of the compound and a suitable powder base suchas lactose or starch. Delivery of aerosols of the present technologyusing sonic nebulizers is advantageous because nebulizers minimizeexposure of the agent to shear, which can result in degradation of thecompound.

For nasal administration, the pharmaceutical formulations andmedicaments may be a spray, nasal drops or aerosol containing anappropriate solvent(s) and optionally other compounds such as, but notlimited to, stabilizers, antimicrobial agents, antioxidants, pHmodifiers, surfactants, bioavailability modifiers and combinations ofthese. For administration in the form of nasal drops, the compounds maybe formulated in oily solutions or as a gel. For administration of nasalaerosol, any suitable propellant may be used including compressed air,nitrogen, carbon dioxide, or a hydrocarbon based low boiling solvent.

Besides those representative dosage forms described above,pharmaceutically acceptable excipients and carriers are generally knownto those skilled in the art and are thus included in the instant presenttechnology. Such excipients and carriers are described, for example, in“Remingtons Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991),which is incorporated herein by reference.

The formulations of the present technology may be designed to beshort-acting, fast-releasing, long-acting, and sustained-releasing asdescribed below. Thus, the pharmaceutical formulations may also beformulated for controlled release or for slow release.

The instant compositions may also comprise, for example, micelles orliposomes, or some other encapsulated form, or may be administered in anextended release form to provide a prolonged storage and/or deliveryeffect. Therefore, the pharmaceutical formulations and medicaments maybe compressed into pellets or cylinders and implanted intramuscularly orsubcutaneously as depot injections or as implants such as stents. Suchimplants may employ known inert materials such as silicones andbiodegradable polymers.

Specific dosages may be adjusted depending on conditions of disease, theage, body weight, general health conditions, sex, and diet of thesubject, dose intervals, administration routes, excretion rate, andcombinations of drugs. Any of the above dosage forms containingeffective amounts are well within the bounds of routine experimentationand therefore, well within the scope of the instant technology.

A therapeutically effective amount of a compound of the presenttechnology may vary depending upon the route of administration anddosage form. Effective amounts of such compounds typically fall in therange of about 0.01 up to about 100 mg/kg/day, or about 0.05 to about 50mg/kg/day, and more typically in the range of about 0.1 up to 5mg/kg/day. Typically, the compound or compounds of the instanttechnology are selected to provide a formulation that exhibits a hightherapeutic index. The therapeutic index is the dose ratio between toxicand therapeutic effects and can be expressed as the ratio between LD₅₀and ED₅₀. The LD₅₀ is the dose lethal to 50% of the population and theED₅₀ is the dose therapeutically effective in 50% of the population. TheLD₅₀ and ED₅₀ are determined by standard pharmaceutical procedures inanimal cell cultures or experimental animals.

In an aspect, method for inhibiting mtPTP opening is provided where themethod includes contacting cells with an effective amount of one or morecompounds disclosed herein.

In some embodiments, the present technology is a method for treating acondition mediated at least in part by [Ca²⁺] dysregulation and/or areactive oxygen species which method comprises administering to apatient an effective amount of one or more compounds disclosed herein.

In some embodiments, the present technology is a method for treating acondition selected from the group consisting of ischemic reperfusioninjury, multiple sclerosis, amyotropic lateral sclerosis, Alzheimer'sdisease, Huntington's disease, Parkinson's disease, insulin-inducedhypoglycemia, cerebral ischemia, brain damage from epilepsy orexperimental trauma, Bethlem myopathy, pancreatitis, hepatitis (type A,and/or B, and/or C), diabetic retinopathy, muscular dystrophy, traumaticbrain injury, type II diabetes, heart infarction, and stroke, whereinwhich method comprises administering to a patient an effective amount ofone or more compounds disclosed herein.

In any of the above embodiments, it may be the compound of the presenttechnology is not one of the following:

3. Compositions and Methods of the Present Technology

The compounds represented by Formula I, II, IIa, III, IV, and/or V ortheir tautomers and/or pharmaceutically acceptable salts thereof mayeffectively inhibit mtPTP and treat conditions mediated at least in partby [Ca²⁺] dysregulation and/or a reactive oxygen species. In one aspect,the present technology provides pharmaceutical compositions comprisingone or more compounds of Formula I, II, IIa, III, IV, and/or V and apharmaceutically acceptable excipient. In another aspect of the presenttechnology, the present technology provides a method for inhibitingmtPTP and/or a method for treating a disease mediated at least in partby accumulating by [Ca²⁺] dysregulation and/or a reactive oxygen specieswith an effective amount of one or more compound of Formula I, II, IIa,III, IV, and/or V as provided herein. The compounds of the presenttechnology are useful in inhibiting mtPTP and treating disorders relatedto [Ca²⁺] dysregulation and/or oxidative stress.

In one of its method aspects, the present technology is directed to amethod for inhibiting mtPTP which method comprises contacting cells(including neurons/microglia/invading macrophages) with an effectiveamount of one or more compound of Formula I, II, IIa, III, IV, and/or Vas described herein.

In another of its method aspects, the present technology is directed toa method for treating a disease mediated at least in part by [Ca²⁺]dysregulation and/or a reactive oxygen species, which method comprisesadministering to a patient an effective amount of one or more compoundsof Formula I, II, IIa, III, IV, and/or V or a pharmaceutical compositioncomprising a pharmaceutically acceptable excipient and one or morecompound of Formula I, II, IIa, III, IV, and/or V as described herein.

Diseases mediated at least in part by [Ca²⁺] dysregulation and/or areactive oxygen species include those selected from the group consistingof Huntington's disease and other polyglutamine disorders, Alzheimer'sdisease, Huntington's disease, Parkinson's disease, insulin-inducedhypoglycemia, cerebral ischemia, brain damage from epilepsy orexperimental trauma, Bethlem myopathy, pancreatitis, hepatitis, diabeticretinopathy, ischemic reperfusion injury, multiple sclerosis, amyotropiclateral sclerosis, muscular dystrophy, traumatic brain injury, type IIdiabetes, heart infarction, stroke, epilepsy, consequences of stroke,cerebral ischemia, hypoxia, multi-infarct dementia, consequences ofcerebral trauma or damage, damage to the spinal cord, AIDS-dementiacomplex, viral or bacterial meningitis, general central nervous system(CNS) infections such as viral, bacterial or parasites, for example,poliomyelitis, Lyme disease (Borrelia burgdorferi infection) andmalaria, cancers with cerebral localization, Tourette's syndrome,hepatic encephalopathy, systemic lupus, analgesia and opiate withdrawalsymptoms, feeding behavior, schizophrenia, chronic anxiety, depressivedisorders, disorders of the developing or aged brain, diseases ofaddiction, diabetes, and complications thereof.

The compounds of the present technology are useful in the diagnosis andtreatment of a variety of human diseases including neurodegenerative andneurological disorders, consequences of stroke and/or cerebral ischemia,hypoxia, multi-infarct dementia, consequences of trauma and damages tothe cerebrum or spinal cord, autoimmune disease, and psychiatricillness. For example, the compounds of the present technology areparticularly useful in treating neurodegenerative disorders such asHuntington's disease and other polyglutamine disorders, ischemicreperfusion injury, multiple sclerosis, amyotropic lateral sclerosis,Alzheimer's disease, Huntington's disease, Parkinson's disease,insulin-induced hypoglycemia, cerebral ischemia, brain damage fromepilepsy or experimental trauma, Bethlem myopathy, pancreatitis,hepatitis, diabetic retinopathy, muscular dystrophy, traumatic braininjury, type II diabetes, heart infarction, stroke, high-pressureneurological syndrome, dystonia, olivopontocerebellar atrophy,frontotemporal dementia, amyotrophic lateral sclerosis, multiplesclerosis, epilepsy, consequences of stroke, cerebral ischemia, hypoxia,multi-infarct dementia, consequences of cerebral trauma or damage,damage to the spinal cord, AIDS-dementia complex, viral or bacterialmeningitis, general central nervous system (CNS) infections such asviral, bacterial or parasites, for example, poliomyelitis, Lyme disease(Borrelia burgdorferi infection) and malaria, cancers with cerebrallocalization, Tourette's syndrome, hepatic encephalopathy, systemiclupus, analgesia and opiate withdrawal symptoms, feeding behavior,schizophrenia, chronic anxiety, depressive disorders, disorders of thedeveloping or aged brain, diseases of addiction, all peripheralindications such as diabetes, and complications thereof.

Compounds of the present technology are shown or contemplated to haveimproved safety and potency, such as the potency of inhibiting mtPTP atlow nanomolar concentrations. In some embodiments, the compounds havelittle or no neuroleptic activity.

The amount of active compound administered will vary depending upon thedisease treated, the mammalian species, and the particular mode ofadministration, etc. Suitable doses for the compounds of the presenttechnology can be, for example, between 0.1 mg to about 1000 mg, between1 mg to about 500 mg, between 1 mg to about 300 mg, or between 1 mg toabout 100 mg per day. Such doses can be administered once a day or morethan once a day, for example 2, 3, 4, 5 or 6 times a day, but preferably1 or 2 times per day. In some embodiments, the total dosage for a 70 kgadult is in the range of 0.001 to about 15 mg per kg weight of subjectper administration or 0.01 to about 1.5 mg per kg weight of subject peradministration, and such therapy can extend for a number of days, anumber of weeks or months, and in some cases, years. It will beunderstood, however, that the specific dose level for any particularpatient will depend on a variety of factors including the activity ofthe specific compound employed; the age, body weight, general health,sex and diet of the individual being treated; the time and route ofadministration; the rate of excretion; other drugs that have previouslybeen administered; and the severity of the particular disease undergoingtherapy, as is well understood by those of skill in the area.

4. General Synthetic Methods

The compounds of the present technology may be prepared from readilyavailable starting materials using the following general methods andprocedures. It will be appreciated that where typical or preferredprocess conditions (i.e., reaction temperatures, times, mole ratios ofreactants, solvents, pressures, etc.) are given, other processconditions can also be used unless otherwise stated. Optimum reactionconditions may vary with the particular reactants or solvent used, butsuch conditions can be determined by one skilled in the art by routineoptimization procedures.

Additionally, as will be apparent to those skilled in the art,conventional protecting groups may be necessary to prevent certainfunctional groups from undergoing undesired reactions. Suitableprotecting groups for various functional groups as well as suitableconditions for protecting and deprotecting particular functional groupsare well known in the art. For example, numerous protecting groups aredescribed in T. W. Greene and P. G. M. Wuts, Protecting Groups inOrganic Synthesis, Third Edition, Wiley, New York, 1999, and referencescited therein.

If the compounds of the present technology contain one or more chiralcenters, such compounds can be prepared or isolated as purestereoisomers, i.e., as individual enantiomers or diastereomers, or asstereoisomer-enriched mixtures. All such stereoisomers (and enrichedmixtures) are included within the scope of the present technology,unless otherwise indicated. Pure stereoisomers (or enriched mixtures)may be prepared using, for example, optically active starting materialsor stereoselective reagents well-known in the art. Alternatively,racemic mixtures of such compounds can be separated using, for example,chiral column chromatography, chiral resolving agents and the like.

The starting materials for the following reactions are generally knowncompounds or can be prepared by known procedures or obviousmodifications thereof. For example, many of the starting materials areavailable from commercial suppliers such as Aldrich Chemical Co.(Milwaukee, Wis., USA), Bachem (Torrance, Calif., USA), Emka-Chemce orSigma (St. Louis, Mo., USA). Others may be prepared by procedures, orobvious modifications thereof, described in standard reference textssuch as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15(John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds,Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989),Organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March'sAdvanced Organic Chemistry, (John Wiley, and Sons, 5^(th) Edition,2001), and Larock's Comprehensive Organic Transformations (VCHPublishers Inc., 1989).

Synthesis of Representative Compounds of the Present Technology

In one general embodiment, the method involves reacting an appropriateaniline starting material with an electrophilic partner such as acarboxylic acid or the corresponding acyl halide in order to make abenzamide or benzene sulfonamide. It is appreciated that thenucleophilic component of the aniline preferentially adds to thecarbonyl of the electrophilic component. Additionally, isoxazolinecompounds are made by cyclization after condensing an appropriatediketo-compound with hydroxyl amine. The isolated adduct can then befurther functionalized.

In another general embodiment, the method involves reacting anappropriately functionalized aniline or diketo-compound, as synthesizedfrom above, with a partner. It is further appreciated that the partnerselectively reacts at one functional group of the aniline ordiketo-compound. Thus, the partner should not be added under anyreaction conditions that might react with any other functionality.

For example, the compounds of general Formula I, II, IIa, III, IV,and/or V can be prepared according to representative Scheme 1:

Amino, keto, thio, hydroxyl, and any other necessary protecting groupsand their methods of deprotection are known in the art, such as thosedescribed in T. W. Greene and P. G. M. Wuts, Protecting Groups inOrganic Synthesis, Third Edition, Wiley, New York, 1999. When Prt ishydrogen, the deprotection step can be omitted.

5. Administration and Pharmaceutical Composition

The present technology provides compounds possessing mtPTP inhibitoryactivity and, accordingly, are useful in treating disorders mediated by(or at least in part by) [Ca²⁺] dysregulation and/or the accumulation ofby a reactive oxygen species. Such diseases include, for example,Huntington's disease and other polyglutamine disorders, ischemicreperfusion injury, multiple sclerosis, amyotropic lateral sclerosis,Alzheimer's disease, Huntington's disease, Parkinson's disease,insulin-induced hypoglycaemia, cerebral ischemia, brain damage fromepilepsy or experimental trauma, Bethlem myopathy, pancreatitis,hepatitis, diabetic retinopathy, muscular dystrophy, traumatic braininjury, type II diabetes, heart infarction, stroke, high-pressureneurological syndrome, dystonia, olivopontocerebellar atrophy,frontotemporal dementia, amyotrophic lateral sclerosis, multiplesclerosis, epilepsy, consequences of stroke, cerebral ischemia, hypoxia,multi-infarct dementia, consequences of cerebral trauma or damage,damage to the spinal cord, AIDS-dementia complex, viral or bacterialmeningitis, general central nervous system (CNS) infections such asviral, bacterial or parasites, for example, poliomyelitis, Lyme disease(Borrelia burgdorferi infection) and malaria, cancers with cerebrallocalization, Tourette's syndrome, hepatic encephalopathy, systemiclupus, analgesia and opiate withdrawal symptoms, feeding behaviour,schizophrenia, chronic anxiety, depressive disorders, disorders of thedeveloping or aged brain, diabetes, and complications thereof.

In general, the compounds of the present technology will be administeredin a therapeutically effective amount by any of the accepted modes ofadministration for agents that serve similar utilities. The actualamount of the compound of the present technology, i.e., the activeingredient, will depend upon numerous factors such as the severity ofthe disease to be treated, the age and relative health of the subject,the potency of the compound used, the route and form of administration,and other factors well known to the skilled artisan. The drug can beadministered at least once a day, preferably once or twice a day.

An effective amount of such agents can readily be determined by routineexperimentation, as can the most effective and convenient route ofadministration, and the most appropriate formulation. Variousformulations and drug delivery systems are available in the art. See,e.g., Gennaro, A. R., ed. (1995) Remington's Pharmaceutical Sciences,18^(th) ed., Mack Publishing Co.

A therapeutically effective dose can be estimated initially using avariety of techniques well-known in the art. Initial doses used inanimal studies may be based on effective concentrations established incell culture assays. Dosage ranges appropriate for human subjects can bedetermined, for example, using data obtained from animal studies andcell culture assays.

An effective amount or a therapeutically effective amount or dose of anagent, e.g., a compound of the present technology, refers to that amountof the agent or compound that results in amelioration of symptoms or aprolongation of survival in a subject. Toxicity and therapeutic efficacyof such molecules can be determined by standard pharmaceuticalprocedures in cell cultures or experimental animals, e.g., bydetermining the LD50 (the dose lethal to 50% of the population) and theED50 (the dose therapeutically effective in 50% of the population). Thedose ratio of toxic to therapeutic effects is therapeutic index, whichcan be expressed as the ratio LD50/ED50. Agents that exhibit hightherapeutic indices are preferred.

The effective amount or therapeutically effective amount is the amountof the compound or pharmaceutical composition that will elicit thebiological or medical response of a tissue, system, animal or human thatis being sought by the researcher, veterinarian, medical doctor or otherclinician. Dosages particularly fall within a range of circulatingconcentrations that includes the ED50 with little or no toxicity.Dosages may vary within this range depending upon the dosage formemployed and/or the route of administration utilized. The exactformulation, route of administration, dosage, and dosage interval shouldbe chosen according to methods known in the art, in view of thespecifics of a subject's condition.

Dosage amount and interval may be adjusted individually to provideplasma levels of the active moiety that are sufficient to achieve thedesired effects; i.e., the minimal effective concentration (MEC). TheMEC will vary for each compound but can be estimated from, for example,in vitro data and animal experiments. Dosages necessary to achieve theMEC will depend on individual characteristics and route ofadministration. In cases of local administration or selective uptake,the effective local concentration of the drug may not be related toplasma concentration.

The amount of agent or composition administered may be dependent on avariety of factors, including the sex, age, and weight of the subjectbeing treated, the severity of the affliction, the manner ofadministration, and the judgment of the prescribing physician.

The present technology is not limited to any particular composition orpharmaceutical carrier, as such may vary. In general, compounds of thepresent technology will be administered as pharmaceutical compositionsby any one of the following routes: oral, systemic (e.g., transdermal,intranasal or by suppository), or parenteral (e.g., intramuscular,intravenous or subcutaneous) administration. The preferred manner ofadministration is oral using a convenient daily dosage regimen that canbe adjusted according to the degree of affliction. Compositions can takethe form of tablets, pills, capsules, semisolids, powders, sustainedrelease formulations, solutions, suspensions, elixirs, aerosols, or anyother appropriate compositions. Another preferred manner foradministering compounds of the present technology is inhalation.

The choice of formulation depends on various factors such as the mode ofdrug administration and bioavailability of the drug substance. Fordelivery via inhalation the compound can be formulated as liquidsolution, suspensions, aerosol propellants or dry powder and loaded intoa suitable dispenser for administration. There are several types ofpharmaceutical inhalation devices-nebulizer inhalers, metered doseinhalers (MDI), and dry powder inhalers (DPI). Nebulizer devices producea stream of high velocity air that causes therapeutic agents (which areformulated in a liquid form) to spray as a mist that is carried into thepatient's respiratory tract. MDI's typically are formulation packagedwith a compressed gas. Upon actuation, the device discharges a measuredamount of therapeutic agent by compressed gas, thus affording a reliablemethod of administering a set amount of agent. DPI dispenses therapeuticagents in the form of a free flowing powder that can be dispersed in thepatient's inspiratory air-stream during breathing by the device. Inorder to achieve a free flowing powder, therapeutic agent is formulatedwith an excipient such as lactose. A measured amount of therapeuticagent is stored in a capsule form and is dispensed with each actuation.

Pharmaceutical dosage forms of a compound of the present technology maybe manufactured by any of the methods well-known in the art, such as,for example, by conventional mixing, sieving, dissolving, melting,granulating, dragée-making, tableting, suspending, extruding,spray-drying, levigating, emulsifying, (nano/micro-) encapsulating,entrapping, or lyophilization processes. As noted above, thecompositions of the present technology can include one or morephysiologically acceptable inactive ingredients that facilitateprocessing of active molecules into preparations for pharmaceutical use.

Pharmaceutical formulations have been developed especially for drugsthat show poor bioavailability based upon the principle thatbioavailability can be increased by increasing the surface area i.e.,decreasing particle size. For example, U.S. Pat. No. 4,107,288 describesa pharmaceutical formulation having particles in the size range from 10to 1,000 nm in which the active material is supported on a crosslinkedmatrix of macromolecules. U.S. Pat. No. 5,145,684 describes theproduction of a pharmaceutical formulation in which the drug substanceis pulverized to nanoparticles (average particle size of 400 nm) in thepresence of a surface modifier and then dispersed in a liquid medium togive a pharmaceutical formulation that exhibits remarkably highbioavailability.

The compositions are comprised of, in general, a compound of the presenttechnology in combination with at least one pharmaceutically acceptableexcipient. Acceptable excipients are non-toxic, aid administration, anddo not adversely affect therapeutic benefit of the claimed compounds.Such excipient may be any solid, liquid, semi-solid or, in the case ofan aerosol composition, gaseous excipient that is generally available toone of skill in the art.

Solid pharmaceutical excipients include starch, cellulose, talc,glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silicagel, magnesium stearate, sodium stearate, glycerol monostearate, sodiumchloride, dried skim milk and the like. Liquid and semisolid excipientsmay be selected from glycerol, propylene glycol, water, ethanol andvarious oils, including those of petroleum, animal, vegetable orsynthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesameoil, etc. Preferred liquid carriers, particularly for injectablesolutions, include water, saline, aqueous dextrose, and glycols.

Compressed gases may be used to disperse a compound of the presenttechnology in aerosol form. Gases suitable for this purpose arenitrogen, carbon dioxide, etc. Other suitable pharmaceutical excipientsand their formulations are described in Remington's PharmaceuticalSciences, edited by E. W. Martin (Mack Publishing Company, 18th ed.,1990).

The present compositions may, if desired, be presented in a pack ordispenser device containing one or more unit dosage forms containing theactive ingredient. Such a pack or device may, for example, comprisemetal or plastic foil, such as a blister pack, or glass, and rubberstoppers such as in vials. The pack or dispenser device may beaccompanied by instructions for administration. Compositions comprisinga compound of the present technology formulated in a compatiblepharmaceutical carrier may also be prepared, placed in an appropriatecontainer, and labeled for treatment of an indicated condition.

The amount of the compound in a formulation can vary within the fullrange employed by those skilled in the art. Typically, the formulationwill contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt% of a compound of the present technology based on the totalformulation, with the balance being one or more suitable pharmaceuticalexcipients. Preferably, the compound is present at a level of about 1-80wt %. Representative pharmaceutical formulations are described below.

FORMULATION EXAMPLES

The following are representative pharmaceutical formulations including acompound of Formula I, II, IIa, III, IV, and/or V.

Formulation Example 1—Tablet Formulation

The following ingredients are mixed intimately and pressed into singlescored tablets.

Quantity per Ingredient tablet, mg compound of the present technology400 cornstarch 50 croscarmellose sodium 25 lactose 120 magnesiumstearate 5

Formulation Example 2—Capsule Formulation

The following ingredients are mixed intimately and loaded into ahard-shell gelatin capsule.

Quantity per Ingredient capsule, mg compound of the present technology200 lactose, spray-dried 148 magnesium stearate 2

Formulation Example 3—Suspension Formulation

The following ingredients are mixed to form a suspension for oraladministration.

Ingredient Amount compound of the present technology 1.0 g fumaric acid0.5 g sodium chloride 2.0 g methyl paraben 0.15 g propyl paraben 0.05 ggranulated sugar 25.0 g sorbitol (70% solution) 13.00 g Veegum K(Vanderbilt Co.) 1.0 g flavoring 0.035 mL colorings 0.5 mg distilledwater q.s. to 100 mL

Formulation Example 4—Injectable Formulation

The following ingredients are mixed to form an injectable formulation.

Ingredient Amount compound of the present technology 0.2 mg-20 mg sodiumacetate buffer solution, 0.4M 2.0 mL HCl (1N) or NaOH (1N) q.s. tosuitable pH water (distilled, sterile) q.s. to 20 mL

Formulation Example 5—Suppository Formulation

A suppository of total weight 2.5 g is prepared by mixing the compoundof the present technology with Witepsol® H-15 (triglycerides ofsaturated vegetable fatty acid; Riches-Nelson, Inc., New York), and hasthe following composition:

Ingredient Amount Compound of the present technology 500 mg Witepsol ®H-15 balance

The following synthetic and biological examples are offered toillustrate the present technology and are not to be construed in any wayas limiting the scope of the present technology. Unless otherwisestated, all temperatures are in degree Celsius.

Examples

The present technology is further understood by reference to thefollowing examples, which are intended to be purely exemplary of thepresent technology. The present technology is not limited in scope bythe exemplified embodiments, which are intended as illustrations ofsingle aspects of the present technology only. Any methods that arefunctionally equivalent are within the scope of the present technology.Various modifications of the present technology in addition to thosedescribed herein will become apparent to those skilled in the art fromthe foregoing description and accompanying figures. Such modificationsfall within the scope of the appended claims.

In the examples below, the following abbreviations have the followingmeanings. If an abbreviation is not defined, it has its generallyaccepted meaning.

-   aq.=aqueous-   CaCl₂)=calcium chloride-   LC-MS=liquid chromatography-mass spectrometry-   MS=mass spectrometry-   THF=tetrahydrofuran-   NaHCO₃=sodium bicarbonate-   DIPEA=diisopropylethylamine-   MS=mass spectrometry-   NaH=sodium hydride-   o/n=overnight-   HATU=1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium    3-oxid hexafluorophosphate-   r.t.=room temperature-   LAH=lithium aluminum hydride-   DCM=dichloromethane-   DMF=dimethylformamide-   DMSO=dimethyl sulfoxide-   equiv.=equivalent-   EtOAc=ethyl acetate-   EtOH=ethanol-   g=gram-   h=hours-   HCl=hydrochloric acid-   HCHO=formaldehyde-   HPLC=high-performance liquid chromatography-   HOAc=acetic acid-   M=molar-   m-CPBA=m-chloroperoxybenzoic acid-   MeOH=methanol-   mg=milligrams-   mL=milliliters-   mmol=millimols-   mp=melting point-   m/z=mass to charge ratio-   NaCl=sodium chloride-   Na₂CO₃=sodium carbonate-   NMR=nuclear magnetic resonance-   NaOH=sodium hydroxide-   Na₂SO₄=sodium sulfate-   TLC=thin layer chromatography-   UV=ultraviolet-   wt %=weight percent-   μM=micromolar

General Experimental Details:

Purity of all final compounds was confirmed by HPLC/MS analysis anddetermined to be ≥90%. ¹H and ¹³C NMR spectra were recorded on a BrukerAM 400 spectrometer (operating at 400 and 101 MHz respectively) or aBruker AVIII spectrometer (operating at 500 and 126 MHz respectively) inCDCl₃ (residual internal standard CHCl₃=δ 7.26), DMSO-d₆ (residualinternal standard CD₃SOCD₂H=62.50), or acetone-d₆ (residual internalstandard CD₃COCD₂H=δ 2.05). The chemical shifts (δ) reported are givenin parts per million (ppm) and the coupling constants (J) are in Hertz(Hz). The spin multiplicities are reported as s=singlet, bs=broadsinglet, bm=broad multiplet=doublet, t=triplet, q=quartet, p=pentuplet,dd=doublet of doublet, ddd=doublet of doublet of doublet, dt=doublet oftriplet, td=triplet of doublet, tt=triplet of triplet, and m=multiplet.

HPLC/MS analysis was carried out with gradient elution (5% CH₃CN to 100%CH₃CN) on an Agilent 1200 RRLC with a photodiode array UV detector andan Agilent 6224 TOF mass spectrometer (also used to produce highresolution mass spectra). Automated preparative RP HPLC purification wascarried out by Mass Directed Fractionation with gradient elution (anarrow CH₃CN gradient was chosen based on the retention time of thetarget from LCMS analysis of the crude sample) on an Agilent 1200instrument with photodiode array detector, an Agilent 6120 quadrupolemass spectrometer, and a HTPAL LEAP autosampler. Fractions weretriggered using an MS and UV threshold determined by HPLC/MS analysis ofthe crude sample. One of two column/mobile phase conditions were chosenfor both analysis and purification to promote the targets neutral state:0.02% formic acid with Waters Atlantis T3 Sum, 19×150 mm (Prep scale),Waters Atlantis T3 1.7 um, 2.1×50 mm (Analytical Scale); pH 9.8 NH4OHwith Waters XBridge C18 5 um, 19×150 mm (Prep scale), Waters BEH C-181.7 um, 2.1×50 mm (Analytical Scale). Medium pressure liquidchromatography (MPLC) was performed on a Teledyne Icso CombiFlash Rfpurification system using gradient elution through standard RediSep Rfcolumns. Microwave irradiated reactions were carried out using a BiotageInitiator Classic synthesizer.

The following are experimental reactions used to synthesizeintermediates and the final isoxazole and benzamide compounds.

General Procedure (isoxazole amide) 1:

To a solution of isoxazole carboxylic acid (0.390 mmol, 1 eq.) in dryTHF (1.5 mL) in a 4 dram vial was added thionyl chloride (0.558 mmol,1.43 eq.) and was stirred at reflux for 0.5 h. After cooling to about35° C., a solution of the requisite aniline (0.390 mmol, 1 eq.) andtriethylamine (1.560 mmol, 4 eq.) in dry THF (1 mL) was added drop wise.After stirring at room temperature for 2 hours the reaction mixture wasquenched with 1N HCl and extracted with ethyl acetate (×3). The combinedorganic layer was dried over anhydrous Na₂SO₄, filtered, and evaporatedto dryness. The resulting residue was purified according to thepreparative RP-HPLC methods described herein.

General Procedure (isoxazole amide) 2:

To a solution of the appropriate aniline (0.049 mmol, 1 eq.) in DMF (0.1M, 0.5 mL) was added PyBOP (0.097 mmol, 2 eq.), Hunig's base (0.107mmol, 2.2 eq.), and the appropriate benzoic acid (0.049 mmol, 1 eq.).The reaction mixture was subjected to microwave radiation at 120° C. for20 min, following which the resulting residue was purified according tothe preparative RP HPLC methods described herein.

Synthesis of Intermediates

KSC-392-136

(Z)-Methyl 4-hydroxy-4-(3-(methylsulfonamido)phenyl)-2-oxobut-3-enoate(KSC-392-136): To a solution of N-(3-acetylphenyl)methanesulfonamide(0.5 g, 2.345 mmol, 1 eq.) in Et₂O (9.4 mL, 0.25M) was added sodiummethoxide (1.126 ml, 4.92 mmol, 2.1 eq.), followed by dimethyl oxalate(0.277 g, 2.345 mmol, 1 eq.) and the mixture was stirred for 24 h atroom temperature. Upon completion, the mixture was quenched with 1N HCland extracted with EtOAc (×3). The combined organic layers were washedwith brine, dried over anhydrous Na₂SO₄, and evaporated to dryness. Theresulting residue was purified via MPLC (silica, 10-100% hexanes/EtOAc)to provide (Z)-methyl4-hydroxy-4-(3-(methylsulfonamido)phenyl)-2-oxobut-3-enoate (0.844 g,2.115 mmol, 90% yield) (KSC-392-136) as light yellow solid. ¹H NMR (500MHz, DMSO-d₆) δ 10.10 (s, 1H), 7.92-7.79 (m, 2H), 7.61-7.41 (m, 2H),7.06 (s, 1H), 3.87 (s, 3H), 3.05 (s, 3H); HRMS (ESI-TOF) m/z: [M−H]⁻Calcd for C₁₂H₁₂NO₆S 298.0391; Found 298.0378.

KSC-392-147

Methyl 5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylate(KSC-392-147): To a stirred solution of (Z)-methyl4-hydroxy-4-(3-(methylsulfonamido)phenyl)-2-oxobut-3-enoate (0.400 g,1.336 mmol) in MeOH (4.86 mL, 0.2 M) was added hydroxylaminehydrochloride (0.203 g, 2.91 mmol) at room temperature. The resultingmixture was then heated to reflux for 24 h. Upon completion, thereaction mixture was concentrated under reduced pressure. The cruderesidue was dissolved in EtOAc, washed with water, dried over anhydrousNa₂SO₄, and evaporated to dryness. The resulting residue was purifiedvia MPLC (silica, 10-100% hexanes/EtOAc) to provide methyl5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylate (0.368 g, 1.242mmol, 93% yield) (KSC-392-147) as off-white solid. ¹H NMR (400 MHz,Acetone-d₆) δ 7.91-7.85 (m, 1H), 7.71 (dt, J=7.6, 1.4 Hz, 1H), 7.55 (td,J=7.8, 0.6 Hz, 1H), 7.50 (ddd, J=8.1, 2.2, 1.3 Hz, 1H), 7.22 (s, 1H),3.96 (s, 3H), 3.09 (s, 3H); ¹³C NMR (101 MHz, Acetone-d₆) δ 171.70,160.73, 157.74, 140.33, 131.23, 128.46, 122.99, 122.45, 117.66, 101.41.HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd for C₁₄H₁₀ClO₃ 261.0324; Found261.0237.

KSC-392-152

5-(3-(Methylsulfonamido)phenyl)isoxazole-3-carboxylic acid(KSC-392-152): To methyl5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylate (0.360 g, 1.215mmol) in a mixture of EtOH (7.23 ml):THF (3.62 ml) (2:1, 0.112M) wasadded 1 M NaOH (2.065 ml, 2.065 mmol) and heated to reflux for 4 h. Uponcompletion, the reaction mixture was concentrated and diluted with 1NHCl. The aqueous layer was extracted with EtOAc (×3). The combinedorganic layers were washed with brine, dried over anhydrous Na₂SO₄, andconcentrated in vacuo to provide5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylic acid (0.332 g,1.176 mmol, 97% yield) (KSC-392-152) as off-white solid. ¹H NMR (400MHz, DMSO-d₆) δ 10.03 (s, 1H), 7.74-7.65 (m, 2H), 7.57-7.48 (m, 1H),7.38 (s, 1H), 7.35 (ddd, J=8.1, 2.2, 1.0 Hz, 1H), 3.07 (s, 3H); HRMS(ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₁H₁₁N₂O₅S 283.0383; Found 283.0374.

KSC-392-122

Methyl 4-(3-hydroxy-4-methoxyphenyl)-2,4-dioxobutanoate (KSC-392-122):To a solution of 1-(3-hydroxy-4-methoxyphenyl)ethanone (0.533 g, 1.901mmol) in Et₂O (7.60 ml, 0.25M) was added sodium methoxide (0.652 ml,2.85 mmol), followed by dimethyl oxalate (0.224 g, 1.901 mmol) and themixture was stirred for 24 h at room temperature. Upon completion, themixture was quenched with 1N HCl and extracted with EtOAc (×3). Thecombined organic layers were washed with brine, dried over anhydrousNa₂SO₄, and evaporated to dryness. The resulting residue was purifiedMPLC (silica, 10-100% hexanes/EtOAc) to provide4-(3-hydroxy-4-methoxyphenyl)-2,4-dioxobutanoate (0.250 g, 0.991 mmol,52.2% yield) (KSC-392-122) as yellow solid. ¹H NMR (400 MHz, Acetone-d₆)δ 7.68 (dd, J=8.5, 2.2 Hz, 1H), 7.55 (d, J=2.2 Hz, 1H), 7.13 (d, J=8.5Hz, 1H), 7.06 (s, 1H), 3.97 (s, 3H), 3.89 (s, 3H); HRMS (ESI-TOF) m/z:[M+Na]⁺ Calcd for C₁₂H₁₂NaO₆ 275.0526; Found 275.0543.

KSC-392-089

Methyl 5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylate(KSC-392-089): To a stirred solution of (Z)-methyl4-hydroxy-4-(3-hydroxy-4-methoxyphenyl)-2-oxobut-3-enoate (0.245 g,0.971 mmol) in MeOH (4.86 ml, 0.2 M) was added hydroxylaminehydrochloride (0.203 g, 2.91 mmol) at room temperature. The resultingmixture was then heated to reflux for 24 h. Upon completion, thereaction mixture was concentrated under reduced pressure. The cruderesidue was dissolved in EtOAc, washed with water, dried over anhydrousNa₂SO₄, and evaporated to dryness. The resulting residue was purifiedvia MPLC (silica, 10-100% hexanes/EtOAc) to provide methyl5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylate (0.222 g, 0.891mmol, 92% yield) (KSC-392-089) as off-white solid. ¹H NMR (400 MHz,DMSO-d₆) δ 9.47 (s, 1H), 7.41 (dd, J=8.4, 2.2 Hz, 1H), 7.33 (d, J=2.1Hz, 1H), 7.29 (s, 1H), 7.09 (d, J=8.5 Hz, 1H), 3.93 (s, 3H), 3.86 (s,3H); ¹³C NMR (101 MHz, DMSO) δ 171.35, 159.91, 156.47, 150.09, 146.92,118.77, 117.83, 112.48, 112.44, 99.09, 55.68, 52.71; HRMS (ESI-TOF) m/z:[M+H]⁺ Calcd for C₁₂H₁₂NO₅ 250.0710; Found 250.0707.

KSC-392-095

5-(3-Hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (KSC-392-095):To methyl 5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylate (0.223 g,0.895 mmol) in a mixture of EtOH (5.3 mL):THF (2.7 mL) (2:1, 0.112M) wasadded 1 M NaOH (1.5 ml, 1.521 mmol) and heated to reflux for 4 h. Uponcompletion, the reaction mixture was concentrated and diluted with 1NHCl. The aqueous layer was extracted with EtOAc (×3). The combinedorganic layers were washed with brine, dried over anhydrous Na₂SO₄, andconcentrated in vacuo to provide5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (0.208 g, 0.884mmol, 99% yield) as off-white solid. ¹H NMR (400 MHz, Acetone-d₆) δ 7.42(dd, J=8.3, 2.2 Hz, 1H), 7.39 (d, J=2.1 Hz, 1H), 7.11 (d, J=8.4 Hz, 1H),7.05 (s, 1H), 3.92 (s, 3H); ¹³C NMR (101 MHz, Acetone) 6172.53, 161.24,158.15, 150.73, 147.99, 120.76, 118.90, 113.28, 112.77, 99.84, 56.39;HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₁H₁₀NO₅ 236.0553; Found 236.0545.

KSC-392-097

Methyl 4-(4-fluoro-3-hydroxyphenyl)-2,4-dioxobutanoate (KSC-392-097): Toa solution of 1-(4-fluoro-3-hydroxyphenyl)ethanone (0.120 g, 0.779 mmol)in Et₂O (3 ml, 0.25M) was added sodium methoxide (0.267 ml, 1.168 mmol),followed by dimethyl oxalate (0.092 g, 0.779 mmol) and the mixture wasstirred for 24 h at room temperature. Upon completion, the mixture wasquenched with 1N HCl and extracted with EtOAc (×3). The combined organiclayers were washed with brine, dried over anhydrous Na₂SO₄, andevaporated to dryness. The resulting residue was purified MPLC (silica,10-100% hexanes/EtOAc) to provide methyl4-(4-fluoro-3-hydroxyphenyl)-2,4-dioxobutanoate (0.133 g, 0.554 mmol,71% yield) (KSC-392-097) as light yellow liquid which solidified oncooling. ¹H NMR (400 MHz, Acetone-d₆) δ 7.72 (dd, J=8.5, 2.3 Hz, 1H),7.66 (ddd, J=8.6, 4.4, 2.3 Hz, 1H), 7.31 (dd, J=10.7, 8.5 Hz, 1H), 7.08(s, 1H), 3.90 (s, 3H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₄H₁₀ClO₃261.0324; Found 261.0348.

KSC-392-083

Methyl 5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylate(KSC-392-083): To a stirred solution of (Z)-methyl4-(4-fluoro-3-hydroxyphenyl)-4-hydroxy-2-oxobut-3-enoate (0.198 g, 0.824mmol, 1 eq.) in MeOH (4 mL, 0.2 M) was added hydroxylamine hydrochloride(0.172 g, 2.473 mmol) at room temperature. The resulting mixture wasthen heated to reflux for 24 h. Upon completion, the reaction mixturewas concentrated under reduced pressure. The crude residue was dissolvedin EtOAc, washed with water, dried over anhydrous Na₂SO₄, and evaporatedto dryness. The resulting residue was purified via MPLC (silica, 10-100%hexanes/EtOAc) to provide methyl methyl5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylate (0.080 g, 0.337mmol, 41% yield) (KSC-392-083) as off-white solid. ¹H NMR (400 MHz,DMSO-d₆) δ 10.39 (d, J=0.9 Hz, 1H), 7.49 (dd, J=8.3, 2.2 Hz, 1H),7.47-7.38 (m, 2H), 7.34 (dd, J=11.0, 8.5 Hz, 1H), 3.92 (s, 3H); HRMS(ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₁H₉FNO₄ 238.0510; Found 238.0501.

KSC-392-088

5-(4-Fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (KSC-392-088):To methyl 5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylate (0.08 g,0.337 mmol) in a mixture of EtOH (2 mL):THF (1 mL) (2:1, 0.112M) wasadded 1 M NaOH (0.573 ml, 0.573 mmol) and heated to reflux for 4 h. Uponcompletion, the reaction mixture was concentrated and diluted with 1NHCl. The aqueous layer was extracted with EtOAc (×3). The combinedorganic layers were washed with brine, dried over anhydrous Na₂SO₄, andconcentrated in vacuo to provide5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (0.070 g, 0.314mmol, 93% yield) as off-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.38(bs, 1H), 7.47 (dd, J=8.3, 2.1 Hz, 1H), 7.42-7.38 (m, 1H), 7.35-7.31 (m,1H), 7.30 (s, 1H); ¹³C NMR (101 MHz, DMSO-d₆) δ 170.09, 160.75, 157.75,152.53 (d, J=246.5 Hz), 145.58 (d, J=12.9 Hz), 123.01, 117.69 (d, J=7.2Hz), 117.18 (d, J=19.3 Hz), 114.95 (d, J=3.7 Hz), 100.54; HRMS (ESI-TOF)m/z: [M+H]⁺ Calcd for C₁₀H₇FNO₄ 224.0354; Found 224.0342.

KSC-338-013

N-(2-Bromo-4,6-difluorophenyl)-5-propylisoxazole-3-carboxamide(KSC-338-013): ¹H NMR (400 MHz, DMSO-d₆) δ 10.53 (s, 1H), 7.67-7.59 (m,1H), 7.56-7.45 (m, 1H), 6.70 (s, 1H), 2.83 (t, J=7.4 Hz, 2H), 1.70 (h,J=7.4 Hz, 2H), 0.95 (t, J=7.4 Hz, 3H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcdfor C₁₃H₁₂BrF₂N₂O₂ 345.0045; Found 345.0045.

KSC-338-014

N-(4-Bromophenyl)-5-cyclopropylisoxazole-3-carboxamide (KSC-338-014): ¹HNMR (400 MHz, DMSO-d₆) δ 10.72 (s, 1H), 7.80-7.65 (m, 2H), 7.58-7.43 (m,2H), 6.59 (s, 1H), 2.29-2.15 (m, 1H), 1.17-1.06 (m, 2H), 1.01-0.85 (m,2H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₃H₁₂BrN₂O₂ 307.0077; Found307.0077.

KSC-338-015

N-(2,4-Difluorophenyl)-5-isopropylisoxazole-3-carboxamide (KSC-338-015):¹H NMR (400 MHz, DMSO-d₆) δ 10.45 (s, 1H), 7.61-7.49 (m, 1H), 7.41-7.29(m, 1H), 7.18-7.08 (m, 1H), 6.67 (d, J=0.9 Hz, 1H), 3.24-3.11 (m, 1H),1.29 (d, J=6.9 Hz, 6H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd forC₁₃H₁₃F₂N₂O₂ 267.0940; Found 267.0945.

KSC-338-016

N-(4-Bromophenyl)-5-propylisoxazole-3-carboxamide (KSC-338-016): ¹H NMR(400 MHz, DMSO-d₆) δ 10.75 (s, 1H), 7.76-7.65 (m, 2H), 7.59-7.49 (m,2H), 6.67 (s, 1H), 2.80 (t, J=7.4 Hz, 2H), 1.68 (h, J=7.4 Hz, 2H), 0.92(t, J=7.3 Hz, 3H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₃H₁₄BrN₂O₂309.0233; Found 309.0234.

KSC-338-018

5-(4-Fluorophenyl)-N-(5-methylisoxazol-3-yl)isoxazole-3-carboxamide(KSC-338-018): ¹H NMR (400 MHz, DMSO-d₆) δ 11.71 (s, 1H), 8.08-7.98 (m,2H), 7.53 (s, 1H), 7.49-7.38 (m, 2H), 6.71 (d, J=1.1 Hz, 1H); HRMS(ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₄H₁₁FN₃O₃ 288.0779; Found 288.0773.

KSC-338-020

5-Phenyl-N-(2-(trifluoromethyl)phenyl)isoxazole-3-carboxamide(KSC-338-020): ¹H NMR (400 MHz, DMSO-d₆) δ 10.50 (s, 1H), 8.02-7.91 (m,2H), 7.86-7.72 (m, 2H), 7.67-7.60 (m, 1H), 7.63-7.53 (m, 4H), 7.50 (s,1H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₂F₃N₂O₂ 333.0845; Found333.0831.

KSC-338-021

N-(2,4-Difluorophenyl)-5-phenylisoxazole-3-carboxamide (KSC-338-021): ¹HNMR (400 MHz, DMSO-d₆) δ 10.57 (s, 1H), 8.02-7.87 (m, 2H), 7.67-7.53 (m,4H), 7.51 (s, 1H), 7.40 (ddd, J=10.6, 9.1, 2.9 Hz, 1H), 7.20-7.10 (m,2H); HRMS (ESI-TOF) m/z: [M+NH₄]⁺ Calcd for C₁₆H₁₄F₂N₃O₂ 318.1049; Found318.1059.

KSC-338-023

5-Chloro-N-ethyl-2-methoxy-N-phenylbenzamide (KSC-338-010): ¹H NMR (400MHz, DMSO-d₆) δ 10.28 (s, 1H), 8.02-7.90 (m, 2H), 7.63-7.52 (m, 3H),7.48 (s, 1H), 7.40-7.28 (m, 2H), 7.30-7.22 (m, 2H), 2.64 (q, J=7.6 Hz,2H), 1.15 (t, J=7.5 Hz, 3H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd forC₁₈H₁₇N₂O₂ 293.1285; Found 293.1283.

KSC-338-024

N-(4-Chlorophenyl)-5-phenylisoxazole-3-carboxamide (KSC-338-024): ¹H NMR(400 MHz, DMSO-d₆) δ 10.92 (s, 1H), 8.01-7.93 (m, 2H), 7.89-7.81 (m,2H), 7.62-7.53 (m, 3H), 7.50 (s, 1H), 7.49-7.40 (m, 2H); HRMS (ESI-TOF)m/z: [M+H]⁺ Calcd for C₁₆H₁₂ClN₂O₂ 299.0582; Found 299.0572.

KSC-338-074

N-(2-(Benzyloxy)phenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-338-074): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (10 mg, 0.049 mmol) and2-(benzyloxy)aniline (10 mg, 0.049 mmol). Yield: 5 mg (25%); 100%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 9.90 (s, 1H), 9.64 (s, 1H),8.06-7.98 (m, 2H), 7.55-7.48 (m, 2H), 7.47-7.28 (m, 7H), 7.23-7.14 (m,2H), 7.05-6.99 (m, 2H), 6.95 (ddd, J=7.7, 2.4, 1.4 Hz, 1H), 5.25 (s,2H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₃H₁₉N₂O₄ 387.1339; Found387.1343.

KSC-338-075

N-(3-Chloro-4-methoxyphenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-338-075): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (10 mg, 0.049 mmol) and3-chloro-4-methoxyaniline (8 mg, 0.049 mmol). Yield: 3 mg (16%); 100%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.78 (s, 1H), 9.90 (s, 1H), 7.94(d, J=2.5 Hz, 1H), 7.72 (dd, J=9.0, 2.6 Hz, 1H), 7.43-7.32 (m, 3H),7.34-7.27 (m, 1H), 7.18 (d, J=9.1 Hz, 1H), 6.95 (ddd, J=7.2, 2.5, 1.8Hz, 1H), 3.85 (s, 3H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₄ClN₂O₄345.0637; Found 345.0649.

KSC-338-094

N-(4-Chlorophenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-338-094): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (20 mg, 0.097 mmol) and4-chloroaniline (12 mg, 0.097 mmol). Yield: 9 mg (28%); 100% purity. ¹HNMR (400 MHz, DMSO-d₆) δ 10.90 (s, 1H), 9.94 (s, 1H), 7.88-7.79 (m, 2H),7.48-7.40 (m, 2H), 7.43-7.32 (m, 3H), 7.33-7.27 (m, 1H), 6.98-6.91 (m,1H); HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd for C₁₆H₁₀ClN₂O₃ 313.0385; Found313.0393.

KSC-338-095

N-(3-Fluorophenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-338-095): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (20 mg, 0.097 mmol) and3-fluoroaniline (11 mg, 0.097 mmol). Yield: 7 mg (23%); 100% purity. ¹HNMR (400 MHz, DMSO-d₆) δ 10.94 (s, 1H), 7.69 (dt, J=11.5, 2.3 Hz, 1H),7.57 (ddd, J=8.2, 2.0, 0.9 Hz, 1H), 7.46-7.31 (m, 4H), 7.31-7.23 (m,1H), 7.04-6.88 (m, 2H); HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd for C₁₆H₁₀FN₂O₃297.0681; Found 297.0663.

KSC-338-100

N-(3-Chloro-4-methylphenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-338-100): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (20 mg, 0.097 mmol) and3-chloro-4-methylaniline (14 mg, 0.097 mmol). Yield: 14 mg (45%); 100%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.85 (s, 1H), 9.94 (s, 1H), 7.95(d, J=2.2 Hz, 1H), 7.64 (dd, J=8.3, 2.2 Hz, 1H), 7.43-7.31 (m, 4H),7.33-7.27 (m, 2H), 6.98-6.90 (m, 1H), 2.30 (s, 3H); HRMS (ESI-TOF) m/z:[M+H]⁺ Calcd for C₁₇H₁₄ClN₂O₃ 329.0687; Found 329.0679.

KSC-392-008

N-(3-Chlorophenyl)-5-(4-chlorophenyl)isoxazole-3-carboxamide(KSC-392-008): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(4-chlorophenyl)isoxazole-3-carboxylic acid (30 mg, 0.134 mmol) and3-chloroaniline (17 mg, 0.134 mmol). Yield: 28 mg (62%); 100% purity. ¹HNMR (400 MHz, DMSO-d₆) δ 10.97 (s, 1H), 8.03-7.95 (m, 2H), 7.95 (t,J=2.0 Hz, 1H), 7.73 (ddd, J=8.2, 2.0, 1.0 Hz, 1H), 7.69-7.60 (m, 2H),7.52 (s, 1H), 7.41 (t, J=8.1 Hz, 1H), 7.22 (ddd, J=8.1, 2.1, 0.9 Hz,1H); HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd for C₁₆H₉Cl₂N₂O₂ 331.0046; Found331.0027.

KSC-392-009

N-(3-Chloro-4-methoxyphenyl)-5-(4-chlorophenyl)isoxazole-3-carboxamide(KSC-392-009): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(4-chlorophenyl)isoxazole-3-carboxylic acid (30 mg, 0.134 mmol) and3-chloro-4-methoxyaniline (21 mg, 0.134 mmol). Yield: 8 mg (15%); 98.9%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.81 (s, 1H), 8.04-7.97 (m, 2H),7.94 (d, J=2.5 Hz, 1H), 7.72 (dd, J=9.0, 2.6 Hz, 1H), 7.68-7.62 (m, 2H),7.54 (s, 1H), 7.18 (d, J=9.0 Hz, 1H), 3.85 (s, 3H); HRMS (ESI-TOF) m/z:[M+H]⁺ Calcd for C₁₇H₁₃Cl₂N₂O₃ 363.0298; Found 363.0277.

KSC-392-010

N-(3-Chlorophenyl)-5-phenylisoxazole-3-carboxamide (KSC-392-010): Thiscompound was prepared following the General Procedure (isoxazole amide)2 using 55-phenylisoxazole-3-carboxylic acid (30 mg, 0.159 mmol) and3-chloroaniline (20 mg, 0.159 mmol). Yield: 30 mg (63%); 100% purity. ¹HNMR (400 MHz, DMSO-d₆) δ 10.95 (s, 1H), 8.00-7.88 (m, 3H), 7.73 (ddd,J=8.3, 2.1, 1.0 Hz, 1H), 7.62-7.53 (m, 3H), 7.48 (s, 1H), 7.41 (t, J=8.1Hz, 1H), 7.22 (ddd, J=8.0, 2.1, 0.9 Hz, 1H); HRMS (ESI-TOF) m/z: [M+H]⁺Calcd for C₁₆H12ClN₂O₂ 299.0582; Found 299.0559.

KSC-392-011

N-(3-Chlorophenyl)-5-(p-tolyl)isoxazole-3-carboxamide (KSC-392-011):This compound was prepared following the General Procedure (isoxazoleamide) 2 using 5-(p-tolyl)isoxazole-3-carboxylic acid (30 mg, 0.148mmol) and 3-chloroaniline (19 mg, 0.148 mmol). Yield: 15 mg (35%); 100%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.93 (s, 1H), 7.95 (t, J=2.0 Hz,1H), 7.88-7.79 (m, 2H), 7.73 (ddd, J=8.3, 2.0, 0.9 Hz, 1H), 7.45-7.34(m, 4H), 7.22 (ddd, J=8.0, 2.1, 0.9 Hz, 1H), 2.38 (s, 3H); HRMS(ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₄ClN₂O₂ 313.0738; Found 313.0726.

KSC-392-012

N-(4-(Benzyloxy)-3-chlorophenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-012): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (30 mg, 0.146 mmol) and4-(benzyloxy)-3-chloroaniline (34 mg, 0.146 mmol). Yield: 16 mg (25%);97.9% purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.78 (s, 1H), 10.00 (s, 1H),7.93 (d, J=2.6 Hz, 1H), 7.66 (dd, J=9.0, 2.6 Hz, 1H), 7.51-7.43 (m, 2H),7.45-7.31 (m, 6H), 7.32-7.26 (m, 1H), 7.26 (d, J=9.1 Hz, 1H), 6.98-6.90(m, 1H), 5.20 (s, 2H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₃H₁₈ClN₂O₄421.0950; Found 421.0935.

KSC-392-032

N-(2,5-Dichlorophenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-032): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (20 mg, 0.097 mmol) and2,5-dichloroaniline (16 mg, 0.097 mmol). Yield: 2 mg (6%); 100% purity;HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd for C₁₆H₉Cl₂N₂O₃ 346.9995; Found347.0006.

KSC-392-033

N-(3-Chloro-2-methoxyphenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-033): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (20 mg, 0.097 mmol) and3-chloro-2-methoxyaniline (15 mg, 0.097 mmol). Yield: 4 mg (13%); 100%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 9.94 (s, 1H), 9.91 (s, 1H),7.92-7.84 (m, 1H), 7.46 (s, 1H), 7.44-7.33 (m, 3H), 7.32 (t, J=2.0 Hz,1H), 7.22 (t, J=8.1 Hz, 1H), 6.95 (ddd, J=7.7, 2.4, 1.6 Hz, 1H), 3.85(s, 3H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₄ClN₂O₄ 345.0637;Found 345.0616.

KSC-392-038

N-(5-Chloro-2-methylphenyl)-5-(3-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-038): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(3-methoxyphenyl)isoxazole-3-carboxylic acid (20 mg, 0.091 mmol) and5-chloro-2-methylaniline (13 mg, 0.091 mmol). Yield: 15 mg (47%); 100%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.36 (s, 1H), 7.59-7.44 (m, 5H),7.33 (d, J=8.3 Hz, 1H), 7.27 (dd, J=8.2, 2.2 Hz, 1H), 7.13 (ddd, J=8.2,2.6, 1.1 Hz, 1H), 3.86 (s, 3H), 2.24 (s, 3H); HRMS (ESI-TOF) m/z: [M+H]⁺Calcd for C₁₈H₁₆ClN₂O₃ 343.0844; Found 343.0828.

KSC-392-041

N-(3-Chlorophenyl)-5-(2-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-041): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (30 mg, 0.146 mmol) and3-chloroaniline (19 mg, 0.146 mmol). Yield: 7 mg (16%); 99.6% purity. ¹HNMR (400 MHz, DMSO-d₆) δ 10.92 (s, 1H), 10.80 (s, 1H), 7.98 (t, J=2.0Hz, 1H), 7.85 (dd, J=7.9, 1.6 Hz, 1H), 7.77 (ddd, J=8.2, 1.8, 0.7 Hz,1H), 7.44-7.33 (m, 2H), 7.26 (s, 1H), 7.21 (ddd, J=8.0, 2.1, 0.9 Hz,1H), 7.10-7.06 (m, 1H), 7.02-6.96 (m, 1H); ¹³C NMR (101 MHz, DMSO-d₆) δ167.60, 159.36, 157.65, 154.95, 139.52, 132.97, 132.02, 130.39, 126.75,124.07, 120.02, 119.52, 118.96, 116.58, 113.14, 102.21; HRMS (ESI-TOF)m/z: [M+H]⁺ Calcd for C₁₆H₁₂ClN₂O₃ 315.0531; Found 315.0483.

KSC-392-042

N-(5-Chloro-2-methylphenyl)-5-(2-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-042): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (30 mg, 0.146 mmol) and5-chloro-2-methylaniline (21 mg, 0.146 mmol). Yield: 7 mg (15%); 99%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.80 (s, 1H), 10.35 (s, 1H), 7.86(dd, J=7.9, 1.7 Hz, 1H), 7.53 (d, J=2.2 Hz, 1H), 7.39 (ddd, J=8.3, 7.3,1.7 Hz, 1H), 7.38-7.30 (m, 1H), 7.28 (dd, J=8.2, 2.3 Hz, 1H), 7.25 (s,1H), 7.09 (dd, J=8.4, 1.1 Hz, 1H), 7.06-6.93 (m, 1H), 2.26 (s, 3H); ¹³CNMR (101 MHz, DMSO-d₆) δ 167.58, 159.12, 157.54, 154.93, 136.53, 132.26,131.98, 131.86, 129.85, 126.75, 126.06, 125.67, 119.52, 116.56, 113.18,102.20, 17.21; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₄ClN₂O₃329.0687; Found 329.0656.

KSC-392-048

N-(5-Chloro-2-methylphenyl)-5-(2-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-048): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (30 mg, 0.146 mmol) and5-chloro-2-methylaniline (21 mg, 0.146 mmol). Yield: 7 mg (15%); 100%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.80 (s, 1H), 10.35 (s, 1H), 7.86(dd, J=7.9, 1.7 Hz, 1H), 7.53 (d, J=2.2 Hz, 1H), 7.39 (ddd, J=8.3, 7.3,1.7 Hz, 1H), 7.38-7.30 (m, 1H), 7.28 (dd, J=8.2, 2.3 Hz, 1H), 7.25 (s,1H), 7.09 (dd, J=8.4, 1.1 Hz, 1H), 7.06-6.93 (m, 1H), 2.26 (s, 3H); ¹³CNMR (101 MHz, DMSO-d₆) δ 167.58, 159.12, 157.54, 154.93, 136.53, 132.26,131.98, 131.86, 129.85, 126.75, 126.06, 125.67, 119.52, 116.56, 113.18,102.20, 17.21; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₁₆ClN₂O₄359.0793; Found 359.0774.

KSC-392-049

N-(5-Chloro-2-methylphenyl)-5-(3,4-dimethoxyphenyl)isoxazole-3-carboxamide(KSC-392-049): This compound was prepared following the GeneralProcedure (isoxazole amide) 2 using5-(3,4-dimethoxyphenyl)isoxazole-3-carboxylic acid (30 mg, 0.120 mmol)and 5-chloro-2-methylaniline (17 mg, 0.120 mmol). Yield: 9 mg (20%);100% purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.31 (s, 1H), 7.58-7.47 (m,3H), 7.43 (s, 1H), 7.36-7.29 (m, 1H), 7.27 (dd, J=8.2, 2.2 Hz, 1H), 7.13(d, J=8.4 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 2.24 (s, 3H); ¹³C NMR(101 MHz, DMSO-d₆) δ 170.89, 159.31, 157.49, 150.99, 149.16, 136.52,132.21, 131.88, 129.87, 126.06, 125.58, 118.89, 112.04, 109.24, 98.92,55.79, 55.65, 17.20; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₉H₁₈ClN₂O₄373.0950; Found 373.0912.

KSC-392-065

N-(5-chloro-2-methylphenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-065): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (80 mg, 0.390 mmol) and5-chloro-2-methylaniline (55 mg, 0.390 mmol). Yield: 55 mg (43%); 99%purity. ¹H NMR (400 MHz, Acetone-d₆) δ 9.19 (s, 1H), 7.95 (d, J=2.3 Hz,1H), 7.50-7.37 (m, 3H), 7.32 (d, J=8.2 Hz, 1H), 7.23 (s, 1H), 7.19 (dd,J=8.2, 2.3 Hz, 1H), 7.03 (ddd, J=7.9, 2.4, 1.2 Hz, 1H), 2.38 (s, 3H);¹³C NMR (101 MHz, Acetone-d₆) δ 172.82, 160.59, 159.11, 158.03, 137.76,132.82, 132.07, 131.58, 130.67, 128.96, 126.42, 124.48, 119.08, 118.30,113.52, 100.39, 17.49; HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd for C₁₇H₁₂ClN₂O₃327.0542, found: 327.0538.

KSC-392-066

N-(3-Chlorophenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-066): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (80 mg, 0.390 mmol) and3-chloroaniline (50 mg, 0.390 mmol). Yield: 26 mg (21%); 95% purity. ¹HNMR (400 MHz, Acetone-d₆) δ 9.81 (s, 1H), 8.10 (t, J=1.9 Hz, 1H),7.85-7.78 (m, 1H), 7.47-7.33 (m, 4H), 7.24-7.17 (m, 1H), 7.03 (ddd,J=7.8, 2.3, 1.2 Hz, 1H). ¹³C NMR (101 MHz, Acetone-d₆) δ 172.64, 160.67,159.07, 158.30, 140.63, 134.92, 131.54, 131.30, 128.93, 125.30, 121.13,119.66, 119.02, 118.26, 113.50, 100.43; HRMS (ESI-TOF) m/z: [M−H]⁻ Calcdfor C₁₆H₁₀ClN₂O₃ 313.0385, found: 313.0377.

KSC-392-067

N-(3,5-Dichlorophenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-067): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (100 mg, 0.487 mmol) and3,5-dichloroaniline (79 mg, 0.487 mmol). Yield: 48 mg (28%); 96.2%purity. ¹H NMR (400 MHz, Acetone-d₆) δ 9.91 (s, 1H), 7.99 (d, J=1.9 Hz,2H), 7.47-7.34 (m, 3H), 7.25 (t, J=1.8 Hz, 1H), 7.21 (s, 1H), 7.02 (ddd,J=7.7, 2.4, 1.4 Hz, 1H); ¹³C NMR (101 MHz, Acetone-d₆) δ 172.66, 160.25,158.95, 158.38, 141.34, 135.68, 131.41, 131.41, 128.71, 124.76, 119.50,119.50, 118.96, 118.15, 113.41, 100.32; HRMS (ESI-TOF) m/z: [M−H]⁻ Calcdfor C₁₆H₉Cl₂N₂O₃ 346.9995, found: 347.0005.

KSC-392-068

N-(5-Chloro-2-fluorophenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-068): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (100 mg, 0.487 mmol) and5-chloro-2-fluoroaniline (71 mg, 0.487 mmol). Yield: 40 mg (24%); 98.5%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.62 (s, 1H), 9.90 (s, 1H),7.80-7.73 (m, 1H), 7.43 (s, 1H), 7.42-7.33 (m, 4H), 7.33-7.29 (m, 1H),6.95 (ddd, J=7.5, 2.4, 1.6 Hz, 1H); ¹³C NMR (101 MHz, DMSO-d₆) δ 170.90,158.96, 157.93, 157.42, 154.18 (d, J=248.2 Hz), 130.52, 127.83 (d, J=3.3Hz), 127.20, 127.03 (d, J=7.9 Hz), 126.01, 125.84, 118.05, 117.56 (d,J=21.8 Hz), 116.73, 112.19, 99.94; HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd forC₁₆H₉ClFN₂O₃ 331.0291, found: 331.0276.

KSC-392-069

N-(3-chloro-2-methylphenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-069): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (100 mg, 0.487 mmol) and3-chloro-2-methylaniline (69 mg, 0.487 mmol). Yield: 35 mg (22%); 100%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.51 (s, 1H), 9.89 (s, 1H),7.43-7.38 (m, 3H), 7.38-7.34 (m, 1H), 7.32-7.30 (m, 1H), 7.30-7.24 (m,1H), 6.95 (ddd, J=7.4, 2.5, 1.6 Hz, 1H), 2.27 (s, 3H); ¹³C NMR (101 MHz,DMSO-d₆) δ 170.74, 159.36, 157.95, 157.52, 136.73, 133.81, 132.06,130.52, 127.29, 127.22, 126.97, 125.77, 117.99, 116.69, 112.18, 99.96,15.20; HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd for C₁₇H₁₂ClN₂O₃ 327.0542,found: 327.0554.

KSC-392-072

N-(2,3-Dichlorophenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-072): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (80 mg, 0.390 mmol) and2,3-dichloroaniline (63 mg, 0.487 mmol). Yield: 33 mg (24%); 100%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.54 (s, 1H), 9.90 (s, 1H), 7.68(dd, J=8.0, 1.2 Hz, 1H), 7.61 (dd, J=8.1, 1.5 Hz, 1H), 7.48-7.34 (m,4H), 7.32 (t, J=2.0 Hz, 1H), 6.95 (ddd, J=7.6, 2.5, 1.5 Hz, 1H); ¹³C NMR(101 MHz, DMSO-d₆) δ 171.01, 159.01, 157.91, 157.31, 135.82, 132.03,130.56, 128.28, 128.25, 127.62, 127.20, 126.31, 118.05, 116.75, 112.15,99.98; HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd for C₁₆H₉Cl₂N₂O₃ 346.9995,found: 347.0001.

KSC-392-073

N-(4-Chlorophenyl)-5-phenylisoxazole-3-carboxamide (KSC-392-073): Thiscompound was prepared following the General Procedure (isoxazole amide)1 using 5-phenylisoxazole-3-carboxylic acid (80 mg, 0.423 mmol) and4-chloroaniline (54 mg, 0.423 mmol). Yield: 72 mg (57%); 99.3% purity.¹H NMR (400 MHz, DMSO-d₆) δ 10.91 (s, 1H), 8.00-7.93 (m, 2H), 7.89-7.82(m, 2H), 7.61-7.53 (m, 3H), 7.50 (s, 1H), 7.47-7.41 (m, 2H); ¹³C NMR(101 MHz, DMSO-d₆) δ 170.61, 159.72, 157.26, 136.96, 130.91, 129.30,128.62, 128.09, 126.17, 125.80, 122.09, 100.11; HRMS (ESI-TOF) m/z:[M−H]⁻ Calcd for C₁₆H₁₁ClN₂O₂ 297.0436, found: 297.0439.

KSC-392-074

N-(3-Chlorophenyl)-5-(4-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-074): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-hydroxyphenyl)isoxazole-3-carboxylic acid (80 mg, 0.390 mmol) and3-chloroaniline (50 mg, 0.390 mmol). Yield: 67 mg (59%); 98.9% purity.¹H NMR (400 MHz, DMSO-d₆) δ 10.89 (s, 1H), 10.19 (s, 1H), 7.98 (t, J=2.0Hz, 1H), 7.82-7.73 (m, 3H), 7.40 (t, J=8.1 Hz, 1H), 7.24 (s, 1H), 7.20(ddd, J=8.0, 2.1, 0.9 Hz, 1H), 6.96-6.90 (m, 2H); ¹³C NMR (101 MHz,DMSO-d₆) δ 171.20, 159.92, 159.50, 157.66, 139.52, 133.01, 130.38,127.71, 124.07, 120.00, 118.94, 117.34, 116.07, 97.87; HRMS (ESI-TOF)m/z: [M−H]⁻ Calcd for C₁₆H₁₀ClN₂O₃ 313.0385, found: 313.0374.

KSC-392-075

N-(5-Chloro-2-methylphenyl)-5-(4-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-075): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-hydroxyphenyl)isoxazole-3-carboxylic acid (80 mg, 0.390 mmol) and5-chloro-2-methylaniline (55 mg, 0.390 mmol). Yield: 48 mg (38%); 93.5%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.78 (s, 1H), 9.90 (s, 1H), 7.94(d, J=2.5 Hz, 1H), 7.72 (dd, J=9.0, 2.6 Hz, 1H), 7.43-7.32 (m, 3H),7.34-7.27 (m, 1H), 7.18 (d, J=9.1 Hz, 1H), 6.95 (ddd, J=7.2, 2.5, 1.8Hz, 1H), 3.85 (s, 3H); ¹³C NMR (101 MHz, DMSO-d₆) δ 171.20, 159.90,159.25, 157.55, 136.54, 132.14, 131.88, 129.89, 127.69, 126.03, 125.54,117.38, 116.06, 97.85, 17.21; HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd forC₁₇H₁₂ClN₂O₃ 327.0542, found: 327.0506.

KSC-392-077

N-(5-Chloro-2-cyanophenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-077): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (80 mg, 0.390 mmol) and2-amino-4-chlorobenzonitrile (59 mg, 0.390 mmol). Yield: 10 mg (7%);96.7% purity. ¹H NMR (400 MHz, DMSO-d₆) δ 11.15 (s, 1H), 9.91 (s, 1H),7.96 (d, J=8.5 Hz, 1H), 7.81 (d, J=2.1 Hz, 1H), 7.57 (dd, J=8.4, 2.1 Hz,1H), 7.46 (s, 1H), 7.45-7.38 (m, 1H), 7.42-7.33 (m, 1H), 7.36-7.30 (m,1H), 6.96 (ddd, J=7.8, 2.4, 1.3 Hz, 1H); ¹³C NMR (101 MHz, DMSO-d₆) δ171.09, 158.90, 157.93, 157.69, 140.71, 138.26, 134.67, 130.53, 127.16,126.79, 126.34, 118.09, 116.77, 115.95, 112.21, 107.70, 100.04; HRMS(ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₁ClN₃O₃ 340.0484, found: 340.0475.

KSC-392-078

N-(2-(Benzyloxy)-5-chlorophenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-078): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (80 mg, 0.390 mmol) and2-(benzyloxy)-5-chloroaniline (91 mg, 0.390 mmol). Yield: 73 mg (42%);94% purity. ¹H NMR (400 MHz, DMSO-d₆) δ 9.91 (s, 1H), 9.63 (s, 1H), 8.13(s, 1H), 7.53-7.49 (m, 2H), 7.44-7.31 (m, 7H), 7.20 (d, J=1.5 Hz, 2H),6.96 (ddd, J=7.7, 2.5, 1.4 Hz, 1H), 5.24 (s, 2H); ¹³C NMR (101 MHz,DMSO-d₆) δ 171.36, 159.14, 157.94, 156.56, 147.48, 136.30, 130.48,128.46, 128.02, 127.58, 127.41, 127.16, 124.81, 124.40, 121.04, 118.10,116.77, 114.32, 112.25, 99.74, 70.39; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcdfor C₂₃H₁₈ClN₂O₄ 421.0950, found: 421.0939.

KSC-392-080

5-(3-Hydroxyphenyl)-N-(o-tolyl)isoxazole-3-carboxamide (KSC-392-080):This compound was prepared following the General Procedure (isoxazoleamide) 1 using 5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (80 mg,0.390 mmol) and o-toluidine (42 mg, 0.390 mmol). Yield: 45 mg (40%);99.5% purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.24 (s, 1H), 9.90 (s, 1H),7.44-7.32 (m, 4H), 7.34-7.26 (m, 2H), 7.29-7.15 (m, 2H), 6.95 (ddd,J=7.4, 2.5, 1.7 Hz, 1H), 2.26 (s, 3H); ¹³C NMR (101 MHz, DMSO-d₆) δ170.64, 159.58, 157.93, 157.27, 135.14, 133.39, 130.51, 130.37, 127.34,126.39, 126.22, 126.08, 117.95, 116.69, 112.16, 99.92, 17.72; HRMS(ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₅N₂O₃ 295.1077, found: 295.1081.

KSC-392-141

N-(2-Chloro-5-methylpyridin-4-yl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-141): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.122 mmol) and2-chloro-5-methylpyridin-4-amine (17 mg, 0.122 mmol). Yield: 3 mg (7%);96.2% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.56 (s, 1H), 9.50 (s, 1H),8.44 (d, J=2.3 Hz, 1H), 8.00 (d, J=2.3 Hz, 1H), 7.42 (dd, J=8.4, 2.2 Hz,1H), 7.34 (d, J=2.2 Hz, 1H), 7.29 (s, 1H), 7.10 (d, J=8.5 Hz, 1H), 3.85(s, 3H), 2.45 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 171.16, 159.11,157.84, 152.42, 150.12, 146.98, 144.89, 133.19, 132.23, 127.85, 118.94,117.93, 112.51, 98.58, 55.74, 20.66; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcdfor C₁₆H₁₃ClN₃O₃ 330.0640, found: 330.0682.

KSC-392-125

N-(5-Chloro-2-methylpyridin-3-yl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-125): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (28 mg, 0.136 mmol) and25-chloro-2-methylpyridin-3-amine (19 mg, 0.136 mmol). Yield: 16 mg(34%); 96.2% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.61 (s, 1H), 9.92 (s,1H), 8.44 (d, J=2.3 Hz, 1H), 8.00 (d, J=2.4 Hz, 1H), 7.44 (s, 1H), 7.41(dt, J=7.7, 1.4 Hz, 1H), 7.37 (t, J=7.8 Hz, 1H), 7.32 (dd, J=2.4, 1.6Hz, 1H), 6.95 (ddd, J=7.8, 2.5, 1.2 Hz, 1H), 2.46 (s, 3H); ¹³C NMR (126MHz, DMSO-d₆) δ 170.95, 159.17, 157.99, 157.70, 152.44, 144.94, 133.21,132.19, 130.63, 127.84, 127.27, 118.10, 116.80, 112.21, 100.11, 20.67;HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₁₃ClN₃O₃ 330.0640, found:330.0595.

KSC-392-143

N-(3-Chloro-5-methylphenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-143): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.122 mmol) and3-chloro-5-methylaniline (17 mg, 0.122 mmol). Yield: 9 mg (24%); 100%purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.85 (s, 1H), 9.92 (s, 1H),7.76-7.74 (m, 1H), 7.59 (s, 1H), 7.41 (s, 1H), 7.40-7.34 (m, 2H), 7.31(dd, J=2.5, 1.5 Hz, 1H), 7.06 (s, 2H), 6.95 (ddd, J=7.6, 2.5, 1.5 Hz,1H), 2.31 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 170.78, 159.68, 157.99,157.48, 140.38, 139.26, 132.78, 130.63, 127.29, 124.75, 119.52, 118.09,117.25, 116.78, 112.21, 100.07, 20.99; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcdfor C₁₇H₁₄ClN₂O₃ 329.0687, found: 329.0742.

KSC-392-081

5-(4-Hydroxyphenyl)-N-(o-tolyl)isoxazole-3-carboxamide (KSC-392-081):This compound was prepared following the General Procedure (isoxazoleamide) 1 using 5-(4-hydroxyphenyl)isoxazole-3-carboxylic acid (12 mg,0.058 mmol) and o-toluidine (6 mg, 0.058 mmol). Yield: 12 mg (67%);99.5% purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.19 (s, 1H), 10.17 (s, 1H),7.83-7.74 (m, 2H), 7.42-7.36 (m, 1H), 7.31-7.27 (m, 1H), 7.26-7.15 (m,3H), 6.96-6.89 (m, 2H), 2.25 (s, 3H); ¹³C NMR (101 MHz, DMSO-d₆) δ171.04, 159.83, 159.48, 157.44, 135.18, 133.34, 130.35, 127.65, 126.33,126.19, 126.06, 117.43, 116.03, 97.82, 17.71; HRMS (ESI-TOF) m/z: [M+H]⁺Calcd for C₁₇H₁₅N₂O₃ 295.1077, found: 295.1066.

KSC-392-082

5-(2-Hydroxyphenyl)-N-(o-tolyl)isoxazole-3-carboxamide (KSC-392-082):This compound was prepared following the General Procedure (isoxazoleamide) 1 using 5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (80 mg,0.390 mmol) and o-toluidine (42 mg, 0.390 mmol). Yield: 40 mg (35%); 98%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.80 (s, 1H), 10.25 (s, 1H), 7.85(dd, J=7.9, 1.7 Hz, 1H), 7.43-7.34 (m, 2H), 7.32-7.25 (m, 1H), 7.26-7.17(m, 3H), 7.09 (d, J=8.1 Hz, 1H), 7.04-6.95 (m, 1H), 2.26 (s, 3H); ¹³CNMR (101 MHz, DMSO-d₆) δ 167.52, 159.37, 157.48, 155.02, 135.21, 133.44,131.93, 130.36, 126.76, 126.37, 126.29, 126.07, 119.46, 116.60, 113.28,102.20, 17.74; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₅N₂O₃ 295.1077,found: 295.1068.

KSC-392-086

N-(5-Chloro-2-methylphenyl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-086): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (11 mg, 0.047mmol) and 5-chloro-2-methylaniline (7 mg, 0.047 mmol). Yield: 8 mg(47%); 99.8% purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.28 (s, 1H), 9.49 (s,1H), 7.52 (d, J=2.2 Hz, 1H), 7.41 (dd, J=8.4, 2.2 Hz, 1H), 7.36-7.29 (m,2H), 7.30-7.22 (m, 2H), 7.09 (d, J=8.5 Hz, 1H), 3.85 (s, 3H), 2.24 (s,3H); ¹³C NMR (101 MHz, DMSO-d₆) δ 170.95, 159.27, 157.49, 150.04,146.96, 136.52, 132.16, 131.88, 129.87, 126.04, 125.54, 117.80, 112.50,98.44, 55.70, 17.20; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₁₆ClN₂O₄359.0793, found: 359.0789.

KSC-392-087

N-(3-Chlorophenyl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-087): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (10 mg, 0.043mmol) and 3-chloroaniline (5 mg, 0.043 mmol). Yield: 3 mg (23%); 99.2%purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.89 (s, 1H), 9.50 (s, 1H),8.00-7.94 (m, 1H), 7.75 (ddd, J=8.3, 2.0, 0.9 Hz, 1H), 7.41 (ddd, J=8.1,5.0, 2.8 Hz, 2H), 7.33 (d, J=2.2 Hz, 1H), 7.27 (s, 1H), 7.22 (ddd,J=8.0, 2.1, 0.9 Hz, 1H), 7.09 (d, J=8.5 Hz, 1H), 3.85 (s, 3H); ¹³C NMR(101 MHz, DMSO-d₆) δ 171.16, 159.72, 157.80, 150.28, 147.20, 139.70,133.18, 130.62, 124.29, 120.15, 119.14, 119.12, 118.01, 112.71, 112.70,98.66, 55.91; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₄ClN₂O₄345.0637, found: 345.0630.

KSC-392-099

N-(3,5-Dichlorophenyl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-099): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.106mmol) and 3,5-dichloroaniline (17 mg, 0.106 mmol). Yield: 2 mg (6%);93.9% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 11.08 (bs, 2H), 7.92 (d, J=1.9Hz, 2H), 7.42 (dd, J=8.4, 2.2 Hz, 1H), 7.40 (t, J=1.9 Hz, 1H), 7.33 (d,J=2.2 Hz, 1H), 7.28 (s, 1H), 7.10 (d, J=8.5 Hz, 1H), 3.85 (s, 3H); ¹³CNMR (126 MHz, DMSO-d₆) δ 171.18, 159.42, 157.94, 150.17, 147.03, 140.59,134.11, 118.90, 112.51, 98.61, 55.76; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcdfor C₁₇H₁₃Cl₂N₂O₄ 379.0247, found: 379.0237.

KSC-392-101

N-(2,3-Dichlorophenyl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-101): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.106mmol) and 2,3-dichloroaniline (17 mg, 0.106 mmol). Yield: 7 mg (18%);100% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.50 (s, 1H), 9.49 (s, 1H),7.68 (dd, J=8.1, 1.5 Hz, 1H), 7.60 (dd, J=8.1, 1.5 Hz, 1H), 7.48-7.38(m, 2H), 7.34 (d, J=2.2 Hz, 1H), 7.30 (s, 1H), 7.10 (d, J=8.5 Hz, 1H),3.85 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 171.27, 159.00, 157.48,150.12, 146.96, 135.91, 132.07, 127.58, 118.92, 98.51, 55.73; HRMS(ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₃Cl₂N₂O₄ 379.0247, found: 379.0251.

KSC-392-120-P1

N-(2,5-Dichlorophenyl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-120-P1): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.106mmol) and 2,5-dichloroaniline (17 mg, 0.106 mmol). Yield: 11 mg (26%);98% purity. ¹H NMR (400 MHz, Acetone-d₆) δ 9.32 (s, 1H), 8.49 (d, J=2.5Hz, 1H), 7.59 (d, J=8.6 Hz, 1H), 7.47 (dd, J=8.4, 2.2 Hz, 1H), 7.43 (d,J=2.2 Hz, 1H), 7.28 (dd, J=8.6, 2.5 Hz, 1H), 7.18 (s, 1H), 7.14 (d,J=8.4 Hz, 1H), 3.94 (s, 3H); ¹³C NMR (101 MHz, Acetone-d₆) δ 173.45,160.01, 151.02, 148.11, 136.16, 133.79, 131.48, 126.39, 123.28, 122.75,120.56, 119.14, 113.42, 112.85, 98.73, 56.44; HRMS (ESI-TOF) m/z: [M+H]⁺Calcd for C₁₇H₁₃Cl₂N₂O₄ 379.0247, found: 379.0252.

KSC-392-139

N-(3-Chloro-2-methylphenyl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-139): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.106mmol) and 3-chloro-2-methylaniline (15 mg, 0.106 mmol). Yield: 13 mg(33%); 95.7% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.52 (s, 1H), 9.49 (s,1H), 7.41 (ddd, J=8.0, 4.6, 1.8 Hz, 2H), 7.35 (dd, J=8.0, 1.3 Hz, 1H),7.33 (d, J=2.2 Hz, 1H), 7.31-7.24 (m, 2H), 7.09 (d, J=8.5 Hz, 1H), 3.85(s, 3H), 2.26 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 170.99, 159.37,157.71, 150.07, 146.97, 136.81, 133.87, 132.15, 127.29, 127.07, 125.88,119.03, 117.89, 112.50, 98.56, 55.73, 15.31; HRMS (ESI-TOF) m/z: [M+H]⁺Calcd for C₁₇H₁₆ClN₂O₄ 359.0793, found: 359.0881.

KSC-392-140

N-(2-Chloro-5-methylpyridin-4-yl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-140): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.106mmol) and 2-chloro-5-methylpyridin-4-amine (15 mg, 0.106 mmol). Yield: 2mg (4%); 100% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.33 (s, 1H), 9.50(s, 1H), 8.37-8.20 (m, 1H), 7.82 (s, 1H), 7.42 (dd, J=8.4, 2.2 Hz, 1H),7.34 (d, J=2.2 Hz, 1H), 7.33 (s, 1H), 7.10 (d, J=8.5 Hz, 1H), 3.85 (s,3H), 2.28 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 171.31, 158.99, 157.83,150.17, 148.06, 146.99, 145.30, 125.98, 118.86, 117.61, 112.51, 98.60,55.75, 14.15; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₅ClN₃O₄360.0746, found: 360.0803.

KSC-392-142

N-(5-Chloro-2-methylpyridin-3-yl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-142): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.106mmol) and 5-chloro-2-methylpyridin-3-amine (15 mg, 0.106 mmol). Yield: 9mg (23%); 98.3% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.56 (s, 1H), 9.50(bs, 1H), 8.44 (d, J=2.3 Hz, 1H), 8.00 (d, J=2.3 Hz, 1H), 7.42 (dd,J=8.4, 2.2 Hz, 1H), 7.34 (d, J=2.2 Hz, 1H), 7.29 (s, 1H), 7.10 (d, J=8.5Hz, 1H), 3.85 (s, 3H), 2.45 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ171.16, 159.11, 157.84, 152.42, 150.12, 146.98, 144.89, 133.19, 132.23,127.85, 118.94, 117.93, 112.51, 98.58, 55.74, 20.66; HRMS (ESI-TOF) m/z:[M+H]⁺ Calcd for C₁₇H₁₅ClN₃O₄ 360.0746, found: 360.0816.

KSC-392-121-P1

N-(5-Chloro-2-fluorophenyl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-121-P1): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.106mmol) and 5-chloro-2-fluoroaniline (15 mg, 0.106 mmol). Yield: 8 mg(20%); 96% purity. ¹H NMR (500 MHz, Acetone-d₆) δ 9.32 (s, 1H), 8.29(dd, J=6.8, 2.6 Hz, 1H), 7.47 (dd, J=8.4, 2.2 Hz, 1H), 7.42 (d, J=2.2Hz, 1H), 7.34 (dd, J=10.3, 8.8 Hz, 1H), 7.28 (ddd, J=8.8, 4.5, 2.6 Hz,1H), 7.16 (s, 1H), 7.14 (d, J=8.4 Hz, 1H), 3.94 (s, 3H); ¹³C NMR (126MHz, Acetone-d₆) δ 173.14, 129.81 (d, J=3.4 Hz), 126.43 (d, J=7.9 Hz),123.91, 120.60, 119.11, 117.75 (d, J=21.4 Hz), 113.40, 112.81, 98.86,56.43; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₃ClFN₂O₄ 363.0542,found: 363.0549.

KSC-392-106

N-(5-Chloro-2-methoxyphenyl)-5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxamide(KSC-392-106): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxy-4-methoxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.106mmol) and 5-chloro-2-methoxyaniline (17 mg, 0.106 mmol). Yield: 13 mg(32%); 99.7% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 9.52 (s, 1H), 9.50 (s,1H), 8.12 (d, J=2.7 Hz, 1H), 7.42 (dd, J=8.4, 2.2 Hz, 1H), 7.33 (d,J=2.2 Hz, 1H), 7.31 (s, 1H), 7.24 (dd, J=8.8, 2.6 Hz, 1H), 7.16 (d,J=8.8 Hz, 1H), 7.09 (d, J=8.5 Hz, 1H), 3.90 (s, 3H), 3.85 (s, 3H); ¹³CNMR (126 MHz, DMSO) δ 171.71, 159.28, 156.95, 150.32, 148.73, 147.13,127.30, 125.09, 124.16, 121.08, 119.05, 118.13, 112.99, 112.67, 112.62,98.48, 56.58, 55.88; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₁₆ClN₂O₅375.0742, found: 375.0711.

KSC-392-104

N-(2,3-Dichlorophenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-104): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (12 mg, 0.024mmol) and 2,3-dichloroaniline (8.7 mg, 0.024 mmol). Yield: 2 mg (7%);98.3% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.56 (bs, 1H), 10.43 (bs,1H), 7.67 (dd, J=8.0, 1.5 Hz, 1H), 7.61 (dd, J=8.1, 1.5 Hz, 1H), 7.51(dd, J=8.2, 2.2 Hz, 1H), 7.48-7.41 (m, 3H), 7.36 (dd, J=11.0, 8.5 Hz,1H); ¹³C NMR (126 MHz, DMSO-d₆) δ 170.28, 159.13, 157.32, 152.63 (d,J=246.7 Hz), 145.69 (d, J=13.1 Hz), 135.86, 132.09, 128.35, 128.31,127.69, 126.38, 122.96 (d, J=3.6 Hz), 117.83 (d, J=7.2 Hz), 117.33 (d,J=19.3 Hz), 114.99 (d, J=3.7 Hz), 99.90; HRMS (ESI-TOF) m/z: [M+Na]⁺Calcd for C₁₆H₉Cl₂FN₂NaO₃ 388.9866, found: 388.9826.

KSC-392-158

N-(3,5-Dichlorophenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-158): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.112mmol) and 3,5-dichloroaniline (18 mg, 0.112 mmol). Yield: 8 mg (20%);100% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 11.11 (s, 1H), 10.43 (bs, 1H),7.93 (d, J=1.9 Hz, 2H), 7.51 (dd, J=8.3, 2.2 Hz, 1H), 7.44 (ddd, J=8.4,4.3, 2.2 Hz, 1H), 7.42 (s, 1H), 7.40 (t, J=1.9 Hz, 1H), 7.36 (dd,J=11.0, 8.5 Hz, 1H); ¹³C NMR (126 MHz, DMSO-d₆) δ 170.19, 159.47,157.67, 152.65 (d, J=246.7 Hz), 145.69 (d, J=13.0 Hz), 140.41, 134.11,123.75, 122.92 (d, J=3.4 Hz), 118.70, 117.86 (d, J=7.2 Hz), 117.35 (d,J=19.3 Hz), 115.01 (d, J=3.7 Hz), 99.99; HRMS (ESI-TOF) m/z: [M−H]⁻Calcd for C₁₆H₈Cl₂FN₂O₃ 364.9896, found: 364.9883.

KSC-392-105

N-(2,5-Dichlorophenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-105): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (17 mg, 0.076mmol) and 2,5-dichloroaniline (12 mg, 0.076 mmol). Yield: 6 mg (19%);94.7% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.43 (bs, 2H), 7.85 (d, J=2.5Hz, 1H), 7.63 (d, J=8.6 Hz, 1H), 7.51 (dd, J=8.3, 2.2 Hz, 1H), 7.48-7.39(m, 3H), 7.35 (dd, J=11.0, 8.5 Hz, 1H); ¹³C NMR (126 MHz, DMSO-d₆) δ170.34, 159.06, 157.30, 152.65 (d, J=246.8 Hz), 145.72 (d, J=12.9 Hz),135.14, 131.68, 131.07, 127.53, 127.29, 126.72, 122.93 (d, J=3.5 Hz),117.82 (d, J=7.1 Hz), 117.32 (d, J=19.2 Hz), 115.00 (d, J=3.7 Hz),99.88; HRMS (ESI-TOF) m/z: [M+Na]⁺ Calcd for C₁₆H₉Cl₂FN₂NaO₃ 388.9866,found: 388.9832.

KSC-392-116

N-(3-Chloro-2-methylphenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-116): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (29 mg, 0.130mmol) and 3-chloro-2-methylaniline (18 mg, 0.130 mmol). Yield: 14 mg(30%); 97.9% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.56 (s, 1H), 10.41(s, 1H), 7.50 (dd, J=8.3, 2.2 Hz, 1H), 7.47-7.38 (m, 3H), 7.39-7.31 (m,2H), 7.28 (t, J=8.0 Hz, 1H), 2.26 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ169.99, 158.50 (d, J=247.1 Hz), 153.56, 151.60, 145.66 (d, J=12.8 Hz),136.75, 133.87, 132.17, 127.33, 127.07, 125.90, 123.05 (d, J=3.4 Hz),117.80 (d, J=7.2 Hz), 117.33 (d, J=19.2 Hz), 114.95 (d, J=3.6 Hz),99.95, 15.30; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₃ClFN₂O₃347.0593, found: 347.0597.

KSC-392-149

N-(3-Chlorophenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-149): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.112mmol) and 3-chloroaniline (14 mg, 0.112 mmol). Yield: 10 mg (20%); 100%purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.96 (s, 1H), 10.45 (bs, 1H), 7.97(t, J=2.0 Hz, 1H), 7.76 (ddd, J=8.3, 2.2, 1.0 Hz, 1H), 7.51 (dd, J=8.3,2.2 Hz, 1H), 7.47-7.38 (m, 3H), 7.36 (dd, J=11.0, 8.5 Hz, 1H), 7.23(ddd, J=8.0, 2.1, 0.9 Hz, 1H); ¹³C NMR (126 MHz, DMSO-d₆) δ 170.03,159.71, 157.47, 152.64 (d, J=246.8 Hz), 145.74 (d, J=12.8 Hz), 139.51,133.06, 130.54, 120.01, 119.00, 117.77 (d, J=7.2 Hz), 117.33 (d, J=19.3Hz), 114.99 (d, J=3.7 Hz), 99.95; HRMS (ESI-TOF) m/z: [M+Na]⁺ Calcd forC₁₆H₁₀ClFN₂NaO₃ 355.0262, found: 355.0252.

KSC-392-150

N-(5-Chloro-2-methylphenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-150): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.112mmol) and 5-chloro-2-methylaniline (16 mg, 0.112 mmol). Yield: 7 mg(18%); 100% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.36 (s, 1H), 7.51 (dd,J=7.0, 2.1 Hz, 2H), 7.43 (ddd, J=8.4, 4.3, 2.2 Hz, 1H), 7.40 (s, 1H),7.39-7.30 (m, 2H), 7.27 (dd, J=8.2, 2.3 Hz, 1H), 2.24 (s, 3H); ¹³C NMR(126 MHz, DMSO-d₆) δ 169.99, 159.40, 157.31, 152.60 (d, J=246.5 Hz),145.80 (d, J=12.8 Hz), 136.45, 132.30, 131.92, 129.86, 126.14, 125.67,117.57 (d, J=7.0 Hz), 117.23 (d, J=19.3 Hz), 114.93 (d, J=3.8 Hz),99.84, 17.24; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₃ClFN₂O₃347.0593, found: 347.0599.

KSC-392-155

N-(3-Chloro-5-methylphenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-155): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.112mmol) and 3-chloro-5-methylaniline (16 mg, 0.112 mmol). Yield: 10 mg(25%); 99.4% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.85 (s, 1H), 10.43(s, 1H), 7.75 (t, J=2.0 Hz, 1H), 7.59-7.57 (m, 1H), 7.50 (dd, J=8.3, 2.2Hz, 1H), 7.43 (ddd, J=8.4, 4.3, 2.2 Hz, 1H), 7.39 (s, 1H), 7.35 (dd,J=11.0, 8.5 Hz, 1H), 7.07-7.05 (m, 1H), 2.31 (s, 3H); ¹³C NMR (126 MHz,DMSO-d₆) δ 170.00, 159.74, 157.43, 152.63 (d, J=246.7 Hz), 145.71 (d,J=12.8 Hz), 140.39, 139.24, 132.79, 124.77, 122.99 (d, J=3.5 Hz),119.54, 117.80 (d, J=7.2 Hz), 117.34 (d, J=18.8 Hz), 117.26, 114.99 (d,J=3.7 Hz), 99.93, 20.99; HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd forC₁₇H₁₁ClFN₂O₃ 345.0442, found: 345.0434.

KSC-392-156

N-(5-Chloro-2-methylpyridin-3-yl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-156): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.112mmol) and 5-chloro-2-methylpyridin-3-amine (16 mg, 0.112 mmol). Yield: 5mg (12%); 100% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.60 (bs, 2H), 8.44(d, J=2.4 Hz, 1H), 8.00 (d, J=2.4 Hz, 1H), 7.51 (dd, J=8.3, 2.2 Hz, 1H),7.46-7.39 (m, 2H), 7.35 (dd, J=11.0, 8.5 Hz, 1H), 2.45 (s, 3H); ¹³C NMR(126 MHz, DMSO-d₆) δ 170.20, 159.25, 157.68, 152.70 (d, J=246.7 Hz),152.46, 145.89 (d, J=12.9 Hz), 144.95, 133.23, 132.21, 127.86, 122.97(d, J=3.3 Hz), 117.67 (d, J=7.1 Hz), 117.32 (d, J=19.3 Hz), 115.03 (d,J=3.7 Hz), 99.94, 20.67; HRMS (ESI-TOF) m/z: [M−H]⁻ Calcd forC₁₆H₁₀ClFN₃O₃ 346.0395, found: 346.0386.

KSC-392-157

N-(2-Chloro-5-methylpyridin-4-yl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-157): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.112mmol) and 2-chloro-5-methylpyridin-4-amine (16 mg, 0.112 mmol). Yield: 3mg (6%); 91.2% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.46 (s, 1H), 10.39(s, 1H), 8.32 (t, J=0.7 Hz, 1H), 7.82 (s, 1H), 7.52 (dd, J=8.3, 2.2 Hz,1H), 7.49-7.42 (m, 2H), 7.37 (dd, J=11.0, 8.5 Hz, 1H), 2.28 (s, 3H); ¹³CNMR (126 MHz, DMSO-d₆) δ 170.23, 159.06, 157.59, 152.60 (d, J=246.9 Hz),151.08, 147.99, 145.63 (d, J=12.9 Hz), 145.19, 126.01, 122.84, 117.79(d, J=7.1 Hz), 117.67, 117.30 (d, J=19.3 Hz), 114.93 (d, J=3.7 Hz),99.93, 14.09; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₆H₁₂ClFN₃O₃348.0546, found: 348.0605.

KSC-392-151

N-(5-Chloro-2-fluorophenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-151): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.112mmol) and 5-chloro-2-fluoroaniline (16 mg, 0.112 mmol). Yield: 3 mg(7%); 94.2% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.63 (s, 2H), 7.78-7.70(m, 1H), 7.50 (dd, J=8.3, 2.2 Hz, 1H), 7.45-7.38 (m, 4H), 7.35 (dd,J=11.0, 8.5 Hz, 1H); ¹³C NMR (126 MHz, DMSO-d₆) δ 170.17, 159.10,157.43, 154.47 (d, J=211.3 Hz), 152.51 (d, J=209.9 Hz), 145.75 (d,J=12.8 Hz), 127.88 (d, J=3.2 Hz), 127.19 (d, J=7.8 Hz), 126.21, 125.93(d, J=13.8 Hz), 122.96 (d, J=3.6 Hz), 117.77 (d, J=6.8 Hz), 117.69 (d,J=21.8 Hz), 117.33 (d, J=19.3 Hz), 115.00 (d, J=3.7 Hz), 99.91; HRMS(ESI-TOF) m/z: [M−H]⁻ Calcd for C₁₆H₈ClF₂N₂O₃ 349.0192, found: 349.0180.

KSC-392-107

N-(5-Chloro-2-methoxyphenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-107): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.122 mmol) and5-chloro-2-methoxyaniline (19 mg, 0.122 mmol). Yield: 13 mg (32%); 100%purity. ¹H NMR (500 MHz, DMSO-d₆) δ 9.95 (bs, 1H), 9.58 (bs, 1H), 8.10(d, J=2.7 Hz, 0H), 7.46 (s, 1H), 7.40 (dt, J=7.7, 1.4 Hz, 1H), 7.3-7.34(m, 1H), 7.31 (t, J=2.0 Hz, 0H), 7.25 (dd, J=8.8, 2.6 Hz, 1H), 7.16 (d,J=8.8 Hz, 1H), 6.95 (ddd, J=7.8, 2.5, 1.2 Hz, 1H), 3.90 (s, 3H); ¹³C NMR(126 MHz, DMSO-d₆) δ 171.26, 159.13, 157.97, 156.62, 148.62, 130.53,127.15, 127.03, 124.96, 123.92, 121.03, 118.10, 116.70, 112.79, 112.17,99.79, 56.35; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₄ClN₂O₄345.0637, found: 345.0608.

KSC-392-109

N-(5-Chloro-2-(dimethylamino)phenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-109): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.122 mmol) and4-chloro-N1,N1-dimethylbenzene-1,2-diamine (22 mg, 0.122 mmol). Yield:13 mg (29%); 98.2% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 9.94 (bs, 1H),9.83 (s, 1H), 8.26 (d, J=2.5 Hz, 1H), 7.49 (s, 1H), 7.42 (dt, J=7.7, 1.3Hz, 1H), 7.38-7.36 (m, 1H), 7.35-7.32 (m, 2H), 7.22 (dd, J=8.5, 2.5 Hz,1H), 6.95 (ddd, J=8.0, 2.5, 1.1 Hz, 1H), 2.67 (s, 6H); ¹³C NMR (126 MHz,DMSO-d₆) δ 171.50, 159.30, 157.93, 156.31, 142.82, 132.68, 130.53,127.94, 127.14, 124.47, 122.05, 119.45, 118.12, 116.77, 112.18, 99.77,44.08; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₁₇ClN₃O₃ 358.0953,found: 358.0930.

KSC-392-125

N-(5-Chloro-2-methylpyridin-3-yl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-125): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-hydroxyphenyl)isoxazole-3-carboxylic acid (28 mg, 0.136 mmol) and5-chloro-2-methylpyridin-3-amine (19 mg, 0.136 mmol). Yield: 16 mg(34%); 100% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.61 (s, 1H), 9.92 (s,1H), 8.44 (d, J=2.3 Hz, 1H), 8.00 (d, J=2.4 Hz, 1H), 7.44 (s, 1H), 7.41(dt, J=7.7, 1.4 Hz, 1H), 7.37 (t, J=7.8 Hz, 1H), 7.32 (dd, J=2.4, 1.6Hz, 1H), 6.95 (ddd, J=7.8, 2.5, 1.2 Hz, 1H), 2.46 (s, 3H); ¹³C NMR (126MHz, DMSO-d₆) δ 170.95, 159.17, 157.99, 157.70, 152.44, 144.94, 133.21,132.19, 130.63, 127.84, 127.27, 118.10, 116.80, 112.21, 100.11, 20.67;HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₁₇ClN₃O₃ 330.0640, found:330.0595.

KSC-392-108

N-(5-Chloro-2-(dimethylamino)phenyl)-5-(3-hydroxyphenyl)isoxazole-3-carboxamide(KSC-392-108): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(2-hydroxyphenyl)isoxazole-3-carboxylic acid (25 mg, 0.122 mmol) and5-chloro-2-methoxyaniline (19 mg, 0.122 mmol). Yield: 3 mg (7%); 97.8%purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.87 (bs, 1H), 9.61 (s, 1H), 8.10(d, J=2.7 Hz, 1H), 7.84 (dd, J=7.9, 1.7 Hz, 1H), 7.38 (ddd, J=8.6, 7.3,1.7 Hz, 1H), 7.26 (dd, J=8.8, 2.6 Hz, 1H), 7.24 (s, 1H), 7.19-7.15 (m,1H), 7.08 (dd, J=8.3, 1.1 Hz, 1H), 6.99 (dd, J=8.1, 0.8 Hz, 1H), 3.90(s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 168.19, 158.97, 156.89, 155.17,148.78, 132.22, 127.11, 126.79, 125.04, 123.96, 121.25, 119.53, 116.66,113.05, 112.88, 101.98, 56.41; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd forC₁₇H₁₄ClN₂O₄ 345.0637, found: 345.0596.

KSC-392-125

N-(5-Chloro-2-methylphenyl)-3′-hydroxy-[1,1′-biphenyl]-4-carboxamide(KSC-392-125): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using3′-hydroxy-[1,1′-biphenyl]-4-carboxylic acid (30 mg, 0.140 mmol) and5-chloro-2-methylaniline (20 mg, 0.140 mmol). Yield: 10 mg (20%); 95%purity. ¹H NMR (500 MHz, DMSO-d₆) δ 9.98 (s, 1H), 9.65 (bs, 1H), 8.05(d, J=8.5 Hz, 2H), 7.77 (d, J=8.5 Hz, 2H), 7.51 (d, J=2.3 Hz, 1H),7.34-7.26 (m, 2H), 7.24 (dd, J=8.2, 2.3 Hz, 1H), 7.16 (ddd, J=7.7, 1.8,0.9 Hz, 1H), 7.10 (t, J=2.1 Hz, 1H), 6.83 (ddd, J=8.1, 2.5, 0.9 Hz, 1H),2.25 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 165.11, 157.94, 143.48,140.55, 137.83, 132.96, 132.35, 131.84, 130.12, 129.81, 128.40, 126.59,125.83, 125.58, 117.68, 115.17, 113.68, 17.44; HRMS (ESI-TOF) m/z:[M−H]⁻ Calcd for C₂₀H₁₅ClNO₂ 336.0791, found: 336.0782.

KSC-392-125

N-(5-Chloro-2-methylphenyl)-3′-hydroxy-[1,1′-biphenyl]-4-carboxamide(KSC-392-125): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using3′-hydroxy-[1,1′-biphenyl]-4-carboxylic acid (30 mg, 0.140 mmol) and5-chloro-2-methylaniline (20 mg, 0.140 mmol). Yield: 10 mg (20%); 95%purity. ¹H NMR (500 MHz, DMSO-d₆) δ 9.98 (s, 1H), 9.65 (bs, 1H), 8.05(d, J=8.5 Hz, 2H), 7.77 (d, J=8.5 Hz, 2H), 7.51 (d, J=2.3 Hz, 1H),7.34-7.26 (m, 2H), 7.24 (dd, J=8.2, 2.3 Hz, 1H), 7.16 (ddd, J=7.7, 1.8,0.9 Hz, 1H), 7.10 (t, J=2.1 Hz, 1H), 6.83 (ddd, J=8.1, 2.5, 0.9 Hz, 1H),2.25 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 165.11, 157.94, 143.48,140.55, 137.83, 132.96, 132.35, 131.84, 130.12, 129.81, 128.40, 126.59,125.83, 125.58, 117.68, 115.17, 113.68, 17.44; HRMS (ESI-TOF) m/z:[M−H]⁻ Calcd for C₂₀H₁₅ClNO₂ 336.0791, found: 336.0782.

KSC-392-162

N-(3-Chlorophenyl)-5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxamide(KSC-392-162): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylic acid (25 mg, 0.089mmol) and 3-chloroaniline (11 mg, 0.089 mmol). Yield: 8 mg (23%); 100%purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.97 (s, 1H), 10.06 (s, 1H), 7.97(t, J=2.1 Hz, 1H), 7.79-7.69 (m, 3H), 7.55 (t, J=7.9 Hz, 1H), 7.49 (s,1H), 7.42 (t, J=8.1 Hz, 1H), 7.38 (ddd, J=8.1, 2.2, 1.0 Hz, 1H), 7.23(ddd, J=8.0, 2.1, 0.9 Hz, 1H), 3.08 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆)δ 170.24, 159.74, 157.39, 139.49, 139.40, 133.06, 130.55, 127.14,124.26, 121.86, 121.52, 120.06, 119.04, 116.11, 100.65; HRMS (ESI-TOF)m/z: [M+H]⁺ Calcd for C₁₇H₁₅ClN₃O₄S 392.0466, found: 392.0470.

KSC-392-163

N-(5-Chloro-2-methylphenyl)-5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxamide(KSC-392-163): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylic acid (25 mg, 0.089mmol) and 5-chloro-2-methylaniline (13 mg, 0.089 mmol). Yield: 6 mg(16%); 98.9% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.40 (s, 1H), 10.06(s, 1H), 7.76-7.67 (m, 4H), 7.54 (t, J=7.9 Hz, 1H), 7.51 (d, J=2.3 Hz,1H), 7.48 (s, 1H), 7.37 (ddd, J=8.1, 2.2, 1.0 Hz, 1H), 7.36-7.30 (m,1H), 7.27 (dd, J=8.2, 2.2 Hz, 1H), 3.08 (s, 3H), 2.24 (s, 3H); ¹³C NMR(126 MHz, DMSO-d₆) δ 170.24, 159.50, 157.33, 139.41, 136.51, 132.46,132.01, 130.59, 129.94, 127.19, 126.27, 125.82, 121.79, 121.50, 116.06,100.63, 17.32; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₁₇ClN₃O₄S406.0623, found: 406.063.

KSC-392-164

N-(5-Chloro-2-fluorophenyl)-5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxamide(KSC-392-164): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylic acid (25 mg, 0.089mmol) and 5-chloro-2-fluoroaniline (13 mg, 0.089 mmol). Yield: 3 mg(7%); 97% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.68 (s, 1H), 10.06 (s,1H), 7.78-7.66 (m, 3H), 7.54 (t, J=7.9 Hz, 1H), 7.51 (s, 1H), 7.44-7.34(m, 3H), 3.08 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 170.37, 159.12,157.38, 154.37 (d, J=248.2 Hz), 139.41, 130.60, 127.90 (d, J=3.2 Hz),127.26 (d, J=7.9 Hz), 127.12, 125.90 (d, J=13.7 Hz), 121.85, 121.53,117.71 (d, J=21.8 Hz), 116.06, 100.61, 40.43; HRMS (ESI-TOF) m/z: [M+H]⁺Calcd for C₁₇H₁₄ClFN₃O₄S 410.0372, found: 410.0374.

KSC-392-165

N-(2,5-Dichlorophenyl)-5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxamide(KSC-392-165): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylic acid (25 mg, 0.089mmol) and 2,5-dichloroaniline (14 mg, 0.089 mmol). Yield: 8 mg (21%);95.7% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.47 (s, 1H), 10.07 (s, 1H),7.84 (d, J=2.6 Hz, 1H), 7.77-7.69 (m, 4H), 7.64 (d, J=8.6 Hz, 1H),7.58-7.51 (m, 1H), 7.52 (s, 1H), 7.42 (dd, J=8.7, 2.5 Hz, 1H), 7.38(ddd, J=8.2, 2.2, 1.0 Hz, 1H), 3.09 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆)δ 170.54, 159.10, 157.27, 139.41, 135.13, 131.69, 131.09, 130.60,127.63, 127.43, 127.10, 126.88, 121.86, 121.54, 116.06, 100.58, 40.43;HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₄Cl₂N₃O₄S 426.0077, found:426.0087.

KSC-392-166

N-(3,5-Dichlorophenyl)-5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxamide(KSC-392-166): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylic acid (25 mg, 0.089mmol) and 3,5-dichloroaniline (14 mg, 0.089 mmol). Yield: 6 mg (15%);92.9% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 11.13 (s, 1H), 10.06 (s, 1H),7.93 (d, J=1.9 Hz, 2H), 7.77-7.70 (m, 2H), 7.55 (t, J=7.9 Hz, 1H), 7.50(s, 1H), 7.41 (t, J=1.9 Hz, 1H), 7.38 (ddd, J=8.1, 2.2, 1.0 Hz, 1H),3.08 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 170.40, 159.50, 157.60,140.39, 139.40, 134.11, 130.60, 127.06, 123.79, 121.91, 121.56, 118.75,116.12, 100.68, 40.43; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd forC₁₇H₁₄Cl₂N₃O₄S 426.0077, found: 426.0051.

KSC-392-167

N-(3-Chloro-5-methylphenyl)-5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxamide(KSC-392-167): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylic acid (25 mg, 0.089mmol) and 3-chloro-5-methylaniline (13 mg, 0.089 mmol). Yield: 8 mg(22%); 98.3% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.87 (s, 1H), 10.06(s, 1H), 7.78-7.68 (m, 3H), 7.59 (d, J=1.3 Hz, 1H), 7.54 (t, J=7.9 Hz,1H), 7.47 (s, 1H), 7.37 (ddd, J=8.1, 2.2, 1.0 Hz, 1H), 3.08 (s, 3H),2.32 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ 170.20, 159.75, 157.34,140.39, 139.40, 139.22, 132.78, 130.59, 127.14, 124.79, 121.85, 121.51,119.57, 117.30, 116.10, 100.60, 40.43, 20.99; HRMS (ESI-TOF) m/z: [M+H]⁺Calcd for C₁₈H₁₇ClN₃O₄S 406.0623, found: 406.0633.

KSC-392-170

N-(3-Chloro-2-methylphenyl)-5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxamide(KSC-392-170): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylic acid (25 mg, 0.089mmol) and 3-chloro-2-methylaniline (13 mg, 0.089 mmol). Yield: 8 mg(22%); 98.3% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.60 (s, 1H), 10.07(s, 1H), 7.74 (t, J=1.8 Hz, 1H), 7.71 (dt, J=7.8, 1.3 Hz, 1H), 7.54 (t,J=7.9 Hz, 1H), 7.48 (s, 1H), 7.41 (dd, J=8.0, 1.1 Hz, 1H), 7.40-7.33 (m,2H), 7.28 (t, J=7.9 Hz, 1H), 3.08 (s, 3H), 2.26 (s, 3H); ¹³C NMR (126MHz, DMSO-d₆) δ 170.24, 159.51, 157.47, 139.53, 136.74, 133.89, 132.23,127.38, 127.20, 127.10, 125.95, 121.79, 121.40, 116.05, 100.62, 40.43,15.33; HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₈H₁₇ClN₃O₄S 406.0623,found: 406.0628.

KSC-392-168

N-(5-Chloro-2-methylpyridin-3-yl)-5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxamide(KSC-392-168): This compound was prepared following the GeneralProcedure (isoxazole amide) 1 using5-(3-(methylsulfonamido)phenyl)isoxazole-3-carboxylic acid (25 mg, 0.089mmol) and 5-chloro-2-methylpyridin-3-amine (13 mg, 0.089 mmol). Yield: 2mg (6%); 100% purity. ¹H NMR (500 MHz, DMSO-d₆) δ 10.65 (s, 1H), 10.06(s, 1H), 8.45 (d, J=2.3 Hz, 1H), 8.00 (d, J=2.3 Hz, 1H), 7.78-7.65 (m,2H), 7.55 (t, J=7.9 Hz, 1H), 7.51 (s, 1H), 7.38 (ddd, J=8.1, 2.2, 1.0Hz, 1H), 3.09 (s, 3H), 2.46 (s, 3H); ¹³C NMR (126 MHz, DMSO-d₆) δ170.38, 159.27, 157.60, 152.53, 145.02, 139.41, 133.33, 132.16, 130.60,127.86, 127.13, 121.85, 121.53, 116.07, 100.66, 40.43, 20.68; HRMS(ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₇H₁₆ClN₄O₄S 407.0575, found: 407.0596.

Synthesis of Representative Benzamide Intermediates

KSC-392-022

3-(Benzyloxy)-4-chlorobenzoic acid (KSC-392-022): Benzyl bromide (0.793ml, 6.66 mmol) was added drop wise to a solution of4-chloro-3-hydroxybenzoic acid (0.5 g, 2.90 mmol) in DMF (2.9 ml) andpotassium carbonate (0.881 g, 6.37 mmol). The reaction mixture wasstirred overnight at room temperature. Upon completion, the reactionmixture was mixed with water and extracted with ethyl acetate. Thecombined organic layers were dried with anhydrous sodium sulfate,filtered, and evaporated to dryness. This residue was dissolved in MeOH(1.5 ml 10 M KOH (0.867 ml, 8.67 mmol) was added. The reaction mixturewas stirred for 4 h at 50° C. The reddish solution was diluted withwater and acidified with 3 N aqueous hydrochloric acid. The precipitateformed was extracted with ethyl acetate, washed with water, dried withanhydrous sodium sulfate, filtered, and evaporated to dryness. Theresulting residue was purified according to the preparative RP HPLCmethods described in the General Experimental section. Isolated3-(benzyloxy)-4-chlorobenzoic acid (0.454 g, 1.728 mmol, 59.6% yield) asa white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.68 (d, J=1.7 Hz, 1H),7.60-7.51 (m, 2H), 7.50-7.45 (m, 2H), 7.44-7.38 (m, 2H), 7.37-7.32 (m,1H), 5.27 (s, 2H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₄H₁₀ClO₃261.0318; Found 261.0348.

KSC-392-023

3-(Benzyloxy)-5-chlorobenzoic acid (KSC-392-023): This compound wasprepared following the procedure KSC-392-022 using3-chloro-5-hydroxybenzoic acid (100 mg, 0.579 mmol). Yield: 89 mg (59%),94.7% purity. ¹H NMR (400 MHz, DMSO-d₆) δ 7.49-7.47 (m, 1H), 7.47-7.43(m, 3H), 7.42-7.32 (m, 4H), 5.19 (s, 2H); HRMS (ESI-TOF) m/z: [M−H]⁻Calcd for C₁₄H₁₀ClO₃ 261.0318; Found 261.0237.

KSC-392-024

5-(Benzyloxy)-2-chlorobenzoic acid (KSC-392-024): This compound wasprepared following the procedure KSC-392-022 using2-chloro-5-hydroxybenzoic acid (500 mg, 2.90 mmol). Yield: 131 mg (17%),100% purity. ¹H NMR (400 MHz, DMSO-d₆) δ 13.44 (s, 1H), 7.48-7.30 (m,7H), 7.17 (dd, J=8.8, 3.1 Hz, 1H), 5.15 (s, 2H); HRMS (ESI-TOF) m/z:[M+H]⁺ Calcd for C₁₄H₁₂ClO₃ 263.0469; Found 263.0430.

General Procedure (Benzamides) 1:

To a solution of the appropriate aniline (0.268 mmol, 1 eq.) in DMF(0.32 M, 0.840 mL) was added PyBOP (0.536 mmol, 2 eq.), Hunig's base(0.429 mmol, 1.6 eq.), and the appropriate benzoic acid (0.268 mmol, 1eq.). The reaction mixture was subjected to microwave radiation at 120°C. for 15 min following which the resulting residue was purifiedaccording to the preparative RP HPLC methods described herein.

KSC-338-032

5-Chloro-2-methoxy-N-(4-(piperidin-1-ylmethyl)phenyl)benzamide(KSC-338-032): This compound was prepared following the GeneralProcedure (benzamides) 1 using 4-(piperidin-1-ylmethyl)aniline (51 mg,0.268 mmol) and 5-chloro-2-methoxybenzoic acid (50 mg, 0.268 mmol).Yield: 67 mg (69%). ¹H NMR (400 MHz, DMSO-d₆) δ 10.15 (s, 1H), 7.70-7.60(m, 2H), 7.59 (d, J=2.8 Hz, 1H), 7.54 (dd, J=8.8, 2.8 Hz, 1H), 7.27-7.20(m, 2H), 7.20 (d, J=8.9 Hz, 1H), 3.88 (s, 3H), 3.37 (s, 2H), 2.39-2.16(m, 4H), 1.48 (p, J=5.5 Hz, 4H), 1.42-1.30 (m, 2H); HRMS (ESI-TOF) m/z:[M+H]⁺ Calcd for C₂₀H₂₄ClN₂O₂ 359.1521; Found 359.1517.

KSC-338-071

3-(Benzyloxy)-N-(4-(piperidin-1-ylmethyl)phenyl)benzamide (KSC-338-071):¹HNMR (400 MHz, DMSO-d₆) δ 10.18 (s, 1H), 7.74-7.65 (m, 2H), 7.61-7.55(m, 1H), 7.58-7.50 (m, 1H), 7.52-7.36 (m, 5H), 7.29-7.19 (m, 3H), 5.19(s, 2H), 3.38 (s, 2H), 2.35-2.15 (bm, 4H), 1.48 (p, J=5.4 Hz, 4H),1.42-1.32 (m, 2H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd for C₂₆H₂₉N₂O₂401.2224; Found 401.2219.

KSC-392-029

3-(Benzyloxy)-4-chloro-N-(4-(piperidin-1-ylmethyl)phenyl)benzamide(KSC-392-029): This compound was prepared following the GeneralProcedure (benzamides) 1 using 4-(piperidin-1-ylmethyl)aniline (36 mg,0.190 mmol) and 3-(benzyloxy)-4-chlorobenzoic acid (50 mg, 0.190 mmol).Yield: 49 mg (59%); 100% purity. ¹H NMR (400 MHz, DMSO-d₆) δ 10.26 (s,1H), 7.75 (d, J=1.8 Hz, 1H), 7.70-7.62 (m, 2H), 7.64-7.53 (m, 2H),7.53-7.45 (m, 2H), 7.47-7.38 (m, 2H), 7.40-7.30 (m, 1H), 7.29-7.21 (m,2H), 5.30 (s, 2H), 3.40-3.34 (m, 2H), 2.38-2.18 (bm, 4H), 1.48 (p, J=5.5Hz, 4H), 1.41-1.28 (m, 2H); HRMS (ESI-TOF) m/z: [M+H]⁺ Calcd forC₂₆H28ClN₂O₂ 435.1834; Found 435.1815.

Detailed Assay Protocols

μHTS Identification of Small Molecule Inhibitors of the MitochondrialPermeability Transition Pore Via an Absorbance Assay (Primary ScreeningAssay, Single Concentration, AID No. 602449)

List of Reagents:

Assay Buffer: 250 mM sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mMphosphoric acid, pH 7.4

-   -   Solution 1: 0.5 mg/mL mitochondria in Assay Buffer    -   Solution 2: 2.0 mM EGTA-Tris, pH 7.4 in Solution 3    -   Solution 3: 80-200 μM CaCl₂) depending on mitochondrial        activity, 5.0 mM glutamate, 2.5 mM malate in Assay Buffer. Note:        Concentration of calcium in the assay is dependent upon the        activity of the isolated mitochondria which is determined via a        calcium titration just before each high-throughput screening        batch. A calcium concentration is used that allows for the        arrival at a 2:1 window at the 30 minute time period.

Protocol Summary:

1. Compounds are pre-spotted into assay plates the morning of or thenight before the assay. Via the LabCyte Echo, 16 nL of 5 mM compound istransferred to Greiner, 1536-well, clear assay plates (Greiner 782101)to achieve 10 μM in 8 μL assay final volume. To the control wells inColumns 1-4, 16 nL of DMSO is transferred.

2. Prepare positive and negative control solutions, the mitochondrialsuspension and the calcium solution working stocks according to therecipes in the Reagent Section.

3. Upon determination of activity, freshly isolated mitochondria frommice are suspended in assay buffer (Solution 1) and 4 μL of thissolution is added to all wells of the assay plate with a MultiDropCombi. Final assay concentration of mitochondria will be about 0.25mg/mL (Working Stock ˜0.5 mg/mL).

4. Following the addition of the mitochondrial suspension, 4 μL of thepositive control working stock containing 2.0 mM EGTA-Tris, pH 7.4 inassay buffer (Solution 2) is added to Columns 1-2. Final assayconcentration=1.0 mM EGTA-Tris, pH 7.4.

5. Next, 4 μL of Calcium solution (Solution 3) is added to negativecontrol and test compound wells, Columns 3-48. Final concentration ofcalcium will be 40-100 μM (80-200 μM in the working stock).

6. Assay plate is immediately spun at 1000 rpm for ˜60 seconds.

7. Plate is kept at room temperature for 30 minutes and then read on theBMG Pherastar utilizing absorbance at 540 nm.

Comments:

Compounds that demonstrated a corrected % activity >=50% compared to thecontrols are defined as active in the assay.

The experimental values were normalized by the difference between valuesfrom neutral and stimulator control wells in each plate. Then normalizeddata was corrected to remove systematic plate patterns due to artifactssuch as dispensing tip issues etc. Further information about datacorrection is available at

http://www.genedata.com/products/screener.html.

To simplify the distinction between the inactives of the primary screenand of the confirmatory screening stage, the Tiered Activity ScoringSystem was developed and implemented.

Activity Scoring:

Activity scoring rules were devised to take into consideration compoundefficacy, its potential interference with the assay and the screeningstage that the data was obtained. Details of the Scoring System will bepublished elsewhere. Briefly, the outline of the scoring system utilizedfor the assay is as follows:

-   -   1) First tier (0-40 range) is reserved for primary screening        data. The score is correlated with % activity in the assay:        -   a. If outcome of the primary screen is inactive, then the            assigned score is 0        -   b. If outcome of the primary screen is inconclusive, then            the assigned score is 10        -   c. If outcome of the primary screen is active, then the            assigned score is    -   Scoring for Single concentration confirmation screening is not        applicable to this assay.        -   d. If outcome of the single-concentration confirmation            screen is inactive, then the assigned score is 21        -   e. If outcome of the single-concentration confirmation            screen is inconclusive, then the assigned score is 25        -   f. If outcome of the single-concentration confirmation            screen is active, then the assigned score is 30

This scoring system helps track the stage of the testing of a particularSID. For the primary hits which are available for confirmation, theirscores will be greater than 20. For those which are not furtherconfirmed, their score will stay under 21.

-   -   2) Second tier (41-80 range) is reserved for dose-response        confirmation data and is not applicable in this assay    -   3) Third tier (81-100 range) is reserved for resynthesized true        positives and their analogues and is not applicable in this        assay

Single Concentration Confirmation of pHTS Inhibitor Hits of theMitochondrial Permeability Transition Pore Via a Fluorescent Based Assay(Counterscreen Assay, Single Concentration, AID No. 624504)

List of Reagents:

Assay Buffer: 250 mM sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mMphosphoric acid-Tris, pH 7.4.

-   -   Solution 1: 0.5 mg/mL mitochondria in Assay Buffer.    -   Solution 2: 0.8 μM Rh123, 5.0 mM glutamate and 2.5 mM malate in        Assay Buffer.

Protocol Summary:

1. Compounds are pre-spotted into assay plates the morning of or thenight before the assay. Via a LabCyte Echo, 40 nL of 5 mM compound istransferred to a Greiner, 384-well, black assay plates (Greiner 781076)to achieve 10 μM in 20 μL final assay volume. To the positive controlwells, 40 nL of 0.2 mM carbonyl cyanide4-(trifluoromethoxy)phenylhydrazone (FCCP) is transferred. To thenegative control wells, 40 nL of DMSO is transferred.

2. Prepare Assay Buffer, Rhodamine 123 (Rh123) Solution and themitochondrial suspension working stocks according to the recipes in theReagent Section.

3. Freshly isolated mitochondria from mice are suspended in Assay Buffer(Solution 1) and 10 μL of this solution is added to all wells of theassay plate with a MultiDrop Combi. Final assay concentration ofmitochondria will be about 0.25 mg/mL (Working Stock ˜0.5 mg/mL),depending on relative activity of mitochondrial preparation.

4. Following the addition of the mitochondrial suspension, 10 μL ofRh123 Solution (Solution 2) is added to each well of the assay plate.

5. Assay plate is immediately spun at 1000 rpm for ˜60 seconds.

6. Plate is kept at room temperature for 5 minutes and then read on theBMG Pherastar utilizing a fluorescence intensity optical module thatallows for excitation at 480 nm and a read at an emission wavelength of520 nm.

Comments:

Compounds that demonstrated a % activity_mean>=20% compared to thecontrols are defined as active in the assay.

To simplify the distinction between the inactives of the primary screenand of the confirmatory screening stage, the Tiered Activity ScoringSystem was developed and implemented.

Activity Scoring:

Activity scoring rules were devised to take into consideration compoundefficacy, its potential interference with the assay and the screeningstage that the data was obtained. Details of the Scoring System will bepublished elsewhere. Briefly, the outline of the scoring system utilizedfor the assay is as follows:

-   -   1) First tier (0-40 range) is reserved for primary screening        data. The score is correlated with % activity in the assay.        Scoring for the primary screening is not applicable to this        assay.        -   a. If outcome of the primary screen is inactive, then the            assigned score is 0        -   b. If outcome of the primary screen is inconclusive, then            the assigned score is 10        -   c. If outcome of the primary screen is active, then the            assigned score is    -   Scoring for Single concentration confirmation screening is        applicable to this assay.        -   d. If outcome of the single-concentration confirmation            screen is inactive, then the assigned score is 21        -   e. If outcome of the single-concentration confirmation            screen is inconclusive, then the assigned score is 25        -   f. If outcome of the single-concentration confirmation            screen is active, then the assigned score is 30

This scoring system helps track the stage of the testing of a particularSID. For the primary hits which are available for confirmation, theirscores will be greater than 20. For those which are not furtherconfirmed, their score will stay under 21.

-   -   2) Second tier (41-80 range) is reserved for dose-response        confirmation data and is not applicable in this assay.    -   3) Third tier (81-100 range) is reserved for resynthesized true        positives and their analogues and is not applicable in this        assay.

Dose Response Confirmation of pHTS Inhibitor Hits of the MitochondrialPermeability Transition Pore Via an Absorbance Assay (ConfirmatoryAssay, Concentration-Response, AID No. 651561)

List of Reagents:

Assay Buffer: 250 mM sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mMphosphoric acid-Tris, pH 7.4

-   -   Solution 1: 0.5 mg/mL mitochondria in Assay Buffer    -   Solution 2: 2.0 mM EGTA-Tris, pH 7.4 in Solution 3    -   Solution 3: 80-200 μM CaCl₂) depending on mitochondrial        activity, 5.0 mM glutamate, 2.5 mM malate in Assay Buffer. Note:        Concentration of calcium in the assay is dependent upon the        activity of the isolated mitochondria which is determined via a        calcium titration just before each high-throughput screening        batch. A calcium concentration is used that allows for the        arrival at a 2:1 window at the 30 minute time period.

Protocol Summary:

1. Compounds are pre-spotted into assay plates the morning of or thenight before the assay. Via the LabCyte Echo, varying volumes of 10 mMtest compounds in DMSO are transferred to a Greiner, 1536-well, clearassay plates (Greiner 782101) to achieve appropriate test volumeconcentrations and range. Varying volumes of DMSO are transferred to thewells of the assay plate to equilibrate it's concentration between wellsfor a total volume of 64 nL of DMSO per well or 0.8% final assayconcentration. Positive and negative control wells will also contain 64nL of DMSO.

2. Prepare positive and negative control solutions, the mitochondrialsuspension and the calcium solution working stocks according to therecipes in the Reagent Section.

3. Freshly isolated mitochondria from mice are suspended in assay buffer(Solution 1) and 4 μL of this solution is added to all wells of theassay plate with a MultiDrop Combi. Final assay concentration ofmitochondria will be about 0.25 mg/mL (Working Stock ˜0.5 mg/mL)depending on the relative activity of each batch of mitochondrialpreparation.

4. Following the addition of the mitochondrial suspension, 4 μL of thepositive control working stock containing 2.0 mM EGTA-Tris, pH 7.4 inassay buffer (Solution 2) is added to Columns 1-2. Final assayconcentration=1.0 mM EGTA-Tris, pH 7.4.

5. Next, 4 μL of Calcium solution (Solution 3) is added to negativecontrol and test compound wells, Columns 3-48. Final concentration ofcalcium will be 40-100 μM (80-200 μM in the working stock) depending onmitochondrial activity.

6. Assay plate is immediately spun at 1000 rpm for ˜60 seconds.

7. Plate is kept at room temperature for 30 minutes and then read on theBMG Pherastar utilizing absorbance at 540 nm.

Comments:

Compounds that demonstrated an EC₅₀ of 20 μM or less are defined asactive in this assay.

To simplify the distinction between the inactives of the primary screenand of the confirmatory screening stage, the Tiered Activity ScoringSystem was developed and implemented.

Activity Scoring:

Activity scoring rules were devised to take into consideration compoundefficacy, its potential interference with the assay and the screeningstage that the data was obtained. Details of the Scoring System will bepublished elsewhere. Briefly, the outline of the scoring system utilizedfor the assay is as follows:

-   -   1) First tier (0-40 range) is reserved for primary screening        data. The score is correlated with % activity in the assay.        Scoring for the primary screening is not applicable to this        assay.    -   2) Second tier (41-80 range) is reserved for dose-response        confirmation data        -   a. Inactive compounds of the confirmatory stage are assigned            a score value equal 41.        -   b. The score is linearly correlated with a compound's            potency and, in addition, provides a measure of the            likelihood that the compound is not an artifact based on the            available information.        -   c. The Hill coefficient is taken as a measure of compound            behavior in the assay via an additional scaling factor QC:

QC=2.6*[exp(−0.5*nH{right arrow over ( )}2)−exp(−1.5*nH{circumflex over( )}2)]

This empirical factor prorates the likelihood of target- orpathway-specific compound effect vs. its non-specific behavior in theassay. This factor is based on expectation that a compound with a singlemode of action that achieved equilibrium in the assay demonstrates theHill coefficient value of 1. Compounds deviating from that behavior arepenalized proportionally to the degree of their deviation.

-   -   d. Summary equation that takes into account all the items        discussed above is

Score=44+6*(pIC ₅₀−3)*QC,

Where pIC₅₀ is a negative log(10) of the IC₅₀ value expressed in mole/Lconcentration units. This equation results in the Score values above 50for compounds that demonstrate high potency and predictable behavior.Compounds that are inactive in the assay or whoseconcentration-dependent behavior are likely to be an artifact of thatassay will generally have lower Score values.

3) Third tier (81-100 range) is reserved for resynthesized truepositives and their analogues and is not applicable in this assay.

Dose Response Confirmation of pHTS Inhibitor Hits of the MitochondrialPermeability Transition Pore Via a Fluorescent Based Counterscreen Assay(Counterscreen Assay, Concentration-Response, AID No. 651564)

List of Reagents:

Assay Buffer: 250 mM sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mMphosphoric acid-Tris, pH 7.4.

-   -   Solution 1: 0.5 mg/mL mitochondria in Assay Buffer.    -   Solution 2: 0.8 μM Rh123, 5.0 mM glutamate and 2.5 mM malate in        Assay Buffer.

Protocol Summary:

1. Compounds are pre-spotted into assay plates the morning of or thenight before the assay. Via the LabCyte Echo, varying volumes of 10 mMtest compounds in DMSO are transferred to a Greiner, 1536-well, clearassay plates (Greiner 782101) to achieve appropriate test volumeconcentrations and range. Varying volumes of DMSO are transferred to thewells of the assay plate to equilibrate its concentration between wellsfor a total volume of 64 nL of DMSO per well or 0.8% final assayconcentration. Positive and negative control wells will also contain 64nL of DMSO.

2. Prepare Assay Buffer, Rh123 Solution and the mitochondrial suspensionworking stocks according to the recipes in the Reagent Section.

3. Freshly isolated mitochondria from mice are suspended in Assay Buffer(Solution 1) and 10 μL of this solution is added to all wells of theassay plate with a MultiDrop Combi. Final assay concentration ofmitochondria will be about 0.25 mg/mL (Working Stock ˜0.5 mg/mL),depending on relative activity of mitochondrial preparation.

4. Following the addition of the mitochondrial suspension, 10 μL ofRh123 Solution (Solution 2) is added to each well of the assay plate.

5. Assay plate is immediately spun at 1000 rpm for ˜60 seconds.

6. Plate is kept at room temperature for 5 minutes and then read on theBMG Pherastar utilizing a fluorescence intensity optical module thatallows for excitation at 480 nm and a read at an emission wavelength of520 nm.

Comments:

Compounds that demonstrated an EC₅₀ of 80 μM or less are defined asactive in this assay.

To simplify the distinction between the inactives of the primary screenand of the confirmatory screening stage, the Tiered Activity ScoringSystem was developed and implemented.

Activity Scoring:

Activity scoring rules were devised to take into consideration compoundefficacy, its potential interference with the assay and the screeningstage that the data was obtained. Details of the Scoring System will bepublished elsewhere. Briefly, the outline of the scoring system utilizedfor the assay is as follows:

-   -   1) First tier (0-40 range) is reserved for primary screening        data and is not applicable in this assay.    -   2) Second tier (41-80 range) is reserved for dose-response        confirmation data        -   a. Inactive compounds of the confirmatory stage are assigned            a score value equal 41.        -   b. The score is linearly correlated with a compound's            potency and, in addition, provides a measure of the            likelihood that the compound is not an artifact based on the            available information.        -   c. The Hill coefficient is taken as a measure of compound            behavior in the assay via an additional scaling factor QC:

QC=2.6*[exp(−0.5*nH{circumflex over ( )}2)−exp(−1.5*nH{circumflex over( )}2)]

-   -   This empirical factor prorates the likelihood of target- or        pathway-specific compound effect vs. its non-specific behavior        in the assay. This factor is based on expectation that a        compound with a single mode of action that achieved equilibrium        in the assay demonstrates the Hill coefficient value of 1.        Compounds deviating from that behavior are penalized        proportionally to the degree of their deviation.        -   d. Summary equation that takes into account all the items            discussed above is

Score=44+6*(pIC ₅₀−3)*QC,

Where pIC₅₀ is a negative log(10) of the IC₅₀ value expressed in mole/Lconcentration units. This equation results in the Score values above 50for compounds that demonstrate high potency and predictable behavior.Compounds that are inactive in the assay or whoseconcentration-dependent behavior are likely to be an artifact of thatassay will generally have lower Score values.

-   -   3) Third tier (81-100 range) is reserved for resynthesized true        positives and their analogues and is not applicable in this        assay.

Dry Powder Dose Response Confirmation of pHTS Inhibitor Hits of theMitochondrial Permeability Transition Pore Via an Absorbance.Mitochondrial Swelling (Hit Validation, Confirmatory Assay,Concentration-Response, AID No. 720722)

List of Reagents:

Assay buffer: 250 mM sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mMphosphoric acid-Tris, pH 7.4

-   -   Solution 1. 5.0 mM glutamate and 2.5 mM malate in Assay buffer.    -   Solution 2. 80-120 μM CaCl₂) depending on mitochondrial activity        in Solution 1. Note: Concentration of Ca²⁺ in the assay is        dependent upon the activity of the isolated mitochondria which        is determined via a calcium titration just before each screening        batch. A Ca²⁺ concentration is used that allows for the arrival        at a 2:1 window at the 20 minute time period.    -   Solution 3. 1% DMSO in Solution 2.    -   Solution 4. 2.0 mM EGTA-Tris, pH 7.4 in Solution 3.    -   Solution 5. 0.5 mg/mL mitochondria in Assay Buffer.

Protocol Summary:

1. Freshly isolate mitochondria, prepare solutions according to therecipes in the reagent section

2. Dispense 100 μL of Solution 4 to Columns 1-2 and Solution 3 Columns11-12 (positive and negative controls, respectively) of the 96-wellclear assay plate (Falcon 353072)

3. Dispense 200 μL of Solution 1 to Row A Columns 3-10.

4. Next, dispense 100 μL of Solution 3 to Rows B-H Columns 3-10.

5. Add 4 μL of 5 mM test compounds in DMSO to Row A Columns 3-10,perform 1:2 serial dilutions Row A to H Columns 3-10.

6. Finally, dispense 100 μL of Solution 5 in all wells. The reactionstarts.

7. Keep the plate at room temperature for 20 minutes and then readabsorbance at 540 nm on MultiSkan EX, Thermo Scientific.

Comments:

Compounds that demonstrated an EC₅₀ of 20 μM or less are defined asactive in this assay.

To simplify the distinction between the inactive compounds of theprimary screen and of the confirmatory screening stage, the TieredActivity Scoring System was developed and implemented.

Activity Scoring:

Activity scoring rules were devised to take into consideration compoundefficacy, its potential interference with the assay and the screeningstage that the data was obtained. Details of the Scoring System will bepublished elsewhere. Briefly, the outline of the scoring system utilizedfor the assay is as follows:

-   -   1) First tier (0-40 range) is reserved for primary screening        data and is not applicable in this assay.    -   2) Second tier (41-80 range) is reserved for dose-response        confirmation data and is not applicable in this assay.    -   3) Third tier (81-100 range) is reserved for resynthesized true        positives and their analogues.        -   a. Compounds that failed to reproduce from dry powder or            have IC₅₀>20 M are assigned inactive and a score value of            81.        -   b. The score is linearly correlated with a compound's            potency and, in addition, provides a measure of the            likelihood that the compound is not an artifact based on the            available information. The Hill coefficient is taken as a            measure of compound behavior in the assay via an additional            scaling factor QC:

QC=2.6*[exp(−0.5*nH;2)−exp(−1.5*nH;2)]

-   -   This empirical factor prorates the likelihood of a target- or a        pathway-specific compound effect vs. its non-specific behavior        in the assay. This factor is based on the expectation that a        compound with a single mode of action that achieved an        equilibrium in the assay would demonstrate the Hill coefficient        value of 1. Compounds deviating from that behavior are penalized        proportionally to the degree of their divergence.        -   c. The score is calculated using the following equation:

Score=82+3*(pIC ₅₀−3)*QC,

-   -   where pIC₅₀ is a negative log(10) of the IC₅₀ value expressed in        mole/L concentration units, and QC is calculated using Hill        coefficient as above. This equation results in the Score values        above 85 for compounds that demonstrate high potency and        predictable behavior in the assays.

Dry Powders Dose Response Confirmation of pHTS Inhibitor Hits of theMitochondrial Permeability Transition Pore Via a Fluorescent BasedCounterscreen. Rhodamine 123 Quenching (Hit Validation, CounterscreenAssay, Concentration-Response, AID No. 720723)

List of Reagents:

Assay buffer: 250 mM sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mMphosphoric acid-Tris, pH 7.4

-   -   Solution 1. 5.0 mM glutamate and 2.5 mM malate in Assay Buffer.    -   Solution 2. 1% DMSO in Solution 1.    -   Solution 3. 0.8 μM FCCP (the stock 40 μM in DMSO) in Solution 1.    -   Solution 4. 0.5 mg/mL mitochondria and 0.8 μM Rh123 in Assay        Buffer.

Protocol Summary:

1. Freshly isolate mitochondria, prepare solutions according to therecipes in the Reagent Section.

2. Dispense 100 μL of Solution 3 to Columns 1-2 and Solution 2 Columns11-12 (positive and negative controls, respectively) of the 96-wellblack assay plate (Falcon 353376).

3. Dispense 200 μL of Solution 1 to Row A Columns 3-10.

4. Next, dispense 100 μL of Solution 2 to Rows B-H Columns 3-10.

5. Add 4 μL of 10 mM test compounds in DMSO to Row A Columns 3-10,perform 1:2 serial dilutions Row A to H Columns 3-10.

6. Finally, dispense 100 μL of Solution 4 in all wells. The reactionstarts.

7. Keep the plate at room temperature for 5 minutes and then readfluorescence (excitation 485 nm, emission 538 nm) on Fluoroskan AscentFL, Thermo Scientific.

Comments:

Compounds that demonstrated an EC₅₀ of 100 μM or less are defined asactive in this assay.

To simplify the distinction between the inactives of the primary screenand of the confirmatory screening stage, the Tiered Activity ScoringSystem was developed and implemented.

Activity Scoring:

Activity scoring rules were devised to take into consideration compoundefficacy, its potential interference with the assay and the screeningstage that the data was obtained. Details of the Scoring System will bepublished elsewhere. Briefly, the outline of the scoring system utilizedfor the assay is as follows:

-   -   1) First tier (0-40 range) is reserved for primary screening        data and is not applicable in this assay.    -   2) Second tier (41-80 range) is reserved for dose-response        confirmation data and is not applicable in this assay.    -   3) Third tier (81-100 range) is reserved for resynthesized true        positives and their analogues.        -   a. Compounds that failed to reproduce from dry powder or            have IC₅₀>100 M are assigned inactive and a score value of            81.        -   b. The score is linearly correlated with a compound's            potency and, in addition, provides a measure of the            likelihood that the compound is not an artifact based on the            available information. The Hill coefficient is taken as a            measure of compound behavior in the assay via an additional            scaling factor QC:

QC=2.6*[exp(−0.5*nH;2)−exp(−1.5*nH;2)]

-   -   This empirical factor prorates the likelihood of a target- or a        pathway-specific compound effect vs. its non-specific behavior        in the assay. This factor is based on the expectation that a        compound with a single mode of action that achieved an        equilibrium in the assay would demonstrate the Hill coefficient        value of 1. Compounds deviating from that behavior are penalized        proportionally to the degree of their divergence.        -   c. The score is calculated using the following equation:

Score=82+3*(pIC ₅₀−3)*QC,

-   -   where pIC₅₀ is a negative log(10) of the IC₅₀ value expressed in        mole/L concentration units, and QC is calculated using Hill        coefficient as above. This equation results in the Score values        above 85 for compounds that demonstrate high potency and        predictable behavior in the assays.

Dry Powder Dose Response Confirmation pHTS Inhibitor Hits of theMitochondrial Permeability Transition Pore Via Calcium RetentionCapacity Test (Hit Validation, Confirmatory Assay,Concentration-Response, AID No. 720728)

List of Reagents:

Assay buffer: 250 mM sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mMphosphoric acid-Tris, pH 7.4.

-   -   Solution 1. 10 mM glutamate and 5 mM malate in Assay buffer.    -   Solution 2. 1% DMSO in Solution 2.    -   Solution 3. 0.5 mg/mL mitochondria and 1.0 μM Calcium Green-5N        in Assay Buffer.    -   Solution 4. 0.25 mM CaCl₂).

Protocol Summary:

1. Freshly isolate mitochondria, prepare solutions according to therecipes in the Reagent Section.

2. Dispense 100 μL of Solution 2 to Columns 1-2 (negative control) ofthe 96-well black assay plate (Falcon 353376).

3. Dispense 200 μL of Solution 1 to Row A Columns 3-12.

4. Next, dispense 100 μL of Solution 2 to Rows B-H Columns 3-12.

5. Add 4 μL of 5 mM test compounds in DMSO to Row A Columns 3-12,perform 1:2 serial dilutions Row A to H Columns 3-12.

6. Finally, dispense 100 μL of Solution 3 in all wells.

7. Experiment starts. Read Calcium Green-5N fluorescence (excitation 485nm, emission 538 nm) and perform a train of 4 μL Solution 4 additionswith Fluoroskan Ascent FL, Thermo Scientific.

Comments:

Compounds that demonstrated a CRC/CRC₀ of above 1.1 at 12.5 μM aredefined as active in this assay.

Concentration-response assay to identify compounds that inhibitmitochondrial swelling (SAR Assay AID No. 743359)

List of Reagents:

Assay buffer: 250 mM sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mMphosphoric acid, pH 7.4

-   -   Solution 1. 5.0 mM glutamate and 2.5 mM malate in Assay Buffer.    -   Solution 2. 100-120 μM CaCl₂) depending on mitochondrial        activity in Solution 1. Note: Concentration of Ca²⁺ in the assay        is dependent upon the activity of the isolated mitochondria        which is determined via a calcium titration just before each        screening batch. A Ca²⁺ concentration is used that allows for        the arrival at a 2:1 window at the 20 minute time period.    -   Solution 3. 1% DMSO in Solution 2.    -   Solution 4. 2.0 mM EGTA-Tris, pH 7.4 in Solution 3.    -   Solution 5. 0.5 mg/mL mitochondria in Assay Buffer.

Protocol Summary:

1. Freshly isolate mitochondria, prepare solutions according to therecipes in the Reagent Section.

2. Dispense 100 μL of Solution 4 to Columns 1-2 and Solution 3 Columns11-12 (positive and negative controls, respectively) of the 96-wellclear assay plate (Falcon 353072).

3. Dispense 200 μL of Solution 1 to Row A Columns 3-10.

4. Next, dispense 100 μL of Solution 3 to Rows B-H Columns 3-10.

5. Add 4 μL of 5 mM test compounds in DMSO to Row A Columns 3-10,perform 1:2 serial dilutions Row A to H Columns 3-10.

6. Finally, dispense 100 μL of Solution 5 in all wells. The reactionstarts.

7. Keep the plate at room temperature for 20 minutes and then readabsorbance at 540 nm on MultiSkan EX, Thermo Scientific.

Comments:

Compounds that demonstrated an EC₅₀ of 20 μM or less are defined asactive in this assay.

To simplify the distinction between the inactives of the primary screenand of the confirmatory screening stage, the Tiered Activity ScoringSystem was developed and implemented.

Activity Scoring:

Activity scoring rules were devised to take into consideration compoundefficacy, its potential interference with the assay and the screeningstage that the data was obtained. Details of the Scoring System will bepublished elsewhere. Briefly, the outline of the scoring system utilizedfor the assay is as follows:

-   -   1) First tier (0-40 range) is reserved for primary screening        data and is not applicable in this assay.    -   2) Second tier (41-80 range) is reserved for dose-response        confirmation data and is not applicable in this assay.    -   3) Third tier (81-100 range) is reserved for resynthesized true        positives and their analogues.        -   a. Compounds that failed to reproduce from dry powder or            have IC₅₀>20 M are assigned inactive and a score value of            81.        -   b. The score is linearly correlated with a compound's            potency and, in addition, provides a measure of the            likelihood that the compound is not an artifact based on the            available information. The Hill coefficient is taken as a            measure of compound behavior in the assay via an additional            scaling factor QC:

QC=2.6*[exp(−0.5*nH;2)−exp(−1.5*nH;2)]

-   -   This empirical factor prorates the likelihood of a target- or a        pathway-specific compound effect vs. its non-specific behavior        in the assay. This factor is based on the expectation that a        compound with a single mode of action that achieved an        equilibrium in the assay would demonstrate the Hill coefficient        value of 1. Compounds deviating from that behavior are penalized        proportionally to the degree of their divergence.        -   c. The score is calculated using the following equation:

Score=82+3*(pIC ₅₀−3)*QC,

-   -   where pIC₅₀ is a negative log(10) of the IC₅₀ value expressed in        mole/L concentration units, and QC is calculated using Hill        coefficient as above. This equation results in the Score values        above 85 for compounds that demonstrate high potency and        predictable behavior in the assays.

Concentration-Response Counterscreen Assay to Identify Compounds thatPrevent Mitochondrial Swelling Via Interference with the IMM Potential(SAR Assay AID No. 743361)

List of Reagents:

Assay buffer: 250 mM sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mMphosphoric acid-Tris, pH 7.4

-   -   Solution 1. 5.0 glutamate and 2.5 mM malate in Assay Buffer.    -   Solution 2. 1% DMSO in Solution 1.    -   Solution 3. 0.8 μM FCCP (the stock 40 μM in DMSO) in Solution 1.    -   Solution 4. 0.5 mg/mL mitochondria and 0.8 μM Rh123 in Assay        Buffer.

Protocol Summary:

1. Freshly isolate mitochondria, prepare solutions according to therecipes in the Reagent Section.

2. Dispense 100 μL of Solution 3 to Columns 1-2 and Solution 2 Columns11-12 (positive and negative controls, respectively) of the 96-wellblack assay plate (Falcon 353376).

3. Dispense 200 μL of Solution 1 to Row A Columns 3-10.

4. Next, dispense 100 μL of Solution 2 to Rows B-H Columns 3-10.

5. Add 4 μL of 10 mM test compounds in DMSO to Row A Columns 3-10,perform 1:2 serial dilutions Row A to H Columns 3-10.

6. Finally, dispense 100 μL of Solution 4 in all wells. The reactionstarts.

7. Keep the plate at room temperature for 5 minutes and then readfluorescence (excitation 485 nm, emission 538 nm) on Fluoroskan AscentFL, Thermo Scientific.

Comments:

Compounds that demonstrated an EC₅₀ of 100 μM or less are defined asactive in this assay.

To simplify the distinction between the inactives of the primary screenand of the confirmatory screening stage, the Tiered Activity ScoringSystem was developed and implemented.

Activity Scoring:

Activity scoring rules were devised to take into consideration compoundefficacy, its potential interference with the assay and the screeningstage that the data was obtained. Details of the Scoring System will bepublished elsewhere. Briefly, the outline of the scoring system utilizedfor the assay is as follows:

-   -   1) First tier (0-40 range) is reserved for primary screening        data and is not applicable in this assay    -   2) Second tier (41-80 range) is reserved for dose-response        confirmation data and is not applicable in this assay.    -   3) Third tier (81-100 range) is reserved for resynthesized true        positives and their analogues.        -   a. Compounds that failed to reproduce from dry powder or            have EC₅₀>100 M are assigned inactive and a score value of            81.        -   b. The score is linearly correlated with a compound's            potency and, in addition, provides a measure of the            likelihood that the compound is not an artifact based on the            available information. The Hill coefficient is taken as a            measure of compound behavior in the assay via an additional            scaling factor QC:

QC=2.6*[exp(−0.5*nH;2)−exp(−1.5*nH;2)]

-   -   This empirical factor prorates the likelihood of a target- or a        pathway-specific compound effect vs. its non-specific behavior        in the assay. This factor is based on the expectation that a        compound with a single mode of action that achieved an        equilibrium in the assay would demonstrate the Hill coefficient        value of 1. Compounds deviating from that behavior are penalized        proportionally to the degree of their divergence.        -   c. The score is calculated using the following equation:

Score=82+3*(pIC ₅₀−3)*QC,

-   -   where pIC₅₀ is a negative log(10) of the IC₅₀ value expressed in        mole/L concentration units, and QC is calculated using Hill        coefficient as above. This equation results in the Score values        above 85 for compounds that demonstrate high potency and        predictable behavior in the assays.

Calcium Retention Capacity Assay to Assess the Propensity of the mtPTPto Open as a Function of Test Compound Concentration (SAR Assay AID No.743360)

List of Reagents:

Assay buffer: 250 mM sucrose, 10 mM MOPS-Tris, 0.01 mM EGTA-Tris, 1.0 mMphosphoric acid-Tris, pH 7.4.

-   -   Solution 1. 10 mM glutamate and 5 mM malate in Assay buffer.    -   Solution 2. 1% DMSO in Solution 2.    -   Solution 3. 0.5 mg/mL mitochondria and 1.0 μM Calcium Green-5N        in Assay Buffer.    -   Solution 4. 0.25 mM CaCl₂).

Protocol Summary:

1. Freshly isolate mitochondria, prepare solutions according to therecipes in the Reagent Section.

2. Dispense 100 μL of Solution 2 to Columns 1-2 (negative control) ofthe 96-well black assay plate (Falcon 353376).

3. Dispense 200 μL of Solution 1 to Row A Columns 3-12.

4. Next, dispense 100 μL of Solution 2 to Rows B-H Columns 3-12.

5. Add 4 μL of 5 mM test compounds in DMSO to Row A Columns 3-12,perform 1:2 serial dilutions Row A to H Columns 3-12.

6. Finally, dispense 100 μL of Solution 3 in all wells.

7. Experiment starts. Read Calcium Green-5N fluorescence (excitation 485nm, emission 538 nm) and perform a train of 4 μL Solution 4 additionswith Fluoroskan Ascent FL, Thermo Scientific.

Comments:

Compounds that demonstrated a CRC/CRC₀ of above 1.1 at 12.5 μM aredefined as active in this assay.

Calcium Retention Capacity of Permeabilized Cells

Cell Growth and Permeabilization:

HeLa and MEF cells were cultured in Dulbecco's Modified Eagle Medium(Gibco) in the presence of 10% Fetal Bovine Serum and 1%penicillin-streptomycin for 48 hours to reach a 70-80% confluency. Onthe day of the experiment cells were harvest, suspended in 130 mM KCl,10 MOPS-Tris, 1 mM phosphoric acid-Tris, 1 mM EGTA-Tris, pH 7.4 to 20million/mL, and treated with 100 μM digitonin (Calbiochem) for 10 min onice to permeabilize the plasma membrane. Cells were then washed twiceand resuspended in the above buffer except that 100 μM EGTA-Tris wasused.

List of Reagents:

Assay Buffer: 130 mM KCl, 10 MOPS-Tris, 1 mM phosphoric acid-Tris, 10 μMEGTA-Tris, pH 7.4

-   -   Solution 1. 10 mM glutamate and 5 mM malate in Assay Buffer.    -   Solution 2. 1% DMSO in Solution 2.    -   Solution 3. 8 million/mL cells and 1.0 μM Calcium Green-5N in        Assay Buffer.    -   Solution 4. 0.5 mM CaCl₂).

Protocol Summary:

1. Harvest and permeabilize the cells according to the instructionsabove.

2. Dispense 100 μL of Solution 2 to Columns 1-2 (negative control) ofthe 96-well black assay plate (Falcon 353376).

3. Dispense 200 μL of Solution 1 to Row A Columns 3-12.

4. Next, dispense 100 μL of Solution 2 to Rows B-H Columns 3-12.

5. Add 4 μL of 5 mM test compounds in DMSO to Row A Columns 3-12,perform 1:2 serial dilutions Row A to H Columns 3-12.

6. Finally, dispense 100 μL of Solution 3 in all wells.

7. Experiment starts. Read Calcium Green-5N fluorescence (excitation 485nm, emission 538 nm) and perform a train of 4 μL Solution 4 additionswith Fluoroskan Ascent FL, Thermo Scientific.

HeLa Cell Viability Assay

HeLa cells were plated in a 96-well plate at 1800 cells/well and treatedwith a compound for 72 hours over a 9 point 2-fold dilution series,ranging from 0.78 μM to 200 M. Following 72 hours of treatment, relativeviable cell number was determined using CellTiter 96© AQueous OneSolution Cell Proliferation Assay from Promega. Each compound treatmentwas performed in 8- while DMSO treatment in 16-replicates, the latterones serving as positive controls.

Experimental Procedures for Physiochemcial and In Vitro PharmacokineticProperty Assays

Aqueous Solubility: Solubility analysis was performed using a direct UVkinetic solubility method in a 96-well format. All liquid dispense andtransfer steps were performed with the Freedom Evo automated liquidhandler (Tecan US). Solubility measurements were performed in an aqueousbuffer solution (System Solution, pION Inc, P/N 110151) at pH 5.0, 6.2and 7.4, in duplicate. Samples were incubated at room temperature for aminimum of 18 hrs to achieve equilibrium, then filtered (filter plate,pION Inc, P/N 110322) to remove any precipitate formed. Theconcentration of the compounds was measured by UV absorbance (250-498nm) using the Infinite M200 (Tecan US) and compared to the spectra ofthe precipitation-free reference solutions. Spectroscopically pure1-Propanol (Sigma P/N 256404) was used as a cosolvent to suppressprecipitation in the reference solutions. The solubility of eachcompound was determined using μSOL Evolution Plus software v3.2 (pIONInc) and is expressed as the concentration (μg/mL) of a solute in asaturated solution.

Assay Details:

-   -   Diclofenac Na and Dipyridamole were used as standards.        Diclofenac Na is highly soluble. Dipyridamole is poorly to        moderately soluble.    -   Standards and test compound stocks were made in 100% DMSO    -   Assay concentration of standards: 500 μM and test compound: 300        μM    -   Cosolvent used in the reference solution to suppress        precipitation: 1-Propanol    -   Assay DMSO final concentration: 1%

Aqueous and Thiol Stability: Compound was dissolved at 10 μM in 1:1ACN:PBS and incubated at room temperature with either no thiol source asa negative control, 50 μM glutathione (GSH), or 50 μM dithiothreitol(DTT). The mixtures were sampled every hour for eight hours or every 8hours for 88 hours and analyzed by RP HPLC/UV/HRMS. The analytical RPHPLCUV/HRMS system utilized for the analysis was a Waters Acquity systemwith UV-detection and mass-detection (Waters SQD). The analytical methodconditions included a Waters Acquity HSS Atlantis C18 column (2.1×50 mm,1.8 um) and elution with a linear gradient of 99% water to 100% CH₃CN at0.6 mL/min flow rate. Peaks on the 214 nm chromatographs were integratedusing the Waters OpenLynx software. Absolute areas under the curve werecompared at each time point to determine relative percent compoundremaining. The masses of potential adducts were searched for in thefinal samples to determine if any detectable adduct formed. All sampleswere prepared in duplicate and the average plotted. Ethacrynic acid, aknown Michael acceptor, was used as a positive control.

Plasma Stability: Stability of the compound in human plasma (BioChemedServices, P/N 752PR-EK3-PMG) was determined. All liquid dispense andtransfer steps were performed with the Freedom Evo automated liquidhandler (Tecan US). Plasma was allowed to thaw at room temperature priorto preparing the assay solution of plasma:1×PBS (1:1). The assaysolution was warmed up at 37° C. prior of adding the compound.Immediately after compounds were added, time 0 min aliquots werepromptly collected and mixed with cold acetonitrile (spiked with aninternal standard). The remainder of the reaction volume was incubatedat 37° C. with shaking. Additional aliquots were collected 180 min afterthe start of the reaction and promptly quenched with cold acetonitrile(spiked with an internal standard). Samples were centrifuged at 3000 rpmfor 10 min. The amount of compound in the supernatant was determined byLC/MS/MS (Applied Biosystems, Sciex API4000 Q-Trap) and the percent ofparent compound remaining after 180 min was calculated by the followingformula:

${\%\mspace{14mu}{parent}\mspace{14mu}{compound}\mspace{14mu}{remaining}} = \left\lbrack {\frac{{Concentration}\mspace{14mu}{at}\mspace{14mu} 180\mspace{14mu}\min}{{Concentration}\mspace{14mu}{at}\mspace{14mu} 0\mspace{14mu}\min} \times 100} \right\rbrack$

Results reported are the mean of each reaction duplicate, normalized tothe internal standard, and expressed as a percent of compound remainingafter the incubation time.

Assay details:

-   -   Human Plasma in K3 EDTA    -   Procaine and Procainamide were used as standards. Procaine is        highly unstable in human plasma, Procainamide is highly stable        in human plasma.    -   Assay concentrations of standards and test compound: 1 μM    -   Incubation Time: 3 hrs    -   Reaction pH: 7.4    -   Assay DMSO final concentration: 2.5%

Hepatic Microsome Stability: Metabolic stability was assessed in thepresence of human liver microsomes (XenoTech, P/N H0630) and mouse livermicrosomes (XenoTech, P/N M1000). All liquid dispense and transfer stepswere performed with the Freedom Evo automated liquid handler (Tecan US).NADPH, a required cofactor for CYP450 metabolism, was provided by theNADPH Regenerating System, Solutions A (BD Biosciences, P/N 451220) andB (BD Biosciences, P/N 451200). Compound stock solutions were initiallyprepared in 100% DMSO and subsequently diluted in acetonitrile for theassay. The pH of the reactions was kept at ˜7.4 with potassium phosphatebuffer (BD Biosciences, P/N 451201). The reactions were started afteradding NADPH to the reaction plate containing microsomes and compoundsand time 0 min aliquots were promptly collected and mixed with ice coldacetonitrile (spiked with internal standards) to quench the reactions.The remainder of the reaction volume was incubated at 37° C. withshaking. Additional aliquots were collected 60 min after the start ofthe reaction and promptly quenched with ice cold acetonitrile (spikedwith an internal standard). Samples were centrifuged at 3000 rpm for 10min. The amount of compound in the supernatant was determined byLC/MS/MS (Applied Biosystems, Sciex API4000 Q-Trap) and the percent ofparent compound remaining after 60 min was calculated by the followingformula:

${\%\mspace{14mu}{parent}\mspace{14mu}{compound}\mspace{14mu}{remaining}} = \left\lbrack {\frac{{Concentration}\mspace{14mu}{at}\mspace{14mu} 60\mspace{14mu}\min}{{Concentration}\mspace{14mu}{at}\mspace{14mu} 0\mspace{14mu}\min} \times 100} \right\rbrack$

All reactions were run in triplicate, except negative controls (noNADPH) which were performed as single reactions. Results reported arethe mean of each reaction triplicate, normalized to the internalstandard, and expressed as a percent compound remaining after theincubation time.

Assay details:

-   -   Human and Mouse Liver Microsomes: 0.5 mg/mL protein        concentration    -   NADPH Regenerating System: 1.55 mM NADP+, 1.33 mM        glucose-6-phosphate, 1.33 mM Magnesium chloride, and 0.4 U/mL        glucose-6 phosphate dehydrogenase    -   Incubation Temperature: 37° C.    -   Incubation Time: 60 min    -   Standards: Verapamil-HCl and Testosterone, at 20 μM and 50 μM,        respectively    -   Test compound at 1 μM    -   Assay DMSO final concentration: ≤0.5%    -   Assay ACN final concentration: ≤1.2%

Cellular Permeability: Permeability was assessed using the ParallelArtificial Membrane Permeability Assay, PAMPA in a 96-well format. Allliquid dispense and transfer steps were performed with the Freedom Evoautomated liquid handler (Tecan US). Measurements were performed in 20%ACN and aqueous buffer solution (System Solution, pION Inc, P/N 110151)at pH 5.0, 6.2, and 7.4, in duplicate. A “sandwich” plate (pION Inc, P/N110212) consisting of a donor bottom plate and an acceptor filter platewas used. The donor wells contained the compounds in 180 μl systemsolution, and magnetic stir bars. The filter on the bottom of eachacceptor well was coated with GIT-0 lipid (pION Inc, P/N 110669) andfilled with 200 μl of Acceptor Sink Buffer, pH 7.4 (pION Inc, P/N110139) containing a surfactant to mimic the function of serum proteins.The permeation time was 30 min and moderate stirring (equivalent to 40μm Aqueous Boundary Layer thickness) was applied using the Gut-Box™(pION, Inc, P/N 110205). After the permeation time, the sandwich wasdisassembled and the amount of compound present in both the donor andacceptor wells was measured by UV absorbance (250-498 nm) using theInfinite M200 (Tecan US) and compared to spectra obtained from referencestandards. Mass balance was used to determine the amount of materialembedded in the membrane filter. The effective permeability, Pe, wascalculated using the software PAMPA Evolution Plus, version 3.2 (pIONInc).

Assay Details:

-   -   Verapamil HCl, Metoprolol, and Ranitidine were used as reference        standards    -   Verapamil HCl is considered highly permeable    -   Metoprolol is considered moderately permeable    -   Ranitidine is considered poorly permeable    -   Permeation time: 30 min    -   Moderate stirring (equivalent to 40 μm ABL, aqueous boundary        layer, also known as the unstirred water layer)    -   Donor buffer pH: 5.0, 6.2 and 7.4    -   Double-Sink: pH gradients between donor and acceptor        compartments; acceptor buffer contains chemical sink    -   Assay DMSO final concentration: 0.5%

Membrane Permeability through the blood-brain barrier: Permeability wasassessed using an in vitro model for the passive transport through theblood-brain barrier, BBB-PAMPA. For this, the Parallel ArtificialMembrane Permeability Assay (PAMPA) in a 96-well format was used. Allliquid dispense and transfer steps were performed with the Freedom Evoautomated liquid handler (Tecan US). Measurements were performed in anaqueous buffer solution (System Solution, pION Inc, P/N 110151) at pH7.4, in quadruplicate. A “sandwich” plate (pION Inc, P/N 110212)consisting of a donor bottom plate and an acceptor filter plate wasused. The donor wells contain the compounds in 180 μl system solution,and magnetic stir bars. The filter on the bottom of each acceptor wellis coated with BBB-1 lipid solution (pION Inc, P/N 110672) and filledwith 200 μl of Brain Sink Buffer, pH 7.4 (pION Inc, P/N 110674) alsocontaining a surfactant. The permeation time is 60 min. Moderatestirring (equivalent to 40 μm Aqueous Boundary Layer thickness) isapplied using the Gut-Box™ (pION, Inc, P/N 110205). After the permeationtime, the sandwich is disassembled and the amount of compound present inboth the donor and acceptor wells is measured by UV absorbance (250-498nm) using the Infinite M200 (Tecan US) and compared to spectra obtainedfrom reference standards. Mass balance is used to determine the amountof material embedded in the membrane filter. The effective permeability,P_(e), is calculated using the software PAMPA Evolution Plus, version3.2 (pION Inc). The calculated effective permeability, P_(e), isexpressed as a kinetic parameter (centimeter per second). A largernumber indicates greater speed and thus greater permeability. Log P_(e)is often used to report permeability, and is inversely proportional toP_(e); thus the smaller Log P_(e) value indicates greater permeability.

Assay Details:

-   -   Verapamil-HCl, Corticosterone, and Theophylline are used as        reference standards: Verapamil-HCl is considered highly        permeable, Corticosterone is considered moderately permeable,        and Theophylline is considered poorly permeable.    -   Permeation time: 60 min    -   Moderate stirring (equivalent to 40 μm ABL, aqueous boundary        layer, also known as the unstirred water layer)    -   Donor buffer pH: 7.4; Acceptor buffer pH: 7.4    -   Assay DMSO assay concentration: 0.5%

Plasma Protein Binding: Teflon® Base Plate wells were rinsed with 20%ethanol for 10 minutes. Ethanol was then removed and wells were rinsedwith ultrapure water and allowed to dry. RED Inserts from ThermoScientific (Pierce) were placed (open end up) into the wells of the baseplate. All liquid dispense and transfer steps were performed with theFreedom Evo automated liquid handler (Tecan US). The sample chambers(red ring) contained 300 μl of a mixture of plasma and compound. And 500μl of dialysis buffer (1×PBS, pH7.4) were added to the buffer chambersof the inserts. Duplicate inserts were made for each concentrationtested. The base plate was covered with sealing tape and incubated at37° C. on an orbital shaker at 300 rpm for 4 hours. After the incubationtime, equal volume from both chambers were removed and transferred to a96 well plate containing either plasma or buffer. To precipitateproteins and release compounds, ice cold acetonitrile (with an internalstandard) was added. Samples were centrifuged for 10 minutes at 3000rpm. The amount of compound in the supernatant was determined byLC/MS/MS (Applied Biosystems, Sciex API4000 Q-Trap). The percent of freeand bound compounds were calculated with the following formulas:

${\%\mspace{14mu}{of}\mspace{14mu}{free}\mspace{14mu}{parent}\mspace{14mu}{compound}} = \frac{\left\lbrack {{amount}\mspace{14mu}{of}\mspace{14mu}{compound}\mspace{14mu}{in}\mspace{14mu}{receiver}\mspace{14mu}{chamber} \times 100} \right\rbrack}{{amount}\mspace{14mu}{of}\mspace{14mu}{compound}\mspace{14mu}{in}\mspace{14mu}{donor}\mspace{14mu}{chamber}}$  %  of  bound  parent  compound = 100 − %  of  free  compound

Results reported are the mean of each reaction duplicate, normalized tothe internal standard, and expressed as a percent compound bound afterthe incubation time.

Assay details:

-   -   Human Plasma in K3 EDTA    -   Propanolol and Metoprolol were used as standards. Propanolol is        highly bound, Metoprolol is poorly bound    -   Assay concentrations of standards and test compounds: 1 μM and        10 μM    -   Incubation Time: 4 hrs    -   Reaction pH: 7.4    -   Assay DMSO final concentration: 1%

Cytotoxicity: Immortalized human hepatocytes, Fa2N-4 cells (XenoTech)were seeded at ˜56,000 cells/well, and incubated with a range ofconcentrations (0.01-50 μM) of the test compound, in duplicate, for 24hrs at 37° C., 5% CO₂. Cell viability was determined by cellular ATPlevels using the Luminescence ATP Detection Assay System (ATPlite 1step, Perkin Elmer, #6016731) and the Infinite M200 plate reader(Tecan).

Assay Details:

-   -   Cells used: Fa2N-4, immortalized human hepatocytes    -   Media used for Fa2N-4 cells: MFE Plating and MFE Support (with        1% Penicillin, Streptomycin, and Amphotercin mixture)    -   Assay DMSO final concentration=0.5%    -   Treatment time: 24 hrs    -   Camptothecin and Terfenadine were used as standards.        Camptothecin is highly toxic and Terfenadine is highly non        toxic.

Biological Results

The following are tabulated biological results from the aforementionedassays, were values are given as the average over at least threeexperiments with the standard error of the mean (SEM), e.g.“average±SEM”:

TABLE 1 Isoxazole and Benzamide Calcium Retention Capacity;Mitochondrial Swelling; and Rhodamine 123 (Rh123) uptake CalciumRetention Capacity Mitochondrial Rh123 (CRC/CRC₀ at swelling uptakeStructure 12.5 μM) (EC50) (EC50)

 2.59 ± 0.22  4.710 ± 0.3490 μM >100 μM

 1.17 ± 0.11 (at 1.56 μM)  0.277 ± 0.001 μM >100 μM

 5.21 ± 0.50 (at 1.56 μM)  0.108 ± 0.01 μM >100 μM

13.44 ± 0.93 (9.59 ± 0.85 at 1.56 μM) 0.0000283 ± 0.0000048 μM >100 μM

 4.27 ± 0.40  0.366 ± 0.0475 >100 μM

 5.51 ± 0.99  0.100 ± 0.0096 >100 μM

13.47 ± 1.32 (10.10 ± 1.14 at 1.56 μM)  0.011 ± 0.0011 μM >100 μM

 9.34 ± 1.04  0.078 ± 0.0050 μM >100 μM

10.17 ± 0.69  0.013 ± 0.0020 μM >100 μM

19.28 ± 1.59 (15.21 ± 1.26 at 1.56 μM) 0.000134 ± 0.000016 μM >100 μM

10.07 ± 0.69  0.009 ± 0.0014 μM >100 μM

 9.37 ± 0.65  0.0554 ± 0.0041 μM >100 μM

 6.08 ± 0.52  0.819 ± 0.0589 μM >100 μM

10.69 ± 1.00 (9.12 ± 0.88 at 1.56 μM)  0.016 ± 0.0019 μM >100 μM

 3.48 ± 0.51  2.192 ± 0.1501 μM >100 μM

 7.14 ± 0.69  0.0756 ± 0.0092 >100 μM

12.14 ± 0.55 (at 1.56 μM) 0.000890 ± 0.000141 μM >100 μM

10.09 ± 0.91 (6.62 ± 0.89 at 1.56 μM)  0.024 ± 0.0022 μM >100 μM

11.05 ± 1.35  0.125 ± 0.0071 μM >100 μM

14.99 ± 1.20 (9.63 ± 0.29 at 1.56 μM)  0.0035 ± 0.0007 μM >100 μM

 1.37 ± 0.02  5.849 ± 0.3435 μM >100 μM

 1.23 ± 0.02  9.003 ± 0.4036 μM >100 μM

 1.51 ± 0.01  2.684 ± 0.1661 μM >100 μM

 1.37 ± 0.02  7.614 ± 0.8388 μM >100 μM

 1.33 ± 0.06  9.239 ± 0.8596 μM >100 μM

 1.20 ± 0.00  8.117 ± 0.3877 μM >100 μM

 1.24 ± 0.04  6.866 ± 0.4230 μM >100 μM

 1.80 ± 0.00  1.541 ± 0.1006 μM >100 μM

 1.65 ± 0.06  2.148 ± 0.10 μM >100 μM

 1.31 ± 0.03  7.252 ± 0.5262 μM >100 μM

 1.52 ± 0.06  3.273 ± 0.1498 μM >100 μM

 3.54 ± 0.28  0.885 ± 0.1157 μM 51.22 μM

 1.16 ± 0.02  15.986 ± 1.5816 μM >100 μM

 1.12 ± 0.02  38.723 ± 3.6723 μM >100 μM

 1.05 ± 0.03  37.473 ± 3.6327 μM >100 μM

 1.10 ± 0.02  29.207 ± 2.1016 μM >100 μM

 1.17 ± 0.04  25.555 ± 1.8028 μM >100 μM

 1.09 ± 0.05  21.387 ± 0.9832 μM >100 μM

 1.11 ± 0.03  21.663 ± 1.0810 μM >100 μM

 1.07 ± 0.03  29.058 ± 2.9172 μM >100 μM

 3.26 ± 0.32  0.189 ± 0.028 μM >100 μM

 5.47 ± 0.57  0.0788 ± 0.0058 μM >100 μM

 1.10 ± 0.05  18.023 ± 1.3275 μM >100 μM

 1.16 ± 0.05  9.999 ± 7.7771 μM 64.75 ± 4.19 μM

 1.01 ± 0.02  45.996 ± 1.3574 μM >100 μM

 4.00 ± 0.42  12.488 ± 0.6675 μM >100 μM

 4.67 ± 0.31  1.520 ± 0.0512 μM 38.47 ±3.98 μM

 1.83 ± 0.17  42.728 ± 2.5933 μM >100 μM

12.08 ± 1.92 (5.72 ± 0.25 at 1.56 μM)  0.190 ± 0.017 μM >100 μM

 1.90 ± 0.11 ND ND

14.02 ± 1.63 ND ND

 3.50 ± 0.57  2.210 ± 0.1738 μM >100 μM

13.99 ± 1.50 (7.69 ± 0.61 at 1.56 μM)  0.030 ± 0.0026 μM >100 μM

 1.59 ± 0.33  17.576 ± 2.2110 μM >100 μM

 8.16 ± 0.92  0.030 ± 0.0022 μM >100 μM

 2.94 ± 0.46  2.446 ± 0.1480 μM >100 μM

14.44 ± 0.58 (10.02 ± 0.34 at 1.56 μM) 0.00000756 ± 0.00000122 μM >100μM

 4.13 ± 0.17 (at 1.56 μM)  0.0788 ± 0.0058 μM >100 μM

 3.77 ± 0.17 (at 1.56 μM)  0.172 ± 0.014 μM >100 μM

 8.22 ± 0.58 (at 1.56 μM) 0.000180 ± 0.000042 μM >100 μM

 6.91 ± 0.47 (at 1.56 μM)  0.00134 ± 0.00026 μM >100 μM

 6.21 ± 0.66 (at 1.56 μM) 0.00216 ± 0.00045 μM >100 μM

10.92 ± 0.74 (at 1.56 μM)  0.0014 ± 0.0002 μM 30.4 ± 5.5 μM

 7.51 ± 0.47 (at 1.56 μM)  0.0024 ± 0.0004 μM >100 μM

 8.12 ± 0.59 (at 1.56 μM)  0.0121 ± 0.0014 μM >100 μM

 7.18 ± 0.87  0.035 ± 0.0042 μM >100 μM

11.22 ± 1.22  0.076 ± 0.0092 μM >100 μM

 3.52 ± 0.44  0.277 ± 0.0010 μM >100 μM

11.21 ± 1.38  0.071 ± 0.0011 μM >100 μM

12.15 ± 1.36 (6.50 ± 0.77 at 1.56 μM)  0.066 ± 0.0032 μM >100 μM

 9.89 ± 1.31 (6.62 ± 0.84 at 1.56 μM)  0.097 ± 0.0034 μM >100 μM

10.89 ± 1.34 (6.95 ± 1.15 at 1.56 μM)  0.060 ± 0.0076 μM >100 μM

 2.22 ± 0.38  1.612 ± 0.8658 μM >100 μM

 9.59 ± 1.29 (4.34 ± 0.53 at 1.56 μM)  0.146 ± 0.0115 μM >100 μM

 5.37 ± 0.58  0.217 ± 0.0518 μM >100 μM

 2.10 ± 0.26  6.057 ± 0.7477 μM >100 μM

 2.59 ± 0.22  4.710 ± 0.3490 μM >100 μM

 4.27 ± 0.40  0.366 ± 0.0475 μM >100 μM Cyclosporin A  5.13 ± 0.43 0.095 ± 0.0029 μM >100 μM

TABLE 2 Calcium Retention Capacity; Mitochondrial Swelling; & Rhodamine123 (Rh123) uptake for Additional Examples Calcium RetentionMitochondrial Rh123 Capacity CRC/ swelling Assay EC₅₀ Entry StructureCRC₀ at 12.5 μM EC₅₀ (μM) (μM) 1

10.8 ± 0.6  0.521 ± 0.046 58.6 ± 2.9 2

13.3 ± 1.0  0.372 ± 0.028 >100.00 3

2.26 ± 0.11 3.60 ± 0.17 75.7 ± 1.8 4

8.81 ± 0.39 0.403 ± 0.031 >100 5

14.1 ± 1.1  0.423 ± 0.028 49.6 ± 4.3 6

16.1 ± 1.5  0.286 ± 0.027 42.6 ± 3.1 7

18.3 ± 1.3  0.206 ± 0.021 46.4 ± 3.2 8

6.50 ± 1.20 1.19 ± 0.33 23.2 ± 1.3 9

2.37 ± 0.41 4.00 ± 0.66 >100 10

5.91 ± 0.38 1.24 ± 0.39 24.7 ± 1.5 11

2.59 ± 0.54 1.39 ± 0.17 >100 12

10.1 ± 0.8  0.49 ± 0.08 28.6 ± 1.1 13

7.67 ± 0.35 0.073 ± 0.007 >100 Note: Data are an average of >3experiments ± SEM

Effects of Compounds of the Present Technology on Defects Present inExon 9 col6a1 morphant zebrafish.

Zebrafish and embryo maintenance. Adult zebrafish were maintained in thefacility of the University of Padova containing aerated, 28.5°C.-conditioned saline water according to standard protocols. Fish werekept under a 14 h light-10 h dark cycle. For mating, males and femaleswere separated in the late afternoon, and were freed to start courtshipthe next morning, which ended with egg deposition and fecundation. Eggswere collected, washed with fish water (0.5 mM NaH₂PO₄, 0.5 mM NaIPO₄,0.2 mg/L methylene blue, 3 mg/L instant ocean) and embryos weremaintained at 28.5° C. All protocols and manipulations with zebrafishwere performed as described in C. B. Kimmel, W. W. Ballard, S. R.Kimmel, B. Ullmann, T. F. Schilling, Dev. Dyn. 1995, 203, 253-310.

Morpholino injections. To reproduce the dominant negative UCMD or BMphenotype in zebrafish, we used an exon9 morpholino which targets exon 9of the zebrafish col6a1 gene, as described in W. R. Telfer, A. S. Busta,C. G. Bonnemann, E. L. Feldman, J. J. Dowling, Hum. Mol. Genet. 2010,19, 2433-2444 and A. Zulian, E. Rizzo, M. Schiavone, E. Palma, F.Tagliavini, B. Blaauw, L. Merlini, N. M. Maraldi, P. Sabatelli, P.Braghetta, P. Bonaldo, F. Argenton, P. Bernardi, Hum. Mol. Genet. 2014,23, 5353-5363. Exon 9, col6a1: GAG AGC GGA AGA CGA ACC TTC ATTC(GeneTools, Inc.). A control morpholino, with no sequence homology inzebrafish genome was used. Embryos isolated after paired matings ofwild-type zebrafish were injected at 1-2 cell stage using a WPIpneumatic PicoPump PV820 injector. Morpholino was injected at aconcentration of 0.1 mM, corresponding to ˜4 ng per embryo.

Compound treatment. Morphant embryos were dechorionated at 20 hpf andthen treated with compound 60 (referred to as KSC-392-116 above) at 21hpf, where compound 60 is illustrated below.

Untreated morphants and wild-type embryos were used as controls.Compound 60 was used at 5 and 10 μM and dissolved in fish water with 1%DMSO. Vehicle control treatment consisted of fish water with 1% DMSO.Analyses of compound effects on embryos were performed as described at24 and 48 hpf.

Motor activity. Spontaneous coiling rates were recorded by observing thenumber of coiling events in 15 s for single embryos at 24 hpf usinglight microscopy. Touch-evoked escape response was measured at 48 hpf byobserving the ability of larvae to escape after touching the body with alittle tip. Embryos were subdivided into four groups according to theirability to escape: paralyzed with no ability to move, showing coilingevents only, embryos with minor motor impairments, or normal embryosswimming in the fish water; these were assigned a score of 0, 1, 2, or3, respectively. Statistical analysis was performed on mean scores ateach experimental condition.

Birefringence assay. Muscle birefringence was measured at 48 hpf ontricaine-anesthetized embryos by taking advantage of muscle fiberanisotropy. It was measured using two polarizing filters on a LeicaM165FC stereomicroscope. Briefly, anesthetized embryos were placed on aglass slide, and muscle light refraction was analyzed by using twopolarizing filters. The first filter produces the polarized light toilluminate the sample, and the second polarizing filter, called theanalyzer, calculates the angle of light refracted from muscle fibers. Inparticular, the top polarizing filter was twisted at a 90° angle untilthe light refracting through the muscle was visible through astereomicroscope. Integrated area of birefringence was calculated byusing ImageJ software, as disclosed in J. Berger, T. Sztal, P. D.Currie, Biochem. Biophys. Res. Commun. 2012, 423, 785-788. Birefringencevalues ≥2×10⁶ (typical of wild-type individuals) were rated as normal,values between 1.9×10⁶ and 0.6×10⁶ were considered as an indication ofmild disease, and values ≤0.6×10⁶ were rated as an indication of severemyopathy. Statistical analysis was performed on the mean birefringencevalues at each experimental condition.

Statistical analysis. Differences between control and compound treatedsamples were determined by one-way ANOVA test with Bonferroni correctionusing GraphPad Prism (version 5.1 for Windows). Data represent the meanof at least five independent experiments (n=52 for each condition). SEM;**p<0.01, ***p<0.001 for FIG. 1 . For FIG. 2 , comparison between groupsat different conditions was made using X² test and one-way ANOVA withBonferroni correction; **p<0.01, ***p<0.001. For FIG. 3 , the totalnumber of embryos used is n=35 for each condition; *p<0.05, ***p<0.001,as determined by χ² test and oneway ANOVA with Bonferroni correction.

As reflected in FIGS. 1 & 2 , 87% of embryos injected with exon 9morpholino showed severe motor impairments relative to control embryos.In contrast, exon9 morphants treated with compound 60, simply added tothe fish water, showed a dramatic improvement in motor function asdemonstrated with spontaneous coiling events (FIG. 1 ) or touch-evokedresponse (FIG. 2 ).

To assess structural muscle organization, muscle birefringence wasevaluated at 48 hpf. This technique evaluates muscle structural defectsin zebrafish models of muscular dystrophy. Muscle birefringence wasanalyzed by taking advantage of muscle fiber anisotropy. As can be seenin FIG. 3 , exon9 morphants exhibited severe muscle defects relative tocontrols, and these defects were largely ameliorated following treatmentwith compound 60. Indeed, total birefringence scores demonstrated thattreatment with compound 60 generated significant recovery of muscledefects (ANOVA, p<0.05).

Mouse Model Assays of mtPTP-Dependent Muscular Dystrophy Illustrative ofTherapeutic Effects of Compounds of the Present Technology.

A severe genetic human muscle disorder linked to collagen VI deficiency,resulting in persistent mtPTP opening, can be effectively mimicked inmice through genetic elimination of orthologous collagen VI genes.Importantly, in both humans and mice, defects could be reversed bytreatment with Cyclosporin A (CsA) and with CsA derivatives that inhibitCyclophilin D (CyPD), and hence the mtPTP. Here, followingpharmacokinetic studies in mice, mouse models of these dystrophies willbe used illustrate the therapeutic effects of compounds of the presenttechnology.

Background: Anchoring and adhesion complexes at the surface of cellslink the cytoskeleton to the surrounding extracellular matrix, thusmaintaining cell integrity and cell signal transduction. These anchoringstructures have a critical role in tissues undergoing extensivemechanical stress, like the skeletal muscle. Thus, it comes as nosurprise that genetic defects in these anchoring complexes cause certainhuman muscular dystrophies. As one example, collagen VI (ColVI) is anessential component of the myofiber extracellular matrix, and mutationsin ColVI result in two main human diseases, Ullrich congenital musculardystrophy (UCMD) and Bethlem myopathy (BM)^(1,2). UCMD is a severemuscular dystrophy and segregates as a recessive disorder^(1,3). BM is amilder myopathy and, in contrast, is usually linked to a dominantmutation that generates pathology through dominant-negativemechanisms^(4,5). Mice generated by knock-out of the murine Col6a1 gene⁶are known models of UCMD⁷. Homozygous recessive animals displayphenotypes that closely mimic defects observed in UCMD patients^(7,8).For example, in both humans and mice, muscle fibers have swollen/dilatedmitochondria that lose their normal proton gradient following stimuli,something that does not affect mitochondria in normal fibers. Thesemitochondrial dysfunctions are indicative of defects originating frominappropriate mtPTP activation^(7,9). Consistent with this, inhibitionof the mtPTP, either pharmacologically in humans and mice (CsA andnon-immunosuppressive derivatives like Debio025 or NIM811)¹⁰⁻¹³, orelimination of the mouse gene encoding CyPD¹⁴, has been shown to improvemitochondrial changes and reduce myofiber cell death.

Test in mouse models of a mtPTP-dependent muscular dystrophy: Compoundsof the present technology will be tested by IP injection of vehicle inaddition to a variety of concentrations (e.g., 5 mg/kg, 1 mg/kg, etc.)of compounds of the present technology. In general, the techniques andanalysis to be used will follow those outlined in earlier studies thatshowed that IP injections of CsA, and non-immunosuppressive derivativesof CsA (e.g., NIM811 and Debio025) are able to effectively counter themuscular defects present in these mutant animals^(10,11). In each case,mice will receive two daily doses of inhibitor or vehicle for up to 5days. In each assay, differences between control WT, ColVI-null andColVI-null mice treated with each derivative will be recorded. In allcases, data will be generated from at least 4 animals, expressed asmean±s.e.m, and analyzed with the unpaired Students t-test.

Rescue of muscle contractile strength by compounds of the presenttechnology: Assessed will be tetanic (maximal), twitch tension, andrelaxation time in muscle strips [specifically, the diaphragm and flexordigitorum brevis (FDB)] of the mice outlined above (N≥15). Typically,loss of ColVI results in dramatic loss of contractile strength (measuredas mN/mm²) compared to WT controls. Accordingly, it is expected thattreatment with compounds of the present technology will restorecontractile strength significantly when compared to ColVI-null mice, orrestore muscle strength completely. Briefly, strips (width 1-2 mm) willbe prepared, and mounted between a force transducer and amicromanipulator-controlled shaft in oxygenated Krebs solution at 25° C.The length of the strips will then be increased until force developmentduring tetanus is maximal. The responses to a single stimulus (twitch)or to trains of stimuli at a variety of rates producing unfused or fusedtetani will then be recorded. Cross-sectional area will be calculatedfrom the weight.

Effects of compounds of the present technology on mitochondrialdysfunction in ColVI-null muscle fibers: Initial assessment of mtPTPfunction in treated ColVI-null animals will be by the CRC assay used toidentify and characterize compounds of the present technology. Fivehours after the last injection, mitochondria will be prepared from liverand muscle homogenates and the CRC of mitochondrial preparationsassessed fluorometrically by application of trains of Ca²⁺ pulses in thepresence of Calcium Green 5N. The threshold for mtPTP activation will bedetermined based on the number of pulses required for mtPTP opening andcompared statistically by assessment of the CRC/CRCmax. It is expectedthat, as with animals treated with Debio025, the threshold for mtPTPopening in ColVI-null liver and muscle mitochondria treated withcompounds of the present technology will be increased relative tocontrol, vehicle-injected, ColVI-null animals¹¹. In order to assess theefficacy of compounds of the present technology in the treatment ofColVI-null animals, the mitochondrial transmembrane potential (ΔΨm) willbe determined in situ based on the mitochondrial fluorescence oftetramethylrhodamine methyl ester (TMRM), a probe that accumulates inpolarized mitochondria and is released when the transmembrane potentialdecreases. Addition of oligomycin, an inhibitor of F-ATP synthase, toFDB fibers from ColVI-null animals results in a dramatic decrease ofTMRM mitochondrial fluorescence while, in contrast, fibers prepared fromWT animals should show no immediate change in TMRM fluorescence. It hasbeen shown that the mitochondrial dysfunction unmasked by oligomycin inColVI-null muscle fibers has its basis in inappropriate activation ofthe mtPTP⁷. This anomalous depolarizing response in ColVI-null fibershas been shown to be due to F-ATP synthase operating in reverse and, asexpected for a mtPTP-based phenotype, be corrected by treatment with CsAor CsA derivatives^(7, 8, 10, 11). Consequently, rescue by compounds ofthe present technology of this muscle mitochondrial defect in ColVI-nullfibers will be assessed. Briefly, FDB myofibers will be plated on glasscoverslips, cultured as described in the art, mitochondria loaded byincubation with 20 nM TMRM and the response of control WT and ColVI-nullfibers to application of oligomycin (6 μM) in the presence of vehicle orinhibitor recorded. The percentage of fibers (from at least 6 mice)depolarizing on the addition of oligomycin will be pooled andstatistical significance determined. It is expected that treatment withcompounds of the present technology will normalize the depolarization onapplication of oligomycin in the vast majority of ColVI-null fibers.

Effects of compounds of the present technology on mitochondrialultrastructural defects and muscle cell apoptosis—Electron microscopicanalysis has demonstrated that mitochondria in myofibers from ColVI-nullanimals display significant swelling, a typical feature of mtPTPopening, when compared to mitochondria in WT myofibers as well as anincrease in the level of apoptosis (as assessed by the number ofapoptotic nuclei). The effects of treatments with compounds of thepresent technology will be observed on both these mtPTP responses asdescribed in the art 7's, 1°, ii. FDB fibers from control WT, ColVI-nulland treated ColVI-null mice will be fixed with glutaraldehyde andembedded in Epon E812 resin. Ultrathin sections will be prepared,stained with uranyl acetate and lead citrate, and observed by electronmicroscopy. It is expected that the percentage of fibers with alteredmitochondrial structure (swollen mitochondria with disorganized cristae;average from at least three mice and 300 individual sections) will besignificantly attenuated in ColVI-null animals treated with compounds ofthe present technology. Similarly, the number of apoptotic nuclei willbe determined by TUNEL assay in 7 uM thick sections prepared from thediaphragm of vehicle-treated WT, ColVI-null and ColVI-null mice treatedwith compounds of the present technology. The total number ofTUNEL-positive nuclei will be determined by commercially available kits(e.g., ApoTag) in randomly selected fibers and the number of totalnuclei will be determined following staining with Hoechst staining bylight-level microscopy.

REFERENCES

-   1. Pepe, G.; Bertini, E.; Bonaldo, P.; Bushby, K.; Giusti, B.; de    Visser, M.; Guicheney, P.; Lattanzi, G.; Merlini, L.; Muntoni, F.;    Nishino, I.; Nonaka, I.; Yaou, R. B.; Sabatelli, P.; Sewry, C.;    Topaloglu, H.; van der Kooi, A., Bethlem myopathy (BETHLEM) and    Ullrich scleroatonic muscular dystrophy: 100th ENMC international    workshop, 23-24 Nov. 2001, Naarden, The Netherlands. Neuromuscul    Disord 2002, 12, (10), 984-93.-   2. Lampe, A. K.; Bushby, K. M., Collagen VI related muscle    disorders. J Med Genet 2005, 42, (9), 673-85.-   3. Camacho Vanegas, O.; Bertini, E.; Zhang, R. Z.; Petrini, S.;    Minosse, C.; Sabatelli, P.; Giusti, B.; Chu, M. L.; Pepe, G.,    Ullrich scleroatonic muscular dystrophy is caused by recessive    mutations in collagen type VI. Proc Natl Acad Sci USA 2001, 98,    (13), 7516-21.-   4. Jobsis, G. J.; Boers, J. M.; Barth, P. G.; de Visser, M., Bethlem    myopathy: a slowly progressive congenital muscular dystrophy with    contractures. Brain 1999, 122 (Pt 4), 649-55.-   5. Pepe, G.; Lucarini, L.; Zhang, R. Z.; Pan, T. C.; Giusti, B.;    Quijano-Roy, S.; Gartioux, C.; Bushby, K. M.; Guicheney, P.; Chu, M.    L., COL6A1 genomic deletions in Bethlem myopathy and Ullrich    muscular dystrophy. Ann Neurol 2006, 59, (1), 190-5.-   6. Bonaldo, P.; Braghetta, P.; Zanetti, M.; Piccolo, S.; Volpin, D.;    Bressan, G. M., Collagen VI deficiency induces early onset myopathy    in the mouse: an animal model for Bethlem myopathy. Hum Mol Genet    1998, 7, (13), 2135-40.-   7. Irwin, W. A.; Bergamin, N.; Sabatelli, P.; Reggiani, C.;    Megighian, A.; Merlini, L.; Braghetta, P.; Columbaro, M.; Volpin,    D.; Bressan, G. M.; Bernardi, P.; Bonaldo, P., Mitochondrial    dysfunction and apoptosis in myopathic mice with collagen VI    deficiency. Nat Genet 2003, 35, (4), 367-71.-   8. Maraldi, N. M.; Sabatelli, P.; Columbaro, M.; Zamparelli, A.;    Manzoli, F. A.; Bernardi, P.; Bonaldo, P.; Merlini, L., Collagen VI    myopathies: from the animal model to the clinical trial. Adv Enzyme    Regul 2009, 49, (1), 197-211.-   9. Angelin, A.; Tiepolo, T.; Sabatelli, P.; Grumati, P.; Bergamin,    N.; Golfieri, C.; Mattioli, E.; Gualandi, F.; Ferlini, A.; Merlini,    L.; Maraldi, N. M.; Bonaldo, P.; Bernardi, P., Mitochondrial    dysfunction in the pathogenesis of Ullrich congenital muscular    dystrophy and prospective therapy with cyclosporins. Proc Natl Acad    Sci USA 2007, 104, (3), 991-6.-   10. Zulian, A.; Rizzo, E.; Schiavone, M.; Palma, E.; Tagliavini, F.;    Blaauw, B.; Merlini, L.; Maraldi, N. M.; Sabatelli, P.; Braghetta,    P.; Bonaldo, P.; Argenton, F.; Bernardi, P., NIM811, a cyclophilin    inhibitor without immunosuppressive activity, is beneficial in    collagen VI congenital muscular dystrophy models. Hum Mol Genet    2014, 23, (20), 5353-63.-   11. Tiepolo, T.; Angelin, A.; Palma, E.; Sabatelli, P.; Merlini, L.;    Nicolosi, L.; Finetti, F.; Braghetta, P.; Vuagniaux, G.; Dumont, J.    M.; Baldari, C. T.; Bonaldo, P.; Bernardi, P., The cyclophilin    inhibitor Debio 025 normalizes mitochondrial function, muscle    apoptosis and ultrastructural defects in Col6a1−/− myopathic mice.    Br J Pharmacol 2009, 157, (6), 1045-52.-   12. Merlini, L.; Sabatelli, P.; Armaroli, A.; Gnudi, S.; Angelin,    A.; Grumati, P.; Michelini, M. E.; Franchella, A.; Gualandi, F.;    Bertini, E.; Maraldi, N. M.; Ferlini, A.; Bonaldo, P.; Bernardi, P.,    Cyclosporine A in Ullrich congenital muscular dystrophy: long-term    results. Oxid Med Cell Longev 2011, 2011, 139194.-   13. Merlini, L.; Angelin, A.; Tiepolo, T.; Braghetta, P.; Sabatelli,    P.; Zamparelli, A.; Ferlini, A.; Maraldi, N. M.; Bonaldo, P.;    Bernardi, P., Cyclosporin A corrects mitochondrial dysfunction and    muscle apoptosis in patients with collagen VI myopathies. Proc Natl    Acad Sci USA 2008, 105, (13), 5225-9.-   14. Palma, E.; Tiepolo, T.; Angelin, A.; Sabatelli, P.; Maraldi, N.    M.; Basso, E.; Forte, M. A.; Bernardi, P.; Bonaldo, P., Genetic    ablation of cyclophilin D rescues mitochondrial defects and prevents    muscle apoptosis in collagen VI myopathic mice. Hum Mol Genet 2009,    18, (11), 2024-31.-   15. Shah, V. P.; Midha, K. K.; Dighe, S.; McGilveray, I. J.;    Skelly, J. P.; Yacobi, A.; Layloff, T.; Viswanathan, C. T.; Cook, C.    E.; McDowall, R. D.; et al., Analytical methods validation:    bioavailability, bioequivalence and pharmacokinetic studies.    Conference report. Eur J Drug Metab Pharmacokinet 1991, 16, (4),    249-55.-   16. Xu, X.; Zhou, Q.; Korfmacher, W. A., Development of a low volume    plasma sample precipitation procedure for liquid    chromatography/tandem mass spectrometry assays used for drug    discovery applications. Rapid Commun Mass Spectrom 2005, 19, (15),    2131-6.-   17. International Patent Pub. “Acrylamino derivative useful as    inhibitors of the mitochondrial permeability transition.” WO    2010/049768 A1.-   18. Di Lisa, F.; Carpi, A.; Giorgio, V.; Bernardi, P., The    mitochondrial permeability transition pore and cyclophilin D in    cardioprotection. Biochim Biophys Acta 2011, 1813, (7), 1316-22.-   19. Di Lisa, F.; Menabo, R.; Canton, M.; Barile, M.; Bernardi, P.,    Opening of the mitochondrial permeability transition pore causes    depletion of mitochondrial and cytosolic NAD+ and is a causative    event in the death of myocytes in postischemic reperfusion of the    heart. J Biol Chem 2001, 276, (4), 2571-5.-   20. Di Lisa, F.; Bernardi, P., Mitochondria and ischemia-reperfusion    injury of the heart: fixing a hole. Cardiovasc Res 2006, 70, (2),    191-9.-   21. Su, K. G.; Savino, C.; Marracci, G.; Chaudhary, P.; Yu, X.;    Morris, B.; Galipeau, D.; Giorgio, M.; Forte, M.; Bourdette, D.,    Genetic inactivation of the p66 isoform of ShcA is neuroprotective    in a murine model of multiple sclerosis. Eur J Neurosci 2012, 35,    (4), 562-71.-   22. Forte, M.; Gold, B. G.; Marracci, G.; Chaudhary, P.; Basso, E.;    Johnsen, D.; Yu, X.; Fowlkes, J.; Rahder, M.; Stem, K.; Bernardi,    P.; Bourdette, D., Cyclophilin D inactivation protects axons in    experimental autoimmune encephalomyelitis, an animal model of    multiple sclerosis. Proc Natl Acad Sci USA 2007, 104, (18), 7558-63.-   23. Wang, X.; Carlsson, Y.; Basso, E.; Zhu, C.; Rousset, C. I.;    Rasola, A.; Johansson, B. R.; Blomgren, K.; Mallard, C.; Bernardi,    P.; Forte, M. A.; Hagberg, H., Developmental shift of cyclophilin D    contribution to hypoxic-ischemic brain injury. J Neurosci 2009, 29,    (8), 2588-96.

Effect of Compounds of the Present Technology on Myocardial Function andResponse to Reperfusion Injury.

In this example, the ability of compounds of the present technology toprevent ischemia/reperfusion (IR) injury will be assessed.

Modified Langendorff Model

The Langendorff rodent heart model is widely employed in studies ofmyocardial function and responses to injury (e.g. ischaemia). Forwhole-heart studies, male Sprague-Dawley rats (7-9 weeks old) will beinjected with pentobarbital (35 m/kg, ip injection) and hearts excisedwith midline thoracotomy. The aortas will be secured around a cannula ofa modified Langendorff apparatus and retrogradely perfused (perfusionpressure of 75 mm Hg) with a modified Krebs-Henseleit buffer containing(in mM): 118 NaCl, 24 NaHCO₃, 4.75 KCl, 1.2 KH₂PO₄, 1.2 MgSO₄, 2.0CaCl₂), and 10 glucose (gassed with 95/5% O₂/CO₂). Hearts will be bathedin a buffer-filled perfusion chamber maintained at 37° C. for theduration of the experiments. Following the initiation of perfusion,hearts will be instrumented for the simultaneous observation ofmechanical and electrical function. A buffer-filled latex balloon (size5, Harvard Apparatus, Holliston, Mass., USA), calibrated at thebeginning of each day using a digital manometer, will be inserted intothe left ventricle (via the mitral valve) for the measurement of leftventricular developed pressure (LVDP), with balloon volume adjusted toestablish a diastolic pressure of 5-8 mm Hg. Three electrodes will beplaced into the buffer filled perfusion chamber for the measurement ofthe volume-conducted electrocardiogram (ECG). Coronary flow rates willbe monitored constantly with a flow probe (Transconic Systems, Ithaca,N.Y., USA) connected in series with the perfusion line, and normalizedto heart wet weight (in grams) at the end of each experiment. Allphysiological parameters will be continuously monitored and stored on apersonal computer using commercially available software (e.g., Chart, ADInstruments, Colorado Springs, Colo., USA). Heart rate will becalculated using the LVDP trace, and maximal rates of contraction andrelaxation (±dP/dt) will be calculated using the derivative of the LVDPtrace.

Ischemia Reperfusion Protocol and Compound Treatments

Following a 10 minute baseline period, ischemia/reperfusion will beinitiated. Hearts will be exposed to global no-flow ischemia by stoppingperfusion for 20 min. At the end of the index ischemia, static bufferfrom the perfusion lines will be washed out (via an accessory portproximal to the aortic cannula), and reperfusion will be ensued for 2 heither with Krebs buffer alone (control) or Krebs buffer containing apredetermined concentration of the compound of the present technology.At the end of reperfusion, the left ventricle will be dissected, slicedinto 5 mm-thick slices, incubated in 1% triphenyltetrazolium chloride(TTC) for 10 min (37° C.) and digitally photographed for subsequentinfarct size analysis. Infarct size will be expressed as a percentage ofthe left ventricle (% area at risk (AAR))(calculated using ImageJsoftware, NIH, Bethesda, Md., USA).

The results are expected to show that treatment with a compound of thepresent technology significantly decrease infarct size and LVDP, and/orincreases the maximal rates of contraction and relaxation (±dP/dt).Thus, the results are expected to show that compounds of the presenttechnology are useful to prevent or treat ischemia/reperfusion injury ofthe heart in a subject in need thereof.

While some embodiments have been illustrated and described, a personwith ordinary skill in the art, after reading the foregoingspecification, can effect changes, substitutions of equivalents andother types of alterations to the compounds of the present technology orsalts, pharmaceutical compositions, derivatives, prodrugs, metabolites,tautomers or racemic mixtures thereof as set forth herein. Each aspectand embodiment described above can also have included or incorporatedtherewith such variations or aspects as disclosed in regard to any orall of the other aspects and embodiments.

The present technology is also not to be limited in terms of theparticular aspects described herein, which are intended as singleillustrations of individual aspects of the present technology. Manymodifications and variations of this present technology can be madewithout departing from its spirit and scope, as will be apparent tothose skilled in the art. Functionally equivalent methods within thescope of the present technology, in addition to those enumerated herein,will be apparent to those skilled in the art from the foregoingdescriptions. Such modifications and variations are intended to fallwithin the scope of the appended claims. It is to be understood thatthis present technology is not limited to particular methods, reagents,compounds, compositions, labeled compounds or biological systems, whichcan, of course, vary. It is also to be understood that the terminologyused herein is for the purpose of describing particular aspects only,and is not intended to be limiting. Thus, it is intended that thespecification be considered as exemplary only with the breadth, scopeand spirit of the present technology indicated only by the appendedclaims, definitions therein and any equivalents thereof.

The embodiments, illustratively described herein may suitably bepracticed in the absence of any element or elements, limitation orlimitations, not specifically disclosed herein. Thus, for example, theterms “comprising,” “including,” “containing,” etc. shall be readexpansively and without limitation. Additionally, the terms andexpressions employed herein have been used as terms of description andnot of limitation, and there is no intention in the use of such termsand expressions of excluding any equivalents of the features shown anddescribed or portions thereof, but it is recognized that variousmodifications are possible within the scope of the claimed technology.Additionally, the phrase “consisting essentially of” will be understoodto include those elements specifically recited and those additionalelements that do not materially affect the basic and novelcharacteristics of the claimed technology. The phrase “consisting of”excludes any element not specified.

In addition, where features or aspects of the disclosure are describedin terms of Markush groups, those skilled in the art will recognize thatthe disclosure is also thereby described in terms of any individualmember or subgroup of members of the Markush group. Each of the narrowerspecies and subgeneric groupings falling within the generic disclosurealso form part of the present technology. This includes the genericdescription of the present technology with a proviso or negativelimitation removing any subject matter from the genus, regardless ofwhether or not the excised material is specifically recited herein.

As will be understood by one skilled in the art, for any and allpurposes, particularly in terms of providing a written description, allranges disclosed herein also encompass any and all possible subrangesand combinations of subranges thereof. Any listed range can be easilyrecognized as sufficiently describing and enabling the same range beingbroken down into at least equal halves, thirds, quarters, fifths,tenths, etc. As a non-limiting example, each range discussed herein canbe readily broken down into a lower third, middle third and upper third,etc. As will also be understood by one skilled in the art all languagesuch as “up to,” “at least,” “greater than,” “less than,” and the like,include the number recited and refer to ranges which can be subsequentlybroken down into subranges as discussed above. Finally, as will beunderstood by one skilled in the art, a range includes each individualmember.

All publications, patent applications, issued patents, and otherdocuments (for example, journals, articles and/or textbooks) referred toin this specification are herein incorporated by reference as if eachindividual publication, patent application, issued patent, or otherdocument was specifically and individually indicated to be incorporatedby reference in its entirety. Definitions that are contained in textincorporated by reference are excluded to the extent that theycontradict definitions in this disclosure.

Other embodiments are set forth in the following claims, along with thefull scope of equivalents to which such claims are entitled.

1. A compound according to Formula I:

or a pharmaceutically acceptable salt thereof, wherein: Y¹ and W¹ areeach independently 0, N, NH, NR⁶, S, CH, or CR⁷, or Y¹ and W¹ are eachindependently CR⁸ or NR⁸ where R⁸ joins Y¹ and W¹ to form an aryl,heteroaryl, or heterocylyl ring; Z¹, Z², and Z³ are each independentlyCH, C—R⁹, or N; m is 1 or 2; G¹ is C═O, C═S, SO, or SO₂; R¹, R², R⁴, R⁵,R⁶, R⁷, and R⁹ are independently at each occurrence hydrogen, halogen,hydroxyl, alkyl, cycloalkyl, alkenyl, alkoxy, alkynyl, amino,aminosulfinyl, aminosulfonyl, sulfinyl, sulfonyl, sulfonyloxy,aminosulfonyloxy, aminosulfinyloxy, aminosulfonylamino, acylamino,aminocarbonyloxy, aminocarbonylamino, aminothiocarbonylamino,aminocarbonyl, acyloxy, aryl, heteroaryl, cyano, nitro, carboxyl,carboxyl ester, (carboxyl ester)amino, (carboxyl ester)oxy, acyl, orformyl; or two adjacent R¹, R², R⁴, R⁵, R⁶, R⁷, and R⁹ together form anaryl, heteroaryl, or heterocyclyl ring; and R³ is hydrogen, alkyl,cycloalkyl, alkenyl, or alkynyl.
 2. The compound of claim 1, wherein thecompound of Formula I is a compound of Formula II or III:

or a pharmaceutically acceptable salt thereof, wherein: Y¹ is O, NH,NR⁶, or S; W¹ is N, CH, or CR⁷; G² is C═O, C═S, SO, or SO₂; R¹⁰, R¹¹,R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independently at eachoccurrence hydrogen, halogen, hydroxyl, alkyl, cycloalkyl, alkenyl,alkoxy, alkynyl, amino, aminosulfinyl, aminosulfonyl, sulfinyl,sulfonyl, sulfonyloxy, aminosulfonyloxy, aminosulfinyloxy,aminosulfonylamino, acylamino, aminocarbonyloxy, aminocarbonylamino,aminothiocarbonylamino, aminocarbonyl, acyloxy, aryl, heteroaryl, cyano,nitro, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxylester)oxy, acyl, or formyl; or two adjacent R¹⁰, R¹¹, R¹², R¹³, R¹⁴,R¹⁵, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ together form an aryl, heteroaryl, orheterocyclyl ring; and R²⁰ is hydrogen, alkyl, cycloalkyl, alkenyl, oralkynyl.
 3. The compound of claim 1, wherein R¹, R², R⁴, R⁵, R⁶, R⁷, andR⁹ are independently at each occurrence hydrogen, C₁-C₈ alkyl, C₃-C₈cycloalkyl, C₁-C₈ alkenyl, C₂-C₈ alkynyl, aryl, cyano, carboxyl,carboxyl ester, acyl, formyl, C₃-C₇ heteroaryl, or C₃-C₇ heterocyclyl,or two adjacent R¹, R², R⁴, R⁵, R⁶, R⁷, and R⁹ together form an aryl,heteroaryl, or heterocyclyl ring.
 4. The compound of claim 2, whereinthe compound of Formula II is a compound of Formula IIa:

or a pharmaceutically acceptable salt thereof, wherein R²¹ is H, F, Cl,or alkoxy.
 5. The compound of claim 4, wherein R²¹ is H, F, Cl, ormethoxy.
 6. The compound of claim 2, wherein Y¹ is O and W¹ is N or Y¹is NH and W¹ is N.
 7. The compound of claim 2, wherein Z¹ is CH.
 8. Acomposition comprising a compound of claim 1 and a pharmaceuticallyacceptable excipient.
 9. The composition of claim 8, wherein thecompound of Formula I is a compound of Formula II or III:

or a pharmaceutically acceptable salt thereof, wherein: Y¹ is O, NH,NR⁶, or S; W¹ is N, CH, or CR⁷; G² is C═O, C═S, SO, or SO₂; R¹⁰, R¹¹,R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independently at eachoccurrence hydrogen, halogen, hydroxyl, alkyl, cycloalkyl, alkenyl,alkoxy, alkynyl, amino, aminosulfinyl, aminosulfonyl, sulfinyl,sulfonyl, sulfonyloxy, aminosulfonyloxy, aminosulfinyloxy,aminosulfonylamino, acylamino, aminocarbonyloxy, aminocarbonylamino,aminothiocarbonylamino, aminocarbonyl, acyloxy, aryl, heteroaryl, cyano,nitro, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxylester)oxy, acyl, or formyl; or two adjacent R¹⁰, R¹¹, R¹², R¹³, R¹⁴,R¹⁵, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ together form an aryl, heteroaryl, orheterocyclyl ring; and R²⁰ is hydrogen, alkyl, cycloalkyl, alkenyl, oralkynyl.
 10. The composition of claim 9, wherein the compound of FormulaII is a compound of Formula IIa:

or a pharmaceutically acceptable salt thereof, wherein R²¹ is H, F, Cl,or alkoxy. 11.-12. (canceled)
 13. A method for treating a disease in asubject, wherein the method comprises administering an effective amountof a compound of claim 1, to the subject, wherein the disease ismultiple sclerosis, amyotropic lateral sclerosis, ischemic reperfusioninjury, Alzheimer's disease, Huntington's disease, Parkinson's disease,insulin-induced hypoglycemia, cerebral ischemia, brain damage fromepilepsy or experimental trauma, Bethlem myopathy, pancreatitis,hepatitis (type A, and/or B, and/or C), type II diabetes, diabeticretinopathy, muscular dystrophy, traumatic brain injury, heartinfarction, and/or stroke.
 14. The method of claim 13, wherein thecompound of Formula I is a compound of Formula II or III:

or a pharmaceutically acceptable salt thereof, wherein: Y¹ is O, NH,NR⁶, or S; W¹ is N, CH, or CR⁷; G² is C═O, C═S, SO, or SO₂; R¹⁰, R¹¹,R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ are independently at eachoccurrence hydrogen, halogen, hydroxyl, alkyl, cycloalkyl, alkenyl,alkoxy, alkynyl, amino, aminosulfinyl, aminosulfonyl, sulfinyl,sulfonyl, sulfonyloxy, aminosulfonyloxy, aminosulfinyloxy,aminosulfonylamino, acylamino, aminocarbonyloxy, aminocarbonylamino,aminothiocarbonylamino, aminocarbonyl, acyloxy, aryl, heteroaryl, cyano,nitro, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxylester)oxy, acyl, or formyl; or two adjacent R¹⁰, R¹¹, R¹², R¹³, R¹⁴,R¹⁵, R¹⁶, R¹⁷, R¹⁸, and R¹⁹ together form an aryl, heteroaryl, orheterocyclyl ring; and R²⁰ is hydrogen, alkyl, cycloalkyl, alkenyl, oralkynyl.
 15. The method of claim 14, wherein the compound of Formula IIis a compound of Formula IIa:

or a pharmaceutically acceptable salt thereof, wherein R²¹ is H, F, Cl,or alkoxy.
 16. A method for inhibiting the mitochondrial permeabilitytransition pore, wherein the method comprises contacting a cell with aneffective amount of a compound of claim
 1. 17. A method for treating acondition in a subject, wherein the method comprises administering to apatient an effective amount of a compound of claim 1; and the conditionin the subject is mediated at least in part by [Ca²⁺] dysregulationand/or a reactive oxygen species.
 18. A method for treating multiplesclerosis, amyotropic lateral sclerosis, ischemic reperfusion injury,Alzheimer's disease, Huntington's disease, Parkinson's disease,insulin-induced hypoglycemia, cerebral ischemia, brain damage fromepilepsy or experimental trauma, Bethlem myopathy, pancreatitis,hepatitis, type II diabetes, diabetic retinopathy, muscular dystrophy,traumatic brain injury, heart infarction, and/or stroke, wherein themethod comprises administering to a patient a composition of claim 8.19. A compound according to Formula IV:

or a pharmaceutically acceptable salt thereof, wherein: Y² is O, NH,NR²⁵, or S; W² is N, CH, or CR²⁶; where when Y² is NR²⁵ and W² is CR²⁶then R²⁵ and R²⁶ may optionally join Y² and W² to form an aryl,heteroaryl, or heterocylyl ring; Z⁴, Z⁵, and Z⁶ are each independentlyCH, C—R²⁷, or N; and R²², R²³, R²⁴, R²⁵, R²⁶, and R²⁷ are independentlyat each occurrence hydrogen, halogen, hydroxyl, alkyl, cycloalkyl,alkenyl, alkoxy, alkynyl, amino, aminosulfinyl, aminosulfonyl, sulfinyl,sulfonyl, sulfonyloxy, aminosulfonyloxy, aminosulfinyloxy,aminosulfonylamino, acylamino, aminocarbonyloxy, aminocarbonylamino,aminothiocarbonylamino, aminocarbonyl, acyloxy, aryl, heteroaryl, cyano,nitro, carboxyl, carboxyl ester, (carboxyl ester)amino, (carboxylester)oxy, acyl, or formyl; or two R²², R²³, R²⁴, R²⁵, R²⁶, and R²⁷together form an aryl, heteroaryl, or heterocyclyl ring.
 20. Acomposition comprising a compound of claim 19 and a pharmaceuticallyacceptable excipient.
 21. (canceled)
 22. The composition of claim 20,wherein the compound is present in an amount effective for the treatmentof multiple sclerosis, amyotropic lateral sclerosis, ischemicreperfusion injury, Alzheimer's disease, Huntington's disease,Parkinson's disease, insulin-induced hypoglycemia, cerebral ischemia,brain damage from epilepsy or experimental trauma, Bethlem myopathy,pancreatitis, hepatitis, type II diabetes, diabetic retinopathy,muscular dystrophy, traumatic brain injury, heart infarction, and/orstroke.
 23. A method for treating a disease in a subject, wherein themethod comprises administering an effective amount of a compound ofclaim 19, to the subject, wherein the disease is multiple sclerosis,amyotropic lateral sclerosis, ischemic reperfusion injury, Alzheimer'sdisease, Huntington's disease, Parkinson's disease, insulin-inducedhypoglycemia, cerebral ischemia, brain damage from epilepsy orexperimental trauma, Bethlem myopathy, pancreatitis, hepatitis, type IIdiabetes, diabetic retinopathy, muscular dystrophy, traumatic braininjury, heart infarction, and/or stroke.